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Abstract 
Substitutions of the phylogenetically conserved phenylalanine residue F393 were 
constructed in flavocytochrome P450 BM3 from Bacillus megaterium. The high 
degree of conservation of this residue in the P450 superfamily and its proximity to 
the heme (and its ligand Cys400) implies an essential role in P450 activity. Extensive 
kinetic and thermodynamic characterization of mutant enzymes F393A, F393H and 
F393Y highlighted significant differences from wild-type P450 BM3. All enzymes 
expressed to high levels and contained their full complement of heme. Whilst the 
reduction and subsequent treatment of the mutant P450s with carbon monoxide led to 
the formation of the characteristic P450 spectra in all cases, the absolute position of 
the Soret absorption varied across the series WTIF393Y (449 Mn), F393H (445 run) 
and F393A (444 nm). Steady-state turnover rates with both laurate and arachidonate 
showed the trend WT>F393Y>>F393H>F393A. Conversely, the trend in the pre-
steady-state flavin-to-heme electron transfer was the reverse of the steady-state 
scenario, with rates varying F393A>F393H>>F393Y-wild-type. These data are 
consistent with the more positive substrate-free (-312 mV (F393A), -332 mV 
(F393H)) and substrate-bound (451 mV (F393A), -176 mV (F39311)) reduction 
potentials of F393A and F393H heme domains, favouring the stabilization of the 
ferrous-form in the mutant P45 Os relative to wild-type. Elevation of the heme iron 
reduction potential in the F393A and F393H mutants facilitates faster electron 
transfer to the heme. This results in an increase in the stability of the oxy-ferrous 
intermediate, which retards the rate of second electron transfer to the heme, and 
slows the rate of turnover of the mutant P450s. We postulate that the nature of the 
residue at position 393 is important in controlling the delicate equilibrium observed 
in P45 Os, whereby a trade-off is established between the rate of heme reduction and 
the rate at which the ferrous heme can bind and, subsequently, activate molecular 
oxygen. The structural and spectroscopic characterisation of the mutants reveals the 
probable role of the phenylalanine residue to be to preserve the hydrophobic 
environment of the heme. This prevents unfavourable inter- and intra-molecular 
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interactions with the heme or heme-ligand, which have been demonstrated to perturb 
this delicate thermodynamic balance. This study highlights the electronic influence 
the cysteine ligand has in dictating the characteristic reactivity of P45 Os, and its 
sensitivity to its chemical environment. Modulating the electron density of the Fe-S 
bond (introduction of intramolecular hydrogen bonds) has a direct effect on the 
ability of P450s to bind and activate molecular oxygen. This point is key to the high 
degree of conservation of this residue throughout the P450 superfamily - 
monooxygenation requires oxygen activation. This phenylalanine is conserved in 
every member which needs to perform this activation, for the small number that do 
not, the nature of this residue varies. 
The nitrogenous it-acceptor ligand 4-cyanopyridine (4CNPy) exhibits reversible 
ligation, exclusively to ferrous-heme (Kj = 12 .tM for P450 BM3 and 1.0 j.M for 
P450cam) via its pyridine-ring nitrogen. The ferrous-4CNPy adduct displays unusual 
spectral properties which provides a useful spectroscopic handle to probe features of 
the P450 mechanism. 4CNPy is competitively displaced upon substrate binding, and 
allows a convenient route to the determination of substrate dissociation constants for 
ferrous P450 - a previously unquantified property. For P450 BM3, Kd(red)  (laurate) 
36 pM (K(ox) = 241 j.tM); for P450 cam, K(red)(fenchone) = 1.5 j.tM (K1j(ox) = 
52 LM). This result confirms the previously unsubstantiated assumption that 
reduction of substrate-bound P450 decreases the magnitude of the substrate 
dissociation constant, resulting in an increase in the stability of the Michaelis- 
complex (by 4.2 kJmoF' for P450 BM3 with laurate and 8.9 kJmol' for P450cam 
with fenchone). An unusual spectral feature in the blue region of the ferrous-4CNPy 
adduct is a metal-to-ligand charge transfer (MLCT) absorption, the energy of which 
varies linearly with respect to the P450 heme-reduction potential. By studying the 
energy of this MLCT for a series of P450s with differing reduction potential (E 0), the 
relationship Ec = (3.86 x E0) + 17122 cm-1 was deduced. This relation holds for 
both wild-type P450 BM3 and P450cam - the two most intensively characterised 
P450s, and for the F393X series of mutants of P450 BM3. This molecule provides a 
quick and accurate spectrophotometric method of predicting the heme-reduction 
potentials for cytochromes P450, without the requirement for redox potentiometry. 
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List of abbreviations 
Amino acids 
Alanine Ala A Leucine Leu L 
Arginine Arg R Lysine Lys K 
Asparagine Asn N Methionine Met M 
Aspartic acid Asp D Phenylalanine Phe F 
Cysteine Cys C Proline Pro P 
Glutamic acid Glu E Serine Ser S 
Glutamine Gin Q Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 
Isoleucine lie I Valine Vat V 
Mutations 
Amino acid mutations are represented as a code number -+ code, where the first code 
and number represents the original residue and its position on the polypeptide chain, 
and the second code represents the corresponding residue in the mutant enzyme. For 
example, the mutation of a phenylalanine, residue number 393, to an alanine is 
represented by Phe393—*Ala, thus generating the mutant F393A. 
Vii 
The Catalytic Control of Flavocytochrome P450 BM3 
Textual abbreviations 
Abs 	 Absorbance 
B. megaterium Bacillus megaterium 
4CNPy 4-cyanopyridine 
CYP Cytochrome P450 
Ao Octahedral crystal-field splitting parameter 
Da Daltons 
DNA Deoxyribonucleic acid 
DPNH diphosphopyridinenucleotide 
E0 Reduction potential 
E. coil Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
EPR Electron paramagnetic resonance (spectroscopy) 
FAD Flavin adenine dinuclotide 
FMN Flavin mononucleotide 
AG Free energy change 
GC/MS Gas chromatography/mass spectrometry 
HD Herne domain 
Herne Protoporphyrin IX 
KPi K2HPO4/KH2PO4 buffer 
Mb Myoglobin 
MCD Magnetic circular dichroism 
MLCT Metal-to-ligand charge transfer 
MOPS 3-(morpholino)-propanesulfonic acid 
M1 Molecular mass 
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NMIR Nuclear magentic resonance (spectroscopy) 
NADH 13-Nicotinamide adenine dinucleotide 
NADPH -Nicotinamide adenine dinucleotide phosphate 
ODRC o-dianisidine radical cation 
NOS Nitric oxide synhtase 
P450 Cytochrome P450 monooxygenase 
PAGE Polyacrylamide gel electrophoresis 
PMSF Phenylmethylsulfonyifluoride 
P. putida Pseudomonas putida 
SHE Standard hydrogen electrode 
SDS Sodium dodecylsulfate 





KM Michaelis constant 
K1 Inhibition constant 
Kd Dissociation constant 
k,g Rate constant at substrate saturation 
kijm Limiting rate constant 
kobs Observed rate constant 
k0ff Rate constant for oxy-ferrous decay 
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Kdw Apparent Kj 
Standard Units 
m 	metre 	 °C 	degree Celcius 
g 	gram 	 M 	molar 
s 	second 	 V 	volt 
litre A 	Angstrom 
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I 	INTRODUCTION 
1.1 Cytochromes P450 
1.1.1 Discovery 
The serendipitous discovery of cytochromes P450 is attributed to the work of 
Klingenberg [1] in 1958, as a result of a discrepancy in the quantification of 
cytochrome b5 from rat liver microsomes. Only half of the calculated protoheme 
concentration was accounted for by cytochrome b5, the remainder of which was 
observed to generate a CO-protoheme complex upon treatment of the microsomal 
suspension by cholate, in the presence of carbon monoxide. This complex had an 
unusual absorbance band at 450 nm. 
However, the true identification of this "red pigment from liver microsomes" as a 
cytochrome was made by Omura and Sato [2-4] - in the early 1960s. They 
demonstrated that CO had affinity only for the ferrous-form, and that treatment with 
ethylisocyanide gave difference spectra characteristic of hemoglobin and its 
derivatives. By comparison of aerobically and anaerobically DPNH 
(diphosphopyridinenucleotide)-reduced microsomes, spectral interference from 
cytocbrome b5 was removed, allowing the observation of the spectrum of the native 
pigment. This was shown to be that of a b-type cytochrome, different from 
cytochrome b5. It is from these unusual yet characteristic absorbance properties that 
the present terminology of cytochromes P450 ('pigment-450') originates. 
The proposal that cytocbromes P450 (P450s) were components of mixed function 
oxidase systems, catalysing many important reactions in vivo such as steroid 
hydroxylation and the oxidative demethylation and hydroxylation of drugs [5,6] 
implied a fundamental, physiological role for the enzymes, other than CO-binding. 
This impetus, along with the subsequent solubilisation, purification and 
reconstitution of active P450-containing complexes [7,8] has permitted a thorough 
and systematic understanding of the general P450 mechanism and their involvement 
in many biosynthetic and metabolic processes. 
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1.1.2 General Background 
Cytochromes P450 are NAD(P)H-dependent b-type heme containing 
monooxygenases which can catalyse stereo- and regio-specific insertion of an atom 
of oxygen (derived from molecular oxygen) into a diverse range of organic 
compounds, with the concomitant production of water (Figure 1.1). Electrons are 
Figure 1.1: 	RH + NAD(P)H +02+ 2H 	ROH + NAD(P) + H20 
derived from NAD(P)H, and are shuttled to the heme via one or two redox proteins, 
depending on the class of P450, at strategic points in the catalytic cycle. 
P450s are found within organisms from every domain of life (Bacteria, Archaea and 
Eukarya (Table 1.1). By 1993, the number of partial or total nucleotide sequences 
Table 1.1: Examples of cytochromes P450 from every domain of life 
Domain 	 Example Species Ref. 
Bacteria 	 CYP 101 Pseudomonasputida  
CYPI02 Bacillus megaterium 
 
CYP51 Mycobacterium tuberculosis 
 
Eukarya 	 CYP 1 1A1 Human, rat, rabbit, bovine, pig [12-16] 
CYP 2 Caenorhabditis elegans  
CYP 6A2 Drosophila melanogaster  
CYP 55 	Fusarium oysporum 	 [19] 
CYP 51 	Saccharomyces cerevisiae 	 [20] 
CYP 73A 	Arabidopsis thaliana 	 [21] 
Archaea 	 CYP 119 	Sulfiobus sulfotaricus 	 [22] 
identified as P450s exceeded 300 forms [23]. The solutions to the genomes of 
various species identify numerous additional isoforms [24] (53 from human [25], 20 
from Mycobacterium tuberculosis [26], 80 from Caenorhabditis elegans [27], 83 
Chapter 1: Introduction 	 3 
The catalytic Control of Flavocytochrome P450 BM3 
from Drosophila melanogaster [28], 286 from Arabidopsis thaliana [29]), increasing 
the number of members constituting the P450 superfamily to over 500. An up to date 
compilation can be found at http://dmelson.utmem.edu/CytochromeP450.html.  
Cytochromes P450 are implicated in a multitude of biosynthetic, metabolic and 
detoxification processes in vivo, for example: CYP1 lAl converts cholesterol to 
pregnenolone in mammals; CYP1O1 metabolises camphor as an unusual energy 
source for its bacterial host Pseudomonas putida; CYP107A1 is required to 
hydroxylate an important precursor in erythromycin biosynthesis in fungi; CYP1A2 
detoxifies caffeine in the liver and CYP1O7H1 is involved in biotin biosynthesis. 
In most situations, oxygenation of substrates acts either to increase the polarity of the 
product with respect to the substrate to facilitate water solubility and hence excretion, 
or activates the substrate toward further reactions. Whilst this activity is, in the main, 
beneficial to the host, under certain conditions P450s can act as a double-edged-
sword - transforming inert, unreactive species into highly reactive and potentially 
mutagenic/carcinogenic derivatives. Illustrative of this are the epoxidation products 
of vinyl chloride and benzo(a)pyrene [30]. 
1.1.3 Classification 
P450s are classed into three main groups according to their redox cofactor 
arrangement and are depicted in Figure 1.2. 
Class 1: Class 1 P450s are three component systems, typified by the bacterial (Figure 
1.2a) and mitochondrial P450s (Figure 1.2b). Here, electrons are derived from 
NADH and are passed sequentially onto a FAD-containing ferredoxin reductase, to a 
small iron-sulfur cluster (ferredoxin) and finally onto the P450. Bacterial Class 1 
P45 Os are soluble (e.g. putidaredoxin reductase/putidaredoxinfP450cam) [31], 
whereas mitrochondrial Class 1 P450s tend to be associated to the inner 
mitochondrial membrane by hydrophobic contacts (e.g. adrenodoxin 
reductase/adrenodoxin! P450scc) [32]. 
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Figure 1.2: Diagrammatic representation of the three different classes of cytochrome P450 
systems. A and B: Class I systems (microsomal and bacterial respectively) are composed of an 
FAD containing flavodoxin reductase, and iron-sulfur cluster containing ferredoxin and the 
P450. C: Class 2 P450 systems (e.g. mitochondrial P450) are membrane-bound and partnered 
by a dflavin reductase, whereas in D: the Class 3 P450s, the reductase and P450 are fused in 
one continuous polypeptide (e.g. P450 BM3). 
Class 2: Class 2 P450s are two component systems, typified by the microsomal 
P450s whereby electrons are shuttled through a FAD/FMN-containing NADPH-
dependent diflavin P450-reductase onto the P450. These P450s tend to be bound to 
the cytoplasmic side of the endoplasmic reticulum, through N-terminal membrane 
spanning anchors (Figure 1.2c). 
Class 3: Class 3 P450s are one component systems, comprising a FAD/FMN 
containing diflavin NADPH-dependent P450-reductase domain, covalently attached 
to the P450 domain in one continuous polypeptide by a short hydrophilliic 
polypeptide linker. Class 3 P450s are typified by the bacterial P450 BM3 (Figure 
l.2d). 
1.1.4 Structure 
Primary structure: In general, P450s comprise of 450 ± 100 amino acids with a 





CYP 102 392 P F G N G Q R A C I G Q Q F 405 
CYP1O1 349 T F G H G S H L C L G Q H L 362 
CYP4A1 348 A F G F G V H Q C L G Q N L 461 
CYP7B 346 P F G L G T S K C P G R Y F 359 
CYP11A 354 GFGWGVRQCLGRRI 467 
CYP51 341 P F G G G R H R C T G E H F 454 
CYP55A 343 G F G F G D H R C I A E H L 356 
CYP119 309 S F G S G I H L C L G A P L 322 
Figure 1.3: The heme-binding region of cytochrome P450 is located toward the C-terminal end 
of the P450, as indicated by the dark grey shaded region on the cartoon polypeptide. A 
sequence alignment for a selection of P450s shows the high degree of sequence homology in 
this region. The implicitly conserved cysteine residue (which provides the heme ligand, green) 
and the highly conserved phenylalanine (corresponding to Phe393 of P450 BM3, blue) are 
highlighted 
structural feature common to all P450s is the presence of a phylogenetically 
conserved cysteine residue which provides a thiolate as the fifth ligand to the heme 
iron [33] (Figure 1.3). The presence of this thioloate has been proposed to be the key 
to the unique reactivity displayed by P450s [34-37]. This cysteine is the only 
implicitly conserved residue throughout the P450 superfamily, although a small 
number (Ca. 10) residues are very highly conserved (> 95 %), these include a 
threonine residue distal to the heme ligand (Thr268 in P450 BM3 [38]), a tryptophan 
ic-stacking with the heme (Trp96 in P450 BM3) [39] and a proximal phenylalanine 
(Phe393 in P450 BM3) [40], all of which are believed to play critical roles in P450 
mechanism. 
Secondary and tertiary structure: Comparison of the avaliable P450 crystal 
structures shows that despite the relatively low degree of sequence homology 
between these P450s (< 20 % on average), they all have secondary and tertiary 
structural elements in common. The P450 tertiary structure has an approximate 
trigonal prism arrangement, containing both cc-helical and n-sheet regions (Figure 
1.4). Helices dominate the structure, with the majority of these lying parallel to the 
heme plane. The heme is wedged in a relatively hydrophobic cleft between two 
IA 	 a 
4 
C 
Figure 1.4: Schematic representation of the tertiary structure, common to all P450s. Shown are 
the structures of P450s from a eukaryote (a, CYP 2C5 from Rabbit), a prokaryote (b, CYP 102 
from Bacillus megaterium) and from an archaeon (c. CYP 119 from Sulfolobus sulfozaricus). 
The a-helical and/sheet regions are shown in orange and blue respectively, the heme is 
shown in red 
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protein spanning a-helicies (the I- and L-helices) with the cysteine thiolate located at 
the N-terminal end of the L-helix. Being at the positive dipole end of the L-helix 
allows stabilisation of the thiolate anion, a feature key to characteristic P450 activity 
which helps to stabilise the anionic thiolate, thereby influencing P450 reactivity (in 
contrast, the histidine heme-ligand of peroxidases is located at the C-terminus of a 
helix, which stabilises the positive imidazolate ligation observed in this class of 
hemoprotein). The heme is buried within the core of the protein, with the substrate 
binding site on the distal face of the heme, trans to the thiolate ligand. 
1.1.5 The Catalytic Cycle 
The majority of P450 mechanistic information has been determined for the soluble, 
camphor hydroxylase, P450cam, from P. putida. The mechanism shown in 
Figure 1.5 is the product of almost 30 years research into the catalytic mechanism of 
P450. Although P450cam is a bacterial P450, the nature of the reactive species and 
intermediates are believed to be applicable to all members of the P450 family by 
analogy. 
In its resting state, the P450 heme is ferric low-spin, with essentially octahedral 
geometry [41]. The mixed ligand set is comprised of four nitrogenous ligands 
(provided by the porphyrin macrocycle), a thiolate (provided by cysteine) [42] and a 
weakly bound water molecule in the sixth coordination site. 
Step 1: Substrate Binding 
Step 1 of the catalytic cycle shown in Figure 1.5 is substrate binding to the active site 
of the P450. There are a number of structural features which contribute to the overall 
substrate binding energy such as hydrophobicity, electrostatic interactions and 
hydrogen bonding networks. The level of contribution of each of these factors is 
determined by the identity of the substrate and the nature of the substrate-binding 
cavity, and hence are details specific to a particular P450. Yet despite the high degree 
of variability of potential substrates, one generic feature is that substrate binding 
causes a perturbation in the low- to high-spin state equilibrium of the heme iron. 
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Figure 1.5: The P450 catalytic cycle. The individual steps are discussed in detail in the text 
(Section 1.1.5). The dashed lines indicate the three major uncoupling pathways observed in 
P450s, leading to the 1-, 2- and 4-electron reduced forms of molecular oxygen. Substrate is 
shown in blue, oxygen (from molecular oxygen) is shown in red where appropriate. 
Dehydration of the heme by substrate causes the iron to move out of the plane of the 
porphyrin (toward the thiolate) and invokes a change in the iron coordination 
geometry from octahedral to square based pyramidal. This change in geometry is 
accompanied by a modification in the energetic ordering of the d-orbitals 
(Figure 1.6) and a rearrangement of the d-electrons from low-spin (S = 1/2) to 
high-spin (S = 5/2). Perturabations in this low- to high-spin equilibrium are solely 
attributable to the binding equilibrium of the sixth ligand and not as a result of a 
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Figure 1.6: Diagram illustrating the changes in d-orbital arrangement and d-electron 
configuration of A: low spin ferric P450 heme iron, B: upon substrate binding and 
C: reduction. 
purely electronic spin equilibrium (implying iron being hexacoordinate in both spin 
states). All high-spin P450 complexes are pentacoordinate. 
The degree to which the spin state equilibrium is perturbed is dependent on the 
substrate binding affinity. Substrates with low dissociation constants are better 
substrates (by definition) and induce a greater shift to the high-spin form. This is 
clearly illustrated in the case of P450cam and P450 BM3, where the best substrates 
(camphor and arachidonate respectively) induce almost complete spin conversion to 
the high spin form (> 90 %), whereas poorer substrates (norcamphor and laurate 
respectively) only induce a partial (<40 %) shift. This spin state shift is fundamental 
to the P450 catalytic cycle, as substrate binding is accompanied by a large, positive 
increase (- +100 mV) in the heme reduction potential. In this way, substrate binding 
acts as a thermodynamic switch. In the absence of substrate, the heme reduction 
potential is too negative to permit electron transfer from the reductase, preventing the 
futile oxidation of valuable NAD(P)H equivalents and the production of undesirable, 
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uncoupled reduced oxygen species. Instead, P450s have a built in mechanism which 
only allows heme reduction when in the catalytically-prepared, substrate-bound 
form. It also holds true that poorer substrates have a similarly less pronounced effect 
on increasing the reduction potential and are consequently poorer 'switches'. 
Step 2: First Electron Transfer 
The second step in the P450 catalytic cycle is the one-electron reduction of the 
substrate-bound P450. This is essential as molecular oxygen has strict selectivity for 
ferrous-heme, dioxygen does not bind to ferric heme 
The pentacoordinate ferrous-iron is exclusively high-spin (Figure 1.6) as determined 
initially by 1 H-NMR [43] and magnetic susceptibility of camphor-bound P450cam 
[44]. 
Reducing equivalents are ultimately derived from pyridine nucleotides (NAD(P)H) 
in the form of a hydride, with subsequent steps involving the transfer of individual 
electrons through a relay of electron transfer proteins (as described in Section 1. 1.3) 
to the P450. The P450 redox partners constitute a 'potential gradient' to mediate 
electron transfer from NAD(P)H to the P450 heme. Herne reduction causes a 
conformational change in the active site, which is believed (at least for P450 BM3) to 
move substrate closer to the heme, and increase the affinity for substrate [45]. 
Step 3: Dioxygen Binding to Ferrous Herne 
Under normal circumstances, the reaction between organic substrates and molecular 
oxygen is spin forbidden, hence in order for reaction to occur, the oxygen must be 
activated. This is the primary role of cytochromes P450. Oxygen binding is the first 
step in the process of oxygen activation. 
Reduction of ferric P450 allows the ligation of molecular oxygen, to the coordination 
site vacated by the water molecule, trans to the thiolate ligand. The oxy-P450 
complex of P450cam was first reported by Peterson et al in 1971, and has been 
observed since for other P450s. The complex has a red-shifted visible absorbance 
relative to the ferrous P450, indicative of the formation of a hexacoordinate, low-spin 
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P450 [46-48]. Whilst this adduct is readily formed under controlled conditions 
(stoichiometrically reduced P450 in the presence of excess oxygen), it is likely that 
the formal nature of the complex is superoxy-ferric, as opposed to oxy-ferrous. 
Whilst experiments have been conducted to determine features such as the 0-0 
stretching frequency [49], these values correspond to the superoxy-ferric form as 
opposed to the oxy-ferrous form, as demonstrated by Coliman et al [50]. Electronic 
rearrangement is likely to be rapid and athough dioxygen initially binds to the ferrous 
form, the superoxy-ferric adduct is likely to be the favoured (stabilised) cannonical 
form. This can be further justified on thermodynamic grounds, as the heme reduction 
potential is more negative than the one electron reduction potential of oxygen to 
superoxide (-160 mV), this reductive driving force would favour the formation of the 
superoxy-ferric form. 
Steps 4 -8: Second Electron Transfer to Product Dissociation 
The oxy-P450 complex is the last observable intermediate in the P450 catalytic 
cycle. Although the rate of second electron transfer to P450cam has been measured 
and has been reported to be the rate limiting step in P450 catalysis [51-53], the 
identity of the intermediates after this point remain unresolved and their identity only 
speculated upon. It seems likely that reduction leads to the formation of a 
peroxy-ferric complex, the subsequent protonation of which would result in the 
liberation of a water molecule, and the generation of the reactive intermediate. It has 
been proposed that the reactive moiety is an oxy-ferryl radical cation ([Fe IV  =0]
.4-  
). 
Cleavage of the 0-0 bond of heme-bound peroxide: Central to the proposed 
mechanism is the manner in which the peroxide 0-0 bond is cleaved to allow 
generation of the oxy-ferryl intermediate. This oxygen splitting reaction must occur 
after the introduction of the second electron, as the oxy-P450 species itself is 
catalytically incompetent at oxygenating substrates [54]. The peroxy-ferric complex 
can be envisioned to decay to the oxy-ferryl species by one of two mechanisms, 
either the homolytic or heterolytic cleavage of the 0-0 bond. 
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Model porphyrins have been used to probe this feature with the nature of the product 
being illustrative of the pathway of oxygen scission. The validity of this biomimetic 
approach is questionable, since both homolytic and heterolytic 0-0 cleavage can 
been demonstrated, depending on the nature of the oxidant, solvent and coordinating 
ligands. For example, Hirobe et a! [55,56] demonstrated that simple porphyrins such 
as Fe3 TPP catalysed the exclusive conversion of phenylperoxyacetic acid to 
phenylacetic acid (evidence of heterolytic cleavage) in favour of the formation of 
various benzyl-radical derived products (evidence of homolytic cleavage) (Figure 
1.7), whereas Labeque and Marnett [57] have shown that Fe 3 TPP reduces fatty acid 
hydroperoxides homolytically in the absence of a strongly electron donating 
proximal ligand, but heterolytically in the presence of excess imidazole. These types 
of study do demonstrate that either mechanism is chemically feasible for P45 Os, yet 
















Figure 1.7: The mode of 0-0 bond cleavage mediated by phenylperoxyacetic acid (PPAA) in 
the presence of tetraphenylporphyrin (Fe(TPP)) can be used as a convenient mechanistic 
probe. The oxidation of 2,4, 6-tri-tert-butylphenol (TBPH) by PPAA affords only phenylacetic 
acid if the 0-0 bond of PPAA breaks heterolytically (Pathway A), or benzyl radical-derived 
products ifthe 0-0 bond is broken homolytically (Pathway B). Reactions using a sulfur ligated 
Fe(TPP) -derivative catalysed only heterolytic cleavage of the 0-0 bond, suggesting this to be 
analogous to the mechanism operative in the thiolate-ligated cytochromes P450. 
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environment of the active site. This is an important point, as recent studies suggest 
that the features of the protein superstructure are essential for oxygen activation and 
0-0 bond scission. 
In peroxidases, oxygen activation is achieved by what is termed the "push-pull" 
mechanism (Figure 1.8a), first proposed by Poulos [58]. The peroxy-ferric complex 
is activated by a 'push' from the proximal histidine ligand, and a 'pull' from 
interactions with two distal residues, a histidine and an arginine. The imidazolate 
character of the proximal histidine is enhanced by hydrogen bonding interactions 
with neighbouring aspartate, increasing the electron density of the heme iron. In 
association with this, the distal histidine hydrogen-bonds with the bound peroxide 
(providing the outer oxygen atom with the proton required for the formation of 
water) and the cationic guanidino group of the arginine, serves to stabilise the 
negative charge which develops during 0-0 scission. 
Unlike peroxidases, P450s do not have residues in the distal cavity able to provide 
the analogous acid/base interactions required to assist the 0-0 bond cleavage. 
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Figure 1.8: Schematic representation of the "push-pull" model for 0-0 bond cleavage of 
heme-bound peroxide in histidine (A, e.g. peroxidases) and ihiolate (B, e.g. P450s) ligated 
systems 
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Consequently, it has been proposed that the strong electron donating character of the 
thiolate ligand from the proximal cysteine residue is the primary factor responsible 
for the activation of oxygen in P450, by providing a 'big push' (Figure 1.8b). 
Evidence for the strong electron releasing character of cysteinate has been provided 
by comparisons with myoglobin, where thiolate ligands trans to the endogenous 
cysteinate display enhanced bacisity [59,60], whilst small anionic ligands have a 
much lower affinity for ferric P450 than ferric myoglobin. Also, substitution of the 
endogenous histidine ligand of myoglobin (Mb) by cysteine generates a myoglobin 
variant which enhances the heterolytic cleavage of cumene hydroperoxide, as 
observed by a change in the heterolytic/homolytic product ratio [61] from 3.2 
(WTMb) to 7.2 (H93C Mb). 
Recent studies on P450cam by Sugar et a!, have demonstrated that although there are 
no residues in the P450 distal cavity able to perform acid/base catalysis, two residues 
(T252 and D251) were of critical importance for the enzyme to catalyse the 
hydroxylation of camphor. These residues cause a kink in the 1-helix, generating a 
putative oxygen binding cleft. The mutation T252A resulted in extensive uncoupling, 
i.e. only - 5 % of the reducing equivalents from NADH supported the hydroxylation 
of camphor, with the remaining electrons consumed in the 2- or 4-electron reduction 
of oxygen to peroxide or water (respectively). The D25 1 N mutant of P450cam 
decreased the overall rate of reaction by an order of magnitude. Both of these 
residues participate in a distal charge relay [62] (Figure 1.9), creating a hydrogen-
bonding network for the transfer of protons from the bulk solvent to the active site. 
This motif is highly conserved throughout the P450 superfamily, with only a few 
exceptions, suggestive of the fact that it plays an important role in the reaction of 
heme with oxygen. P450EryF is an example of one such P450 lacking the charge 
relay machinery, having an alanine (A245) in place of the threonine [63]. A similar 
kink in the 1-helix of P450EryF is observed to that in P450cam, yet is stabilised (in 
the absence of the threonine side-chain) by a hydrogen-bonding network involving 
substrate and water molecules. The C5 hydroxyl group of the substrate 6-DEB (6-
deoxyerythronolide B) hydrogen bonds to a water molecule, which in turn hydrogen 
bonds to the heme-bound oxygen (Figure 1.10a). In the absence of the threonine, 
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Figure 1.9: The proposed distal charge relay operational in P450cam, involved in the 
sebilisation and activation of heme-oxygen complexes. It also serves to conduit for proton 
transfer from the aqueous solvent, to the buried heme. 
substrate appears to be aiding catalysis [64]. A similar observation has been made for 
nitric oxde sythases (closely related, heme-thiolate monooxygenases) where the 
substrate (L-arginine) forms a hydrogen bond with heme-bound oxygen to activate it 
(Figure 1.1 Ob), due to the absence of distal cavity residues with the required 
functionality [65]. 
In the case of P450s, the requirement for distal residues to perfrom acid/base 
catalysis in parallel with a weakly electron donating proximal ligand (histidine) as 
seen for peroxidases, has been replaced by a strongly electron donating proximal 
ligand (cysteine) acting in concert with hydrogen bonding interactions from 
hydrophilic residues and water molecules in the distal cavity, to achieve efficient 
oxygen activation. 
Mechanism of oxygen insertion: As mentioned previously, the identity of the reactive 
oxygen species responsible for the oxygenation reaction is a reactive iron-oxo 
species, the putative oxy-ferryl radical cation ([Fe"O]). Hydroxylation is believed 
to occur via a hydrogen-abstraction/oxygen insertion reaction, termed the oxygen 
rebound mechanism [66,67] first described by Groves and McClusky in 1976. They 
utilised a modified Fenton reagent (Fe 2 /H2O2/CH3CN) to show that aliphatic 
hydroxylation occurred via an iron-bound oxidant, rather than by a free hydroxyl 
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Figure 1.10: Schematic representation of the substrate-assisted oxygen stabilisation proposed 
for P450 EryF (A) and nitric oxide synthase (B, iNOS numbering). Hydrogen bonds are shown 
by dotted lines. 
radical. The Fe2 -catalysed hydroxylation of cyclohexanol by meta-chloroperbenzoic 
acid (MCPBA) liberated all possible diol products, of which the cis- and trans-1,2- 
diols constituted 75 % of the total product profile (Figure 1.11). The presence of 
180 enriched water did not lead to the incorporation of labelled oxygen into the diol, 
providing evidence that the source of the oxygen atom was the peroxyacid, and that 
the mechanism of hydroxylation occurred without equilibration with water. 
Whilst this mechanism appeared to be non-selective (--1:1 cis:trans diol products), 
examination of the products of the hydroxylation of trans - 2-deuteriocyclohexanol 
showed that cis hydrogen abstraction led preferentially to the formation of the cis 
diol, whilst trans hydrogen abstraction afforded the trans diol. The specific 
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Figure 1.11: The mechanism of oxygen insertion into 2-cis/trans-deuterocyclohexanol by the 
oxygen rebound mechanism. The stabilised ferrous/peracid/substrate complex readily 
rearranges to liberate the highly reactive iron-oxo (Fe''=O) moiety responsible for 
hydroxylation. The intimate association of the Fe 1 O species and substrate is justified by the 
observation that the cis-cyclohexanol affords the cis-diol and vise-versa 
incorporation of the peroxy oxygen and the retention of C-2 H-abstraction/oxygen 
rebound led to the proposal that an an iron-oxo intermediate (formally a ferryl ion) 
was responsible for hydroxylation. 
Although the equivalent species has not been formally identified as the active moiety 
in the P450 catalytic mechanism, the oxygen rebound mechanism reported above can 
be successfully applied to the heme iron of P450s as shown in Figure 1.12. Whilst it 
i i • s incorrect to refer to the oxy-ferryl intermediate formally as [Fe
Iv  =0] .+  (because of 
its various possible cannonical forms), it has become the convention to do so, with 
the radical cation located on either the porphyrin macrocycle, or a neighbouring 
aromatic residue. It is more appropriate to consider the species as a high-valent iron-









Figure 1.12: The oxygen rebound mechanism applied to cytochromes P450. The porphyrin 
macrocycle is represented by the red box. 
1.1.6 Reaction Types and Substrates of Cytochromes P450 
Reaction types: 
Despite the conformity of cytochromes P450 to the same catalytic cycle, the variety 
of reactions catalysed by these versatile enzymes is quite extraordinary. Their ability 
to catalyse reactions unachievable by conventional synthetic chemical routes under 
mild conditions, is remarkable. Various explanations have been proposed to explain 
P450 catalysis, including the generation of mobile oxidants such as superoxide, but 
the mechanism outlined in Section 1.1.5 (in particular the generation of the [FeO] 3+  
species and its participation in the oxygen rebound mechanism) have become 
adopted as the most likely sequence of events leading to reaction. 
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Figure 1.13: Example of carbon hydroxylation performed by cylochrome P450. The 5-exo 
hydroxylalion of camphor by P450cam 
The complilation of a detailed inventory, listing every reaction type or substrate 
specificity displayed by the members of the P450 superfamily, would constitute a 
significant body of work in itself, and hence, is beyond the scope of this thesis. 
However, it is important to demonstrate these diversities in order to establish a 
context within which the catalytic importance of these enzymes can be evaluated. 
The subsequent section is intended to illustrate this point, by considering a few 
pertinent examples of common, yet diverse, reaction types exhibited by P450s. 
Carbon Hydroxylation: This is possibly the most common reaction type displayed by 
P450s (Figure 1.13). There are many examples of this type of reaction, for example, 
the hydroxylation of fatty acids (CYP 4A, CYP 102 [68,69]), the 7a- and 
1 13-hydroxy1ation of steroids (CYP 7, CYP1 1B1 [70,71]), the 5-exo hydroxylation 
of D-camphor by CYP 101 [72] and the hydroxylation of precursors in the 
erythromycin biosynthetic pathway (CYP 107) [73]. 
Aromatic hydroxylation: Aromatic hydrocarbons are notoriously unreactive, the 
derivatisation of which (by conventional chemical synthetic routes) often requires the 
use of forcing conditions. The electron-rich nature of these compounds make 
hydroxylation a particularly difficult reaction to achieve in vitro. P450s can catalyse 
aromatic hydroxylation under mild conditions. The most common mechanism 
involves initial arene epoxidation, followed by epoxide ring opening, hydride 
migration to the generated carbocation, and the subsequent tautomerisation of the 
ketone to give the hydroxylated product [74] (Figure 1.14). This mechanism has been 
termed the NIH shift. Aromatic hydroxylation has been observed for P450s from 
hepatic microsomes. 
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Figure 1.14: The mechanism of the NIH shift for the aromatic hydroxylation by cytochrome 
P450 
Heteroatom Dealkylation and oxygenation: P450s have been shown to add oxygen 
to, and remove alkyl groups from, heteroatoms within organic substrates. The 
reactions are limited to compounds containing N, S, P and halogens as heteroatoms. 
The mechanisms for N-dealkylation and N-oxidation are shown in Figure 1. 15, 
reactions with sulfur and phosphorus are presumed to follow an analogous 
mechanism., although evidence is limited. As shown in Figure 1.15, oxidation of 
alkylamines can result in either N-dealkylation or N-oxidation [75,76]. N-oxides are 
uncommon products, but tend to be favoured over N-dealkylation reactions when the 
nitrogen atom is locked in a ring system. 
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Figure 1.16: An example of the unusual C-C bond cleavage reaction of cylochromes P450. The 
conversion of cholesterol to pregnenolone catalysed by P450 scc. 
Oxidative bond cleavage: The oxidative cleavage of a C-C bond is an example of an 
unusual, yet vitally important, reaction catalysed by P450s. Illustrative of this is 
P450scc which is involved in the metabolism of cholesterol to pregnenolone [77]. 
The oxidative cleavage is the last of three sequential oxygenation steps catalysed by 
the mitochondrial enzyme (Figure 1.16), each involving the consumption of 1 mole 
of NADPH and oxygen. The first two steps involves straightforward carbon 
hydroxylation to generate the 20(S),22(R)-dihydroxy cholesterol [78]. Whilst the 
first two steps are typical reactions, the mechanism of the third C-C cleavage step is 
of mechanistic interest. This step can be considered to occur via one of two possible 
mechanisms, involving either an alkoxy radical or the formation of an iron-
hydroperoxide intermediate with either the 20(S)-, or 22(R)-hydroxyl group. 
Members of the CYP1 1A1 (14a-demethylation of lanosterol) and CYP 17A 
(progesterone 1 7a-hydroxylase/l 7,20-lyase) families are also implicated in oxidative 
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Figure 1.17: A selection of substrates illustrating the wide variety of molecules which act as 
substrates for cytochromes P450. Shown are the A: nitric oxide (P450 nor), B: ethanol (P450 
2E1), C: N-nitrosodimelhylene (P450 2E1), D: camphor (P450cam), E: caffrmne (P450 1A2), 
F: 6-deoxyerythronilide B (P450 EryF), G: cholesterol (P450scc) and H: fatty acids (P450 4A 
and P450 BM3). 
Substrate types: 
A selection of P450 substrates is shown in Figure 1.17, as an illustration of the 
diversity of specificities displayed by members of the P450 superfamily. These range 
in size and reactivity from small diatomic molecules such as nitric oxide (substrate 
for P450 nor) to large polycyclic compounds such as steroids (eg. substrate for 
P450 scc). For a more comprehensive compliation of the variety of P450 substrates, 
the reader is directed to http://www.icgeb.trieste.it/—p450srv. 
1.1.7 Flavocytochrome P450 BM3 
In 1986, Nahri and Fulco reported the barbiturate-induced expression of an 
immunologically cross-reacting, 119 kDa P450-containing fatty acid hydroxylase 
OW 
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from a number of strains of Bacillus megaterium [81]. The soluble P450-containing 
protein from strain ATCC 14581 is known as flavocytochrome P450 BM3 
(P450 BM3) [82]. It is an example of a Class 3 P450, binding all of the necessary 
redox cofactors in one continuous polypeptide. P450 BM3 is comprised of a 55 kDa 
N-terminal b-type heme-binding cytochrome domain, linked via a short, trypsin 
cleavable, hydrophillic linker to the 66 kDa C-terminal FAD/FMN containing 
reductase [83]. P450 BM3 is a catalytically self-sufficient fatty-acid hydroxylase,' 
activity is observed in the presence of substrate, oxygen and NADPH without the 
requirement for additional redox cofactors. The sequence of the intact 
flavocytochrome [84] was established in 1989 and provided evidence for its 
synthesis as a single continuous polypeptide (Appendix III) - the DNA encoded both 
domains within the same continuous reading frame. It has the highest activity of any 
isolated P450 to date, probably as a result of the close association of the redox 
cofactors, and the requirement for intramolecular as opposed to intermolecular 
electron transfer. 
Substrate specificity of P450 BM3 
P450 BM3 catalyses the subterminal (o-n, where n = 1-3) hydroxylation of saturated 
and non-saturated long chain fatty acids, modest activity toward long chain alcohols 
and amides [69], as well as the mid-chain epoxidation of monounsaturated fatty acids 
[85] has also been reported. The crystal structure of the substrate-free [86] and 
palmitoleate-bound [87] forms of the heme domain of P450 BM3 have been solved, 
and enable an insight to be gained as to the reasons for, and determinants of, the 
observed substrate specificity. In contrast to the compact active site of P450cam [88], 
the active site of P450 BM3 consists of a long, hydrophobic channel, extending from 
the distal face of the heme to the protein surface, ideal for the binding of long-chain 
fatty acids. The hydrophobicity of the active site is a major factor in substrate 
binding, facilitating the partitioning of these lipophilic substrates from the aqueous 
bulk solvent, e.g. it has been shown that linear hydrocarbons (e.g. dodecane) can act 
as substrates. In addition to these hydrophobic effects, a number of residues located 
within the active site provide important interactions, these are discussed in detail. 
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Y51/R4 7 binding motif At the mouth of the active site are located the residues Y5 1 
and R47. Fatty-acid substrate binds to P450 BM3 and forms two important 
interactions with the carboxylate head, namely a hydrogen bond from Y5 1 and a salt 
bridge to R47 (Figure 1.18). Site-directed mutagenesis studies have shown that the 
formation of the salt bridge to be the most important of the two interactions, whilst 
Y5 1 may play a more important role in transition state stabilisation. 
F42: One further notable residue at the mouth of the active site is F42, which appears 
to cover the mouth of the active site, providing what might be termed a hydrophobic 
lid. Presumably the presence of such a lid would help to maintain the hydrophobicity 
of the active site, as well preventing water from disrupting the favourable R47 ion 
pair interaction. 
F87: Phenylalanine 87 is located at the base of the active site, whose conformation 
changes when substrate binds. In the substrate-free structure, the phenyl sidechain of 
F87 is at an angle, perpendicular to the heme plane, yet when substrate-binds, the 







Figure 1.18: Key active site residues in P450 BM3, implicated in substrate binding 
(Arg471Y5 I), the control of regiospecflcity  of hydroxylation (Phe87) and prevention of water 
entry into the active site during turnover (Phe42). Also shown are the substrate (palmitoleale), 
the heme, and the cysleine heme ligand (Cys400). 
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ring adopts a more parallel alignment relative to the heme. This feature has control 
over the regiospecificity of P450 BM3, as it prevents the 0)-terminus of the fatty acid 
from becoming hydroxylated. Consistent with this, substitution of F87 by alanine 
converts P450 BM3 from a fatty acid hydroxylase that hydroxylates at the w-1 to 0)-3 
positions, to one that performs terminal 0)-hydroxylation [89], a reaction not 
observed for wild-type P450 BM3 (yet one which is common to many mammalian 
P450s such as the members of the 4A1 family). This change in regiospecificity was 
also accompanied by a decrease in the Kd for laurate binding, suggestive of an 
increase in the affinity of the enzyme toward medium chain length fatty-acids (e.g. 
C12). 
Modelling studies have shown that the absence of the phenyl sidechain enables the 
0)-terminus of laurate to approach closer to the heme in the F87A mutant than in 
wild-type (0)-CH3 .... Fe = 5.1 and 3.1 A respectively) [45]. This may provide 
evidence for the mixed product distribution observed for wild-type P450 BM3, and 
the almost exclusive (> 90 %) 0)-terminal hydroxylation demonstrated by the F87A 
variant. 
Electron transfer in P450 BM3: 
As mentioned earlier, flavocytochrome P450 BM3 is a catalytically self-sufficient 
fatty acid hydroxylase. As a result, it provides a unique system, ideal for studying the 
intimate steps which comprise the total electron transfer reaction from NADPH to 
product, without the complications that arise from protein-protein recognition and 
interaction steps required for other bacterial or eukaryotic systems. The driving force 
for the reaction is the large, positive difference between the midpoint potential of 
NADPH reduction (E0 = - 320 mV vs SHE) and that of the highly oxidising oxy-
ferryl speices (E 0 - + 1.8 V vs SHE) [90]. The electron-transfer steps are outlined in 
Figue 1.19 and are discussed below. Hydride transfer from NADPH is the first step 
in the electron-transfer pathway in P450 BM3, and results in the transient formation 
of the two electron reduced hydroquinone form of FAD. The fully reduced FAD is 
thermodynamically less stable relative to either its semiquinone-form or the less 
negative potential FMN of the same domain, hence spontaneous, thermodynamically 
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Figure 1.19: Electron transfer steps inflavocytochrome P450 BM. Electrons are transferred to 
the FAD from NADPH by hydride transfer. Electrons are shuttled through the FAD and FMN 
and onto the heme at strategic points in the catalytic cycle. The red and blue arrows relate to 
the transfer of the first and second electrons through the FAIN to the heme respectively (as the 
FMN only cycles though its FMN(.,/FMNsQ states). 
favourable, electron transfer occurs from the FADH 2 to generate the FMNH2 
(reduction potentials for all of the species have been determined [40,91], and are 
shown in Table 1.2). In the case of the FMN, the two electron reduced hydroquinone 
form is more stable than its one electron reduced 
Table 1.2: Midpoint reduction potentials for the flavin cofactors in P450 BM3 
F0 ,, + 2e'+-> F 	(mV) F0,, + e' ++ 	(mV) Fsq + & +-* F 	(mV) 
diflavin FAD - 332 -292 -372 
diflavin FMN .203 -213 .193 
holoenzyme FAD - -289 - 
holoenzyme FMN -196 -216 -177 
FAD domain -303 -269 -337 
FMN domain -192 -206 -177 
semiqinone form. This stability is so pronounced that formation the FMN 
hydroquinone allows the formation of a three-electron reduced reductase, a dead-end 
complex from which heme reduction cannot occur. It has been proposed that the 
FMN cycles only through its oxidised and semiquinone states and that second 
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Figure 1.20: The crystal structure of the mammalian NADPH-dependent cytochrome P450 
reductase. The NADPH (red), FAD (green) and FMN (yellow) cofactors are clearly visible and 
in close proximity to eachother. 
electron transfer occurs via a thermodynamically unstable red anionic semiquinone 
[92]. The lifetime of this species is short and hence its reduction potential remains 
unknown so experimental conformation of this scenario is still required. 
The most probable route of interfiavin electron transfer is through-space (see Section 
1.2. 1) involving no intervening species, as the recently solved crystal structure of the 
mammalian P450 reductase [93] shows the FAD and FMN to be exposed and within 
van der Waals contact (Figure 1.20). Although the structure of P450 BM3 reducase 
has not been solved, sequence alignments show a high degree of identity between the 
two proteins, so the arrangement of FAD and FMN in P450 BM3 is likely to be the 
same. Electron transfer from the FMN to the heme occurs by 2 sequential, one 
electron transfers at appropriate points in the catalytic cycle, the first of which cannot 
occur until the long-chain fatty acid has bound (and induced the increase in reduction 
potential discussed in Section 1.1.5). Once substrate has bound, the first electron 
transfer to heme becomes more thermodynamically favourable. The sequence of 
events after first flavin to heme electron transfer (oxidising the FMN Sq to the FMN) 
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must be rapid, i.e. ferrous-oxy formation, else the transient FMN S semiquinone 
would decay prior to supplying the second reducing equivalent to the heme. Once 
oxygen has bound, the final electron transfer can take place (from FMN Sq to the 
FMN), committing P450 BM3 to the unavoidable sequence of events that lead to 
hydroxylation. Under low physiological concentrations of NADPH, P450 BM3 
reductase never becomes more than two-electron reduced. This is believed to be due 
to the tight binding of NADP which prevents recombination with another molecule 
of NADPH prior to the completion of the electron-transfer event [94]. At high 
concentrations of NADPH, the reductase can adopt an inactive three-electron 
reduced form, caused by the competitive displacement of NADP by NADPH. The 
formal route of FMN to heme electron transfer has not been established, although it 
has been discussed in a recent publication reporting the solution to the crystal 
structure of a complex between the FMN- and heme-domains to 2 A resolution [95]. 
The authors propose a convoluted route for protein mediated fiavin-to-heme electron 
transfer which is consistent with their structure (Figure 1.21), but which is unlikely 
for a number of reasons. These include non-stoichiometric equivalents of FMN and 
heme in the asymmetric unit, the excessively long edge-to-edge distance from FMN 
to heme and that a direct, through space route would be more appropriate than the 
doubtful proteinaceous pathway proposed. It is likely that the reported structure is an 
artefact of crystallisation and not a true representation of the catalytically competent 
electron transfer complex. Also, the linker region between the FMN and the heme is 
missing in the structure, suggesting the structure is that of two proteolysed 
fragments. 
The FMN in the mammalian P450 reductase structure is partialy exposed to the 
solvent, a feature which supports the idea that FMN to heme electron transfer is more 
likely to occur directly, through space, rather than through bond. In fact, a modelled 
complex [96] of the two fragments gave a single, energy minimised solution, with a 
more satisfactory distance of closest contact of 9 A, within which a through space 
model of electron transfer could be envisaged (Figure 1.22). This would also be more 
consistent with the high rates of heme reduction (wild-type, k1 1 = 360 s in the 
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Figure 1.21: The proposed FMN/P450 BM3 electron transfer complex. Panel A shows the 
relative orientation of the FMN domain (blue) with respect to the heme domain (orange). Panel 
B shows more clearly the orientation of the FMN relative to the heme, and the proposed 
through bond electron transfer pathway (black). 
1.2 Biological Electron Transfer 
The general principles by which cells obtain energy from their environment are 
central to cell biology. All animal and plant cells are powered by chemical energy 
stored in the chemical bonds of organic molecules. This stored energy is inaccessible 
to the cell directly, and hence must be 'extracted' in a usable form, this is achieved 
by a process of gradual oxidation, often catalysed by proteins. This oxidation is not 
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Figure 1.22: An energy minimised model oJ the interaction of the FAIN domain with the heme 
domain of P450 BM3. Here, the FMN (yellow) adopts a more likely orientation with respect to 
the heme ligand (Cys400, green), allowing a direct through space electron transfer (9,4) from 
the N5 nitrogen of FMN to the heme to be envisioned Also shown are Phe393 (cyan) and an 
intervening residue Asn537 (magenta). 
necessarily due to the direct reaction with oxygen, but due to the transfer (loss) of 
electrons. Often these molecules are substrates for oxidoreductases, which catalyse 
substrate oxidation, coupled to the reduction of a cosubstrate or cofactor. In 
oxidoreductases, there are three different classes of electron-transfer reaction [97]: 
Electron pair exchange: The cooperative removal or insertion of a pair of electrons 
(e.g. NADPH hydride transfer). Typical transfer distances 3- 6 A. 
Transduction: Involving a redox centre which can accumilate multiple electrons, yet 
which can transfer them in multiple, single electron transfer events (e.g. FMN of 
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P450 BM3 can accumilate two electrons from the FAD, yet transfers single electrons 
to the heme at strategic points in the catalytic cycle). 
Non-adiabatic electron transfer: The transfer of electrons between two weakly 
coupled intra- or inter-molecular redox centres e.g. in the capture of light energy 
during photosynthesis (driving the reduction of CO2 and H20 to generate 02 and 
carbohydrates), or in mitochondrial respiration (the four electron reduction of oxygen 
to water which drives ATP synthesis). 
1.2.1 Marcus Theory 
Traditionally, the enzymatic view of the chemical potential energy surface of an 
adiabatic reaction involves the energy minima of reactant and product separated by 
an activation barrier. The activation energy (i.e. the height of the barrier) can be 
empirically evaluated by measuring the temperature dependence of the reaction. 
However, it is difficult to estimate the height of this energy barrier based on the 
relative energies of the reactants and products alone. 
This problem is circumvented in non-adiabatic long range electron transfer, as the 
reactant and product energy surfaces are not strongly coupled. Marcus theory [98] 
describes a basic treatment for non-adiabatic, long range electron transfer, which 
considers the reactants and products as simple harmonic oscillators, lying in separate 
parabolic potential energy wells. In order for reaction to occur, the energy and 
nuclear configuration (according to the Franck-Condon principle) of the reactants 
and products must be identical: the point which corresponds to the intersection of the 
two parabolas (Figure 1.23). 
The activation energy, AG*, is related to the overall driving force, AG, and the 
reorganisation energy, ?. (the energy required to change the nuclear configuration of 




and hence to the rate of electron transfer according to the gaussian function: 
kET = kmax e-(AG-l-X) 2I4XkBT 
where kET is the oberved electron transfer rate, k n. is the electron transfer rate when 
AG* is zero and k11 is the Boltzmann constant. 
According to Marcus theory, for a given system, variation of AG (with constant A.) 
causes the parabolas to shift relative to each other, which has a direct effect on the 
rate of electron transfer. Three distinct cases can be observed and are depicted in 







Figure 1.23: A schematic diagram describing the relationship between free energy (G) and 
nuclear displacement (Q) for a typical electron transfer reaction between reduced (R) and 
oxidised (0) species. Electron transfer occurs at the intersection of the two parabolas. AG is 
the free energy change of reaction, zG*  is the activation energy and A is the reorganisation 
energy 
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Figure 1.24: Potential energy diagrams showing the conditions required for (a) 'normal' 
electron transfer, (b) 'activationless' electron transfer and (c) electron transfer in the Marcus' 
inverted' region. Axes are labeled as in Figure 1.23. 
inverted (X <-AG) regions. In the activationless region, there is no activation energy 
barrier to surmount, at this point, kET = k. The inverted region is counter-intuitive, 
as the activation energy for electron transfer increases as the driving force increases, 
slowing electron transfer. The variation of kET  with AG is shown in Figure 1.25. 
The electron transfer rate is proportional to the overlap of the donor and acceptor 
electronic wavefunctions across the space separating the electron donor and acceptor 
molecules, the greater the degree of overlap, the faster the rate. This overlap 
deteriorates exponentially with edge-to-edge distance (d) and is modified by a 
coefficient () which describes the contribution made by the intervening medium in 
propagating the wavefunction. The rate of decay is given the value P such that: 
cX e - ('/4(d-d)) 
This relationship yields a maximal electron transfer rate at van der Waals contact 
range for two redox cofactors (3.6 A) of 1013 51 which is consistent with the 
characteristic frequency of the nuclei considered in the Franck-Condon term, and the 
transient lifetime of the encounter complex. According to Marcus theory, the 
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Figure 1.25: The variation of the logarithm of the electron transfer rate constant (k) with free 
energy between reactants and products (4G). 
proportionality constant for the equation above is (47r 3/h2Xk BT).Ho2, where H0 is the 
coupling matrix element at distance d0. 
Values of P vary, depending on the nature of the intervening medium, in vacuo 
= 2.8 - 3.5 A' [99,100] and 0.9 A- ' for covalently bridged redox centres in 
synthetic systems [101] and 0.7 A- ' for a peptide bond. Dispute remains over the 
nature of 3 for a protein matrix, the two major schools of thought are discussed 
below. 
The through space model for electron transfer necessitates only a single value for 
(1.4 A'), with electron transfer occurring directly from donor to acceptor, regarding 
the intervening protein as a homogenous matrix akin to an organic glass 
[99,102,103]. The photosynthetic reaction centre form Rhodobacter sphaeroides has 
provided the majority of the experimental evidence for this hypothesis. The 















Figure 1.26: 1. A simplified representation of the photosynthetic reaction centre from the 
bacterium Rhodobacter sphaeroides, clearly showing the close proximity of the redox 
cofactors. Site P is a bacteriochiorophyl dimer (BChI2), B are bacteriochiorophyl monomers 
(BC/il), H are bacteriopheophytins (Bph) and Q are quinones. The approximate rate constants 
are given for the electron transfer steps indicated by the arrows. 
efficiency of the photosynthetic reaction centre is due to the well organised array of 
redox cofactors (Figure 1.26 Dutton 1992) which has evolved to optimise the 
harvesting of energy directly from the sun. The through space model provides a good 
description for these types of system, where the cofactors are sufficiently well 
arranged to maximise orbital overlap and facilitate electron transfer. Such specialised 
systems are the exception rather than the rule, and may not provide a suitable basis 
for a universally rigorous model for electron transfer. 
In such redox systems where the cofactors are less well organised, or the intervening 
matrix is more heterogeneous [104], the through bond model may be more 
applicable. This alternative description considers the route long range electron 
transfer to occur via a series of combinations of discrete tunnelling pathways through 
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Figure 1.27: Schematic diagram illustrating the various types ofpathways for electron transfer 
from donor (D) to acceptor (A): (a) direct through-space (thin continuous arrow); (b) through-
covalent bond (thick line); (c) through-bond and a hop through-space; (d) through covalent and 
hydrogen-bond (dotted line) pathways. 
covalent a-bonds, hydrogen-bonds, or short through-space hops which comprise a 
distinct pathway through the intervening medium [100,105,106]. A simplifying 
approximation can be made that the coupling through all covalent bonds is the same, 
and the coupling through a hydrogen bond is comparable to that across two covalent 
bonds, and that a through space hop is distance dependent (Figure 1.27). Evidence to 
support this model comes from the study of ruthenated derivatives of cytochrome c 
[107]. The variation in electron-transfer rates from ruthenated histidines at differing 
distance from the heme correlate better with the through bond model, rather than a 
single exponential dependence on distance. The azurin from Pseudomonas 
aeruginosa displays an anomalous rate of decay (1.1 k 1 ) as a result of a 
heterogeneous matix arising from preferential electron transfer through its 13-sheet 
domain as opposed to its a-helical domain [108]. 
1.2.2 Conclusions 
Whilst dispute remains over whether or not specific pathways are involved to 
mediate biological electron transfer, it is clear that rates are fundamentally dependent 
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on the distance of separation between the redox centres, the reorganisation energy for 
the process and the overall driving force of reaction. Obviously, the intervening 
protein serves a role in the mediation of electrons but can equally be thought of as an 
insulator or a conductor. The amalgamation of conducting and insulating regions 
could be considered as a homogenous glass, or the separation of conducting regions 
by insulating regions considered as a pathway. Interestingly, in the physiological 
cytochrome c:cytochrome c peroxidase complex, regarded as the quintessential 
example of an optimised through-bond electron transfer pathway (Figure 1.28), the 
route also constitutes the shortest through-space distance. 
Ultimately, the choice of through-bond vs through-space is likely to reduce to one of 
semantics, as there is evidence in support of both, but proponents of both models 
agree that the participation of the protein matrix is essential to propagate electron 
transfer (the rate of electron transfer through a protein is attenuated an order of 
magnitude slower than through a vacuum for each 1.7 A of separation between redox 
centres). In the absence of a universally consistent theory, it may be more acceptable 
to regard electron transfer from a dual perspective, combining features from both 
models where appropriate. In situations where a high density of redox centres are 
present (cell membranes, photosynthetic reaction centre etc.), a through space model 
would be more suitable, whereas if the redox centres were remotely spaced, a 
through bond, tunnelling approach could conceivably provide a selection of the 
minimally attenuated, favoured pathways. In many situations, the decision can be 
made intuitively, for example, if the edge-to-edge distance between donor and 
acceptor is a few angstroms, then electron transfer is more likely to proceed directly 
through space, as opposed to negotiating a convoluted through-bond tunnelling 
pathway. Conversely, if both donor and acceptor are buried within the protein, then a 
conduit for electron transfer may be expected and satisfied by a tunnelling pathway. 
Defined pathways such as these may act as control mechanisms, serving to promote 
the coupling of electron transfer solely between physiological redox partners, 
preventing the possibility of unfavourable transfers to other non-physiological redox 
cofactors in the cellular environment. 
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Figure 1.28: Illustration of the electron transfer complex between cytochrome c (orange) and 
its physiological redox partner yeast cytochrome c peroxidase (blue). The heme cofactors of 
each protein are shown in red. The proposed through bond electron transfer pathway is 
composed solely of residues from cylochrome c peroxidase (residues 191-194, black). Trp 194 
can act as a redox mediator itself by converting to/from  itsftee radical form. 
Statistically less probable events such as molecular collision, interprotein recognition 
and the dynamics of protein association (e.g. the intramolecular interaction of 
reductase and heme in P450 BM3, or the intermolecular association of putidaredoxin 
redcutase/putidaredoxinlP450cam) are more likely to have a governing influence 
over the absolute rate of electron transfer, than the precise route of electron transfer 
between cofactors. Once all of the relevant components of a redox system are 
assembled, and so long as the overall driving force of the reaction is large, the flow 
of electrons will occur regardless of either the nature of, or the route to, intermediates 
along the pathway. A metaphor for this would be the course of a river. Irrespective of 
the number of twists, turns, pools or waterfalls which obstruct the flow of water, the 
driving force (i.e. the height of the spring above sea level) is always sufficient to 
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convey the water downhill to the sea. The importance of distance can also be 
appreciated in this analogy, as although the river may meander its way to the sea, a 
shorter, hence faster path (i.e. a straight pipeline) can be envisioned. 
E 111 
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2 METHODS AND MATERIALS 
2.1 Site-Directed Mutagenesis (with Dr. C.S.Miles) 
Site-directed mutagenesis was performed by the Kunkel method of non-phenotypical 
selection [109], to generate the F393A, F393H and F393Y mutations. E. coil strain 
TG  [supE, hsdL5, thi, t(lac-proAB), F' [trai\36, proAB, laclq, IacZAM15]] was 
used for all cloning work and for overexpression of intact P450 BM3 and its 
component cytochrome domain. The preparation of plasmids for the overexpression 
of intact P450 BM3 (pBM23) and heme domain (P450, residues 1-472; pBM20) has 
been described in previous publications [110,111]. Mutants F393A, F3931-I and 
F393Y (intact) and F393A HI), F393H HD and F393Y HD (1-ID denotes Herne 
Domain) were constructed by oligonucleotide-directed mutagenesis of pBM23 and 
pBM20 respectively. Single-stranded DNA was prepared using the helper phage 
M13K07. Oligonucleotide primers used in the mutagenesis procedures are shown in 
Table 2.1 (mismatches are indicated by the underlined bases and the names of the - 
resulting expression plasmids are in parentheses). 
Table 2.1: Oligonucleotide primers used in the mutagenesis procedures 





5' CTGACCG1TFCCACGGTFTAAACGC 3' 




5' CTGACCGTTFCCAICGGT1TAAACGC 3' 
F393Y pCMI09 5' CCGTTTCCAThCGGTTTAAAC 3' 
F393YHD 	pCMI25 
To ensure that no secondary mutations had occurred, pCM 36, pCM37, pCM 109 and 
pCM 125 were sequenced by the dideoxy chain termination method. These plasmids 
were digested with restriction enzymes SnaBI and Spel, generating a 3 kbp fragment 
containing the required mutation. The SnaBlJSpel fragment was then ligated with the 
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4 kbp band liberated from a similar digestion of pBM23 (containing the WT P450 
BM3 coding sequence under the control of the native CYP 102 promoter) generating 
pJM1, pJM2 and pJM3 respectively. 
Mutants were overexpressed in E. co/i strain TG1 in an identical fashion to the 
wild-type clone. 
2.2 Transformation of E. coil 
5 to 10 ng of supercoiled plasmid DNA were added to 100 tl of competent E. co/i 
cells (pre-treated with 50 mM CaCl 2) in a 1.5 ml eppendorf tube and left on ice for 
30 minutes. The cells were then heat shocked at 42 °C for 90 seconds and returned to 
ice for 5 minutes. I ml of LB broth was added to the cells, and were subsequently 
incubated at 37 °C for 1 hour. The cells were then pelleted in a microfuge (I mm, 
12,000 g) and resuspended in 100 jil LB broth. Aliquots (25 pJ and 75 d) were 
spread onto LB-agar plates supplemented with 100 .tgml' ampicillin. The plates 
were incubated overnight at 37 °C. 
2.3 Growth of E. coil 
20 ml starter cultures of E. coil were grown in LB broth (Table 2.2) supplemented 
with 25 tgml final concentration of carbenicillin (1 pimF', 25 mgml' stock in 
ultrapure water), at 37 °C inoculated from single colonies on LB-agar plates using a 
sterile wire loop. Cultures were grown overnight in a shaker-incubator. A 1 ml 
aliquot from each starter culture was pelleted by centrifugation to check for 
overexpression (pale pink colouration). 
Different strategies were employed for the large-scale growth of the intact 
flavocytrochromes and the isolated heme domain proteins. Inacl fiavocytochromes: 
I ml of overnight starter culture was used to inoculate by sterile transfer, litre flasks 
(unbaffled) containing 400 ml of LB broth supplemented with 25 tgml final 
concentration of carbenicillin. Flasks were grown for 24 hours at 37 °C, 200 r.p.m. 
without induction (proteins constructed from clone pBM23 retained the native 
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CYP 102 promoter sequence, which allowed constitutive expression in the stationary 
growth phase) in a shaker-incubator. Heme domains: 1 ml of overnight starter culture 
was used to inoculate by sterile transfer, litre flasks (baffled) containing 200 ml of 
teriffic broth supplemented with 25 pgml 1 final concentration of carbenicillin. 
Flasks were grown for 6 hours at 37 °C followed by a further 42 hours at 30 °C, at 
100 r.p.m. without induction (under these conditions, the heme domain proteins were 
found to overexpress to high levels without the requirement for IPTG) in a shaker 
incubator. 
Cells were harvested by centrifugation (15 minutes at 6000 g) in a Sorvall RC-5B 
centrifuge, using a SLA 3000 head, and stored at —20 C as frozen cell paste prior to 
protein purification. Typical cell yields, harvested from 5 1 of either LB or TB culture 
were 20 g and 50 g respectively (wet weight). 
Table 2.2: Growth media and agar 
Luria Bertani broth (LB) 	per litre: 10 g Tryptone; 5 g Yeast extract; 5 g NaCI. 
Terrific broth (TB) 	per litre: 20 g Tryptone; 10 g Yeast extract; 4 ml glycerol (800 ml), 
KH2PO4 2.6 g; Na2HPO4 4.3 g (200 ml). 
Broth and buffer solutions were autoclaved separately to avoid 
precipitation. Once cooled, broth and buffer were combined by sterile 
transfer (to 1 litre total) and sub-divided into 200 ml growth volumes. 
All broths were prepared with Millipopre Q ultrapure water and autoclave sterilised at 121 °C and 
allowed to cool to room temperature prior to addition of carbenicillin. 
LB-agar plates 	 Agar 15 gr' dissolved in LB (Table 2.1) 
Sicrilised LB-agar solution was allowed to cool to the touch prior to 
addition of ampicillin (50 .&gr'). Cooled agar was poured into sterile 
petri dishes before solidification. Once poured, plates were kept 
refrigerated at 4 °C and used within I week of manufacture. 
2.4 Purification of Flavocytochrome P450 BM3 
The purification of both intact flavocytochromes and heme domain proteins of P450 
BM3 outlined here follow a well established protocol [112]. The procedure for the 
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purification of each type of protein is essentially identical and are treated as such in 
this section. Specific differences will be remarked upon where appropriate. 
Cell lysis 
Frozen cell paste was defrosted at room temperature prior to resuspension in 
approximately 50 ml of ice cold Buffer A (Table 2.3) to which was added 1 ml of 
60 mgml' PMSF (EtOH) to prevent proteolysis. Lysis was effectively achieved by 
the disruption of the E. coli membranes via ultrasonication. Care was taken to 
prevent overheating of the sample during this procedure and so was performed on 
ice. Somcation (Somprep 150, amplitude 15 microns) for 20 second bursts, 
interrupted by 1 minute periods of stirring in the absence of the ultrasonic probe was 
found to be adequate to maximise yield without denaturing protein. After lysis, cell 
debris was removed by centrifugation at 18 000 g for 1 hour (SS 34 head). The 
resultant supernatants, containing the desired protein, were pooled and kept on ice 
prior to further purification. 
Table 2.3: Buffer A 
50 mM Tris.HCI + 1 mM EDTA, pH 7.40 
Buffer A was prepared in MiIliQ ultrapure water, with the pH corrected by small aliqouts 
of conc. HC1. 
Ammonium sulfate fractionation 
The lysis supernatant was fractionated by the selective precipitation of unwanted 
protein by addition of ammonium sulfate. Solid ammonium sulfate was slowly added 
to the stirring supernatant to 30 % saturation (176 g1 1 ) over a 30 minute period. 
Unwanted proteins from this 30 % 'cut' were discarded as the 18 000 g centrifuged 
pellet. Further slow addition of ammonium sulfate from 30 - 60 % saturation 
(198 gF') caused precipitation of both intact, and the heme domain of 
flavocytochrome P450 BM3. Continual stirring of the suspension at 4 °C for an hour 
ensured maximum yield. This 60 % cut was collected as the centrifuged precipitate, 
and the supernatant discarded. 
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Dialysis 
Prior to column chromatography purification, the 60 % ammonium sulfate pellets 
had to be equilibrated into Buffer A, this was achieved by dialysis. The salt pellets 
were reconstituted in approximately 20 ml Buffer A, and the resultant suspension 
poured into dialysis tubing (12 kDA exclusion limit). Dialysis was performed 
overnight at 4 °C against 5 1 buffer A to ensure the diffusion of ammonim sulfate and 
other small contaminants. The dialysate was centrifuged at 18 000 g to remove any 
aggregated protein. 
Column chromatography 
Extracted P45 Os were further purified by column chromatography. All steps were 
conducted at 4 °C. 
DEAE Sephacel anion exchange column: Sigma DEAE Sephacel anion exchange 
resin consists of diethyl-aminoethyl groups, covalently crosslinked to a cellulose 
matrix. When equilibrated to pH 7.4, the immobilised phase is positively charged and 
hence provides a favourable interaction with negatively charged regions of proteins. 
Typically, 50 ml of DEAE Sephacel was poured into a 30 x 2 cm glass column 
(Biorad) and equilibrated by elution of approximately 20 column volumes of buffer 
A through the resin. This ensured thorough pH equilibration and removed traces of 
storage solvent (ethanol). Protein was loaded directly to the top of the equilibrated 
column. When properly equilibrated, P450 BM3 adheres to the column, and forms a 
tight red band at the top with minimal migration. Once loaded, the bound P450 was 
washed with 10 column volumes of buffer A to remove any non-bound species. 
Elution of this semi-purified band was achieved by running a linear KC1 gradient 
(0 - 500 mM buffer A), fractions were collected in a Pharmacia fraction collecter, 
the 5 most intensely coloured fractions pooled and carried forward for further 
purification. Under this gradient, intact flavocytochrome P450 BM3 elutes at 250 
mM KC1, whereas the heme domain elutes slightly earlier at 200 mM KC1. Column 
regeneration was achieved by elution of 10 column volumes of 1 M KC1 in buffer A 
and subsequent re-equilibration by buffer A. 
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At this stage, the purity of the proteins was typically 25 % based on the UV/visible 
peak height ratio A4 1 9/A280. Pure intact, and heme domain P450 BM3 have 
A419/A280 = 0.5 and 2 respectively. This method uses the Soret peak height to 
quantitate the amount of P450 and the UV peak height as a crude measure of total 
protein concentration [113]. 
Hydroxyapatite column: Hydroxyapatite (Biorad) is a calcium phosphate resin, 
although its interaction with proteins is not fully understood, the affinity is most 
likely to occur between the phosphate anions and positively charged regions of 
proteins, hence providing an opposite interaction to that observed for DEAE 
sephacel. Hydroxyapatite was suspended in 50 ml buffer 25 mM KPi (Table 2.4) and 
washed to remove finings (hydroxyapatite dust). This process was repeated until no 
finings were observed, at which point, the column was poured and the resin 
equilibrated further by elution with 10 column volumes of 25mM KPi. The pooled 
eluate from the DEAE sephacel column was dialysed against 5 1 of 25mM KPi and 
then loaded onto the hydroxyapatite column, forming a tight red band. After washing 
with 10 column volumes of 25mM KPi, the P450s were eluted with a linear gradient 
of 25 - 500 mM KPi. Fractions were collected in a Pharmacia fraction collecter, the 5 
most intensely coloured fractions pooled. Under this gradient, intact flavocytocbrome 
P450 BM3 elutes at 200 mM KPi, whereas the heme domain elutes slightly earlier at 
180 mM KPi. For the majority of experiments, the purity after this stage was 
sufficient to preclude further purification steps. However, for crystallography trials, 
additional steps were introduced to maximise purity. 
ADP agarose affinity chromatography: An additional chromatography step was 
introduced to maximise the purity of intact flavocytochrome P450 BM3. The 
NADPH-binding region of the reductase portion of intact P450 BM3 interacts with 
immobilised N6-(6-aminohexyl) adenosine 2'5' bisphosphate molecules, covalently 
bound to the agarose resin. This provides a highly specific interaction allowing 
ultimate discrimination between P450 BM3 and other contaminants. ADP agarose 
was equilibrated by washing with 10 volumes of buffer A, and poured to form a 10 x 
1 cm column. Intact P450 was loaded onto the gel with the formation of a tight red 
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band which was washed with 10 column volumes of buffer A. The band was eluted 
with 10 mM NADP in buffer A. Excess NADP was removed by exhaustive 
dialysis. 
Strong anion exchange chromatography: The use of a Q-Sephasrose (quaternary 
ammonium bound to agarose) strong anion exchange column was employed to 
further purify the heme domain proteins of P450 BM3. This step was essentially the 
same as outline for the DEAE Sephacel chromatography, except that the purification 
was conducted on a pre-packed HiLoad Q-Sepharose column (Pharmacia) attatched 
to a Pharmacia FPLC. Bound protein was washed with buffer A, and was eluted by 
the linear gradient 0 - 500 mM KC1 in buffer A. Under these conditions, the heme 
domain of P450 BM3 eluted at 230 mM KC1. 
P450 concentration and storage 
Purified P45 Os were dialysed against buffer A and concentrated to 200 jiM by 
ultracentrifugation (using Amicon Centripreps, 30 kDa cut-off), followed bydia1ysis 
into the storage buffer (Table 2.4) and were frozen at —20 °C until required. Proteins 
were used with 1 month of manufacture. 
Table 2.4: Phosphate and Storage buffer 
Buffer 25 mM KPi 25 mM K2HPO4 /25 mM KH2PO4 . pH 6.5 
Buffer made up in MilliQ ultrapure water. pH adjustment achieved by titration 
of 25mM KH2PO4 into 25 mM K2HPO4 
Storage Buffer 	30 % glycerol in Buffer A 
2.5 SDS PAGE 
SDS PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoesis) was used to 
verify the purity of purified P450 BM3 and also to check that intact P450 M3 had not 
become cleaved during purification. Protein separation by molecular weight [114] on 
a denaturing gel should lead to a single band of 119 kDa for the intact P450 BM3, 













Figure 23: Example SDS PAGE gel showing the relative molecular weights of intact (119 
kDa) and the heme domain (55 kDa) of wild-type flavocytochrome P450 BM3. 
and a single band of 55 kDa for the heme domain. Figure 2.1 shows and example gel 
for wild-type P450 BM3 in both its intact and heme domain preparations. 
Gel preparation 
A typical SDS gel is comprised of two regions of different composition. The first 
region consistutes 4/5 of the total gel and is termed the resolving gel - the portion of 
the gel within which the proteins are separated. The second region consitutes 1/5 of 
the total gel, and is termed the stacking gel - this helps to concentrate the loaded 
proteins prior to them being drawn through the resolving gel. The composition of the 
two gels, and their associated buffers are shown in Table 2.5. The components of the 
resolving gel were mixed (addition of TEMED as the final ingredient initiated 
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polymerisation) and the polymerising gel poured between two glass plates. Water-
saturated butanol was added to the top of the resolving gel in order to form a clean 
Table 2.5: SDS PAGE gel preparation 
Resolving gel 	Protogel (30 % acrylamide, 0.8 % bis acrylamide); 10 ml 
4 x resolving buffer (below) 
(10 %; 30 ml) 	 7.5 ml 
H20 
12.3 ml 




Resolving buffer 	H20 	 750 ml 
(4 x) 	 Trizrna base 	 181.6 g 
SDS 	 4.Og 
c.HC1 (added to adjust to pH 8.8) 	 10 ml 
H20 (added to take to final vol 1 L) 	 250 ml 
Stacking gel 	Protogel (30 % acrylamide, 0.8 % bis acrylamide); 1.6 ml 
4 x stacking buffer (below) 
(5 %; 10 ml) 2.5 ml 
H20 
5.9 ml 




Stacking buffer (4 x) 	H20 400 ml 
Trizma base 30.3 g 
SDS 	 2.Og 
c.HCI (added to adjust to pH 6.8) 	 15 ml 
H20 (added to take to final vol 0.5 L) 	 100 ml 
interface between the resolving and stacking gels. The gel was left to set (1 hour) and 
the butanol layer poured off. The stacking gel was mixed in an analogous fashion, 
and poured on top of the resolving gel, a comb was inserted into the unset stacking 
gel to create sample wells. 
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Electrophoresis 
The set gel was clamped into a vertical electrophoresis tank which was filled with 
running buffer (Table 2.6). The comb was removed and protein samples (prepared in 
sample buffer and boiled for 60 seconds) injected into the vacated wells. 
Table 2.6: SDS PAGE electrophoresis conditions 
Sample buffer (2x) 	H20 80 ml 
Tris.HC1 pH 6.8 (1M) 3.3 ml 
SDS 2g 
Glycerol 9 ml 
2-mercaptoethanol 5 ml 
Bromophenol blue (1 %) 1 ml 
Running buffer (5x) 	H20 500 ml 
Trizma base 15.1 g 
Glycine 94 g 
SDS 2g 
HCI (1M) added to adjust to pH 8.8 
Gel stain 	 H20 375 ml 
Isopropanol 125 ml 
Acetic acid 50 ml 
Coomassie brilliant blue 0.5 ml 
Destain 	 H20 50 ml 
Methanol 40 ml 
Acetic acid 10 ml 
The gel was connected to the power supply (200 V) and electrophoresed until the dye 
front reached the foot of the gel. After the removal of the gel from the 
electrophoresis tank, the gel was stained overnight and then destained to reveal the 
position of the migrated proteins. 
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2.6 Substrate and Ligand Binding 
Substrate and ligand binding to P45 Os are often accompanied by quantifiable changes 
in their absorption spectra. Perturbations causing a blue-shift in the ferric P450 
spectrum are typified by substrate binding and reduction, whereas perturbations 
causing a red-shift in the ferric P450 spectrum are typified by the ligation of 
exogenous ligands such as CO. CN- and imidazole. UV/visible spectroscopy 
provides a convenient route to measure the binding characteristics of such 
compounds (Figure 2.2). 
UV/visible absorption spectra were recorded over the 300-800 nm range using a 
Shimadzu 2101 spectrophotometer and quartz cuvettes of 1 cm pathlength. 
Typically, the concentration of wild-type or mutant P450 BM3 used was 1-5 j.M in 
1 ml of assay buffer (Table 2.7) at 30 °C. The total concentration of substrates or 
ligands added never exceeded 1 mlvi. Binding characteristics of certain ligands were 
investigated in both the ferric and ferrous forms of P450 BM3, addition of a 10 il 
aliquot of a S mgmr' solution of sodium dithionite was sufficient to achieve 
reduction anerobically. 
Fatty acid binding titrations 
For enzyme titrations with arachidonic acid, aliquots (0.1-0.5 p.1; not exceeding 5 p.1 
total addition) of a 33 mM solution (EtOH) were added to the enzyme solution. For 
enzyme titrations with sodium laurate, 10 p.1 aliquots of P450 BM3 were withdrawn 
and replaced with aliquots of a solution of enzyme at identical concentration in the 
same buffer, but containing in addition 1 mM sodium laurate. Spectra were recorded 
after each addition of substrate (Figure 2.3). Difference spectra were generated by 
subtraction of each spectrum recorded from the substrate-free spectrum. Substrate 
dissociation constants (Kd) were determined by plotting the maximal absorbance 
changes calculated from each difference spectrum against the concentration of 
substrate, and fitting the data to a rectangular hyperbola using Origin software 
(Microcal). 
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Figure 2.2: Absorbance spectra of wild-type P450 BM3 heme domain. Absolute ferric (black), 
ferric-substrate bound (Panel A, red line) and ferrous-CO bound (Panel B, red line). A 5 x 
magnification of the cu/i region is shown inset for clarity. 
Carbon monoxide binding 
Ferrous-CO complexes of wild-type and the mutant enzymes were prepared in the 
same fashion. P450 solutions were reduced by the addition 10 .tl of 5 mgmr' sodium 
dithionite solution and were converted to the P450-complexes by slow bubbling of 
the solutions with carbon monoxide gas (Sigma) for one minute. 
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Figure 2.3: Typical spectral perturbations induced upon substrate binding to wild-type P450 
BM3 (Panel A). Substrate binding dehydrates the heme iron, and causes a low-spin (A = 419 
nm) to high-spin (A = 392 nm) transition. Inset is a series of difference spectra, generated by 
substration of substrate-free spectrum from each substrate-bound spectrum. Panel B describes 
the relationship between maximal absorbance change (A.4.4 390. 22, difference spectra) versus 
substrate concentration. The data is fitted to the Michaelis-Menten equation, from which 
substrate dissociation constants can be evaluated The equation used to fit the data shown in 
Panel B is shown inset. 
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Table 2.7: Assay buffer 
20 mM MOPS + 100 mM KCI, pH 7.4 
Assay buffer was prepared in MilliQ ultrapur water, with the pH corrected by small 
aliqouts of 5 M NaOH 
2.7 Steady-State Kinetics 
All steady-state kinetic measurements were performed at 300  C in assay buffer using 
1 cm pathlength quartz cuvettes. Initial rates of fatty acid (arachidonate and laurate) 
oxidation were measured as described previously [115], by monitoring the oxidation 
of NADPH at 340 nm (6340 6.21 mM cm') with 10-100 nM enzyme and NADPH at 
saturating concentration (200 LM). The initial arachidonate concentration was varied 
by addition of small volumes (<2.0 i.tl) from a 33 mM or 3.3 mM ethanolic stock 
using a 10 j.tl Hamilton gas-tight syringe (Hamilton, Reno, NV, USA), and the initial 
laurate concentration was varied by dilution of a 1 mM aqueous stock. Rate 
measurements were converted into activity units, s 1 (mol of NADPH oxidised/sec 
per mol of P450) and plotted against fatty acid concentration (Figure 2.4). Data were 
fitted to the Michaelis-Menten equation (Appendix I) using Origin software. 
2.8 Stopped-Flow Spectrophotometry 
Stopped-flow spectrophotometry involves the rapid mixing of two equal volumes of 
two solutions within a spectrophotometric cell of fixed path length. On mixing, the 
instrument is immediately triggered to record the absorbance of the reacting solution 
and to generate a 'trace' with a specified time-base. The resolution of the instrument 
is limited by its dead-time, a value which is derived by calculating the time 
difference between the point at which the reaction can betraced back to (t = 0) and 
the point at which the absorbance is actually recorded (t = dt). The dead-time can be 
measured by recording any single exponential reaction over which the total 
absorbance change is known. The dead-time for the Applied Photophysics instrument 
is estimated to be between 0.9 - 1.1 ms. However, resolution is also impaired by the 
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Figure 2.4: The rectangular hyperbola in Panel A describes the relationship between reaction 
rate and substrate concentration for a typical enzymatic reaction, from which the turnover 
number (k) and the Michaelis constant (l(M)  can be evaluated. KM is defined as the 
concentration of substrate, which gives an initial rate of 0.5k,,,,. The equation used to fit the 
data shown in Panel B is shown inset. 
mixing time, a value which is more difficult to quantify. Once the two solutions are 
in the reaction chamber observation will begin, but until mixing is complete the 
reaction will not be up to maximum velocity and a lag will be observed. This 
phenomenon, as well as the dead-time itself, will depend upn the physical attributes 
of the reacting solutions, including temperature and viscosity. Generally, reactions 
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occurring faster than 1000 s_ I  are impossible to resolve and, depending on the dead-
time, a significant percentage of the absorbance change is lost. All stopped-flow 
experiments were conducted in an Applied Photophysics SF. 17 Micro Volume 
stopped-flow spectrophotometer path length 1 cm, at a single wavelength specified 
for each experiment. 
Kinetics of heme reduction 
Measurement of the rate of the first flavin-to-heme electron transfer step was 
performed at 30 °C as described previously [111] using CO-saturated assay buffer 
(-. 1 mM) [116] and monitoring the formation of the ferrous-CO adduct at 450nm 
using intact wild-type or mutant P450 BM3. Assay conditions are outlined in Table 
2.8. Both syringes contained assay buffer of identical substrate concentration 
(arachidonate or laurate), previously deoxygenated (by bubbling extensively with 
oxygen-free nitrogen) and saturated with CO by bubbling for 5 minutes. 
Table 28: Stopped-flow assay - heme reduction kinetics 
Syringe A 	 CO saturated assay buffer ([CO] 1 mM) 
200 .tM NADPH 
Substrate ([arachidonate] = 0— 80.tM) 
([laurate] = 0 - 1 niM) 
Syringe B 	 CO saturated assay buffer ([CO] 1 mM) 
1 -5 LM Enzyme 
Substrate ([arachidonate] = 0— 80 jiM)) 
([laurate] = 0 - 1 mM) 
Rates for each substrate concentration (kb,)  were obtained by fitting the progress 
curves obtained to a double exponential function using the Applied Photophysics. 
The kijm  values were calculated by plotting the observed rates Abs,  versus fatty acid 
concentration, and fitting the data to the Michaelis-Menten equation using Origin 
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software (in an analogous fashion to the evaluation of the steady-state kinetic 
measurements, see Section 2.7). 
Kinetics of oxyferrous formation and decay 
The rate of formation and decay of the oxy-ferrous complex of the heme domain of 
wild-type and mutant P450 BM3 were measured by anaerobic stopped-flow 
spectrophotometry. Measurements were conducted within a Belle Technology 
anaerobic glovebox with the oxygen conentration maintained at less than 5 ppm. 
Measurements were conducted at 15 °C in both the absence and presence of 
arachidonate (66 j.tM). Assay conditions are shown in Table 2.9. Wild-type and 
mutant P450 heme domain (20 —40 M) were pre-reduced by addition of 10 .t1 of a 
5 mgml sodium dithionite solution. Excess dithionite was removed prior to 
experimentation by elution of the reduced P450s through a pre-equilibrated Biorad 
DS-10 desalting gel-filtration column. Reduction was confirmed by UV/visible 
spectrometry on a Varian Carey 50 Bio spectrophotometer, also contained within the 
glovebox. The decay of the oxy-ferrous P450 complex (Fe 
2+
_02 —* Fe3 + 02) was 
monitored at 424 rim (substrate saturated) and at 380 nm (substrate-free), 
wavelengths at which the decay was monophasic and fitted well to a single 
exponential. 
Table 2.9: Stopped-flow assay - oxygen binding kinetics 
Syringe A 	 Anaerobic buffer (100 mM MOPS, pH 7.0) 
20-40 1tM reduced P450 
Substrate ([arachidonate] = 66 jiM) 
Syringe B 	 Air saturated buffer (100 mM MOPS, pH 7.0) 
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2.9 Redox Potentiometry 
Redox potentiometry was employed in the determination of the midpoint potentials 
of the Fe3 fFe2  redox couple of the heme domain of wild-type and mutant P450 
BM3. All redox titrations were conducted within a Belle Technology glove box 
under a nitrogen atmosphere, with the oxygen concentration maintained at less than 5 
ppm. Degassed, concentrated P450s (3 ml, 20 1.tM) were eluted through an anaerobic 
Biorad Econo-pac 1 ODG gel filtration column, pre-equilibrated with 100 ml degassed 
buffer (100 mM KPi, pH 7.0) immediately upon admission of the sample to the glove 
box. This ensured removal of all traces of oxygen. 
Enzyme solutions were titrated electrochemically according to the method of Dutton 
[117] using sodium dithionite as reductant and potassium ferricyanide as oxidant. 
Electrochemical mediators were added (Table 2.10) to facilitate electrical 
communication between enzyme and electrode, prior to titration. After a sufficient 
equilibration period (typically 10-15 minutes) following each reductive/oxidative 
addition, visible spectra were recorded over a 300-800 nm range using a Shimadzu 
2101 UV-visible spectrophotometer contained within the anaerobic environment. 
Table 2.10: Redoxpotentiometry conditions 
Protein solution 	 3 ml, 20 mM P450 heme domain in 100 mM Kpi pH 7 
Electrochemical mediators 	1.0 jiM phenazine methosulfate 	 E0 	+ 30 mV 
5.0 tM 2-hydroxy-1 ,4-napthoquinone 	 -145 mV 
2.0 .tM FMN 	 -200 mV 
1.0 iM benzyl viologen 	 -310 mV 
0.3 .tM methyl violgen 	 -430 mV 
Reductant 	 30 mM Na2S204 	 - 450 mV 
Oxidant 	 20 mM K3Fe(CN)6 	 + 440 mV 
The electrochemical potentials of the equilibrated sample solutions were monitored 
using a CD740 meter (WPA) coupled to a Pt/calomel combination electrode (Russell 
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pH Ltd.) at 25 ± 2 °C. Both the substrate-free and substrate-saturated heme midpoint 
potentials were determined (Figure 2.5). For substrate-bound redox titrations, 
arachidonate was added to the sample prior to the titration. Conversion to the high-
spin form was observed spectrophotometrically as a shift from 418 to 390 nm. The 
KM values for arachidonate for all the enzymes studied were much lower than 
10 M. Therefore, 33 p.M arachidonate was sufficient in all cases to saturate the 
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Figure 2.5: Visible absorbance spectra showing the spectral shifts associated with reduction 
and re-oxidation of substrate-free and substrate-saturated (33 UM arachidonate) P450 BM3 
heme domain. Inset is a key showing the absorbance shifts with the appropriate redox states. 
The reduction/re-oxidation of all heme domains was freely reversible with minimal observed 
hysteresis. Complete reoxidation of the ferrous forms results in the regeneration of the initial 
ferric starting spectra (low- or high-spin). 
Calibration of the calomel electrode 
The calomel electrode used for the potentiometric measurements was calibrated prior 
to each titration to ensure accuracy. The electrode was calibrated using the 
Fe3t'Fe2  EDTA couple as a standard (+108 mV vs SHE). A factor of +242 mV was 
employed to correct relative to the standard hydrogen electrode. The potential of 40 
p.1 of an Fe 3+  solution (720 p.M FeC13) was recorded initially, and after each 
successive addition of 3 x 10 p.l aliquots of an Fe 
2+  solution (71 mM 
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Figure 2.6: Calibration of the calomel electrode using the Fe3+/Fe2+ EDTA couple as 
standard The above plot should be linear, with an intercept y = -134 mV. This couple has a 
midpoint of + 108 mV vs SHE, so a factor of + 242 mV is employed to correct to the standard 
hydrogen electrode. 
Fe(NI-LI)2(SO4)2). A plot (Figure 2.6) of recorded potential vs log([Fe3]/[Fe24]) (i.e. 
proportion reduced) was linear (intercept = -134 mV) and confirmed the integrity of 
the electrode. 
2.10 Coupling Efficiency 
The coupling of NADPH consumption to product turnover is an important concept as 
it is a measure of the suitability of a substrate is for a particular P450, of enzymatic 
efficiency, and as a probe of how specific mutations effect catalysis. Two methods 
were employed to determine the degree of coupling for wild-type and mutant P450 
BM3 with arachidonate. 
Horseradish peroxidase/o-dianisidine assay 
This simple spectrophotometric assay was used to determine the degree of 
uncoupling to peroxide [118] (the 2 electron reduction of oxygen). The consumption 
of NADPH was monitored in the presence of saturating concentrations of substrate 
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(33 p.M arachidonate) and catalytic concentration of enzyme (ca. 0.2 p.M). The initial 
concentration of NADPH was calculated from its absorbance spectrum 
(E34 
= 6.21 mM'cm'). After complete depletion of NADPH, 40 j.il of 8mM 
o-dianisidine and 10 p.1 of 5 mgml' horseradish peroxidase were added to the 
cuvette. The peroxide generated from the P450 uncoupling pathway reacts 
stoichiometrically with the o-dianisidine to form a blue radical cation with an 
extinction coefficient of Cwo = 11.6 mM 1 cm'. The degree of uncoupling to peroxide 
can be calculating by comparing the concentration of NADPH consumed to ODRC 
produced. 
Negative-ion Electrospray Mass Spectrometry 
The overall coupling P450 efficiency (to account for all uncoupled species, e.g. 
superoxide, peroxide and water) for wild-type and the mutant holoenzymes was 
determined by negative-ion electrospray mass spectrometry. 
Turnover assays were performed on each P450 under limiting concentrations of 
NADPI-I and excess arachidonate and oxygen (980 p.1 20mM MOPS pH 7.4, 4 p.1 
33mM arachidonate, 5 p.119.7 mM NADPH and 10 p.! 4 p.M P450). Reactions were 
initiated by addition of P450. The air-saturated concentration of oxygen in aqueous 
solution [119] was - 260 p.M. Under these conditions, NADPH consumption can 
only be coupled to product formation or oxygen reduction (due to the absence of 
other electron acceptors in the assay and with both [substrate] and [oxygen] in excess 
of [NADPH]). Samples of each reaction mixture were injected into the mass 
spectrometer (Micromass Platform electrospray mass spectrometer) and analysed 
under the following conditions: ESI-ve, cone voltage = 35 V. acquired range 150 - 
500 Da. The concentration of unreacted substrate (mlz = 303) and hydroxylated 
substrate (mlz = 319) in each reaction mixture was evaluated from the total ion 
current for each peak (MassLynx software). The concentration of NADPH was 
calculated from its absorption spectrum (o = 6.21 m1vf'cm). All appropriate 
controls were run, and under these conditions no interfering signals from NADPH, 
buffer or enzyme were observed, with monohydroxylated arachidonate being the 
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only observable product. The reactions were performed at 30 °C and conditions were 
optimised so that each reaction proceeded to completeness (total consumption of 
NADPH) within 30 seconds of initiation by addition of the catalytic concentration of 
enzyme. 
Percentage coupling was calculated from the relative stoichiometries of NADPH 
consumed to product formed, and is an average of 4 separate experiments. 
2.11 Herne Content Determination 
In certain cases, mutagenesis of residues in, or close to, the heme binding site of 
hemoproteins can lead to the dissociation or poor incorporation of heme. This 
problem is more acute for P45 Os, whose b-type heme is non-covalently bound to the 
protein. It is important to quantify heme content as heme loss could be a result of an 
introduced mutation, or could explain changes in measured activity. 
The concentration of P450 was based on the total heme content, determined by the 
pyridine hemoebromagen assay [120]. A solution of P450 (5 PM) was throughly 
mixed with and equal volume of reagent A (Table 2.11), followed by the immediate 
addition of 10 j.tl of 5 mgmi' Na2 S204 solution. Spectra of the reduced pyridine 
Table 2.11: Pyridine hemochromagen assay 
Reagent A 	 200 p.1 of 5 M NaOH 
2.5 ml pyridine 
2.3 ml H20 
Reductant 	 10 p.1 Na2S204 in H20 
Pyridine hemochromagen characteristics 	 = 22.1 mM'cm' 
a-band = 556 mm 
n-band = 524 nm 
y-band = 420 nm 
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hemocbromagen were recorded in 1 ml quartz cuvettes. Herne concentrations were 
calculated using the difference extinction coefficient LC55540 = 22.1 niM'cm 1 
[121]. The appearance of the reduced pyridine hemochromagen was time-dependent 
and so sufficient equilibration was allowed following the addition of dithionite. Each 
determination was performed in triplicate to ensure accuracy. 
2.12 Protein Crystallography (with Dr. C.G. Mowat) 
Crystallization of the heme domains of the F393A, F393H and F393Y mutants of 
P450 BM3 was carried out by hanging drop vapour diffusion at 4 °C in Lmbro 
plates. Crystals were obtained from wells whose composition are shown in 
Table 2.15. Plates of up to 1 x 0.3 x 0.3 mm were formed after about 1 week. 
Crystallisation conditions were the same for all mutants (Table 2.12). 
Crystals were immersed in well solution containing 22 % glycerol as a 
cryoprotectant, before being mounted in nylon loops and flash-cooled in liquid 
nitrogen. Data sets were collected at Daresbury and Hamburg synchrotron sources 
using a MAR CCD detector. All crystals were isomorphous with those of the 
hemoprotein domain of wild-type flavocytochrome P450 BM3 (unit cell dimensions 
of a = 59.4 A, b = 154.0 A, c = 62.2 A, and P = 94.70) [86] and had two molecules in 
the asymmetric unit. Data processing was carried out using the HKL package [122]. 
The wild-type P450 BM3 heme domain structure (PDB: 2HPD), stripped of water, 
was used as the initial model. Electron density fitting was carried out using the 
program 0 [123]. Restraints for the heme group were calculated from the CNS 
parameter file. Structure refinement was carried out using SHELX-97 [124]. 
Table 2.12: Crystallisation conditions 
Well solution 
	 Hanging drop 
40 mM MgSO4, 	 2 il, 41.7 mgml' protein 
100 mM Na PIPES, pH 6.5, 	 2 jtl well solution 
18-21 % PEG 8000 
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2.13 Product Characterisation (with Dr. A.J. Fulco) 
The products of the catalytic turnover of myristic acid (tetradecanoic acid) by wild-
type P450 BM3 and F393H mutant were determined using gas chromatography/mass 
spectrometry according to the following methodology. A Hewlett Packard 5971A 
GC/MS utilizing electron impact ionisation (70 eV) instrument was used to 
determine structural information on the monohydroxylated metabolites of myristic 
acid. Metabolites were generated by incubation of 120 PM myristate in the presence 
of 5 mM NADPH and a catalytic amount of P450 (Ca. 1 nM) in 2 ml samples of 
100mM K2HPO4/KH2PO4 pH 8. 
The metabolites were extracted into diethylether and converted to their methyl ester 
derivatives using diazomethane, before analysis by GC/MS. Chromatography of the 
samples was performed on a HP-35 capillary column (30 m x 0.25 mm id x 0.25 M 
film thickness) with a thermal gradient beginning at 100 °C for 0.5 mins and 
increasing to 200 °C at a rate of 5 °C/min for 5 min and then to a final temperature of 
250 °C at a rate of 10 °C/min. Injector temperature was set to 250 °C and the GC/MS 
transfer line was set at 280 °C. Column flow rate was set at 0.76 ml/min. 
The mass spectra of the products from the control run (wild-type P450 BM3) were 
used to identify each GC peak. Monohydroxylated products were identified by their 
characteristic fragmentation pattern [125]. The distribution of products was based on 
the relative peak area of the gas chromatogram, in which the total ion current was 
used to assess quantity. 
2.14 Electron Paramagnetic Resonance (with Dr. M.R. Cheesman) 
EPR spectra were recorded on an EPR spectrometer comprising an ER-200D 
electromagnet and microwave bridge interfaced to an EMIX control system (BrOker 
Spectrospin) and fitted with a liquid helium flow cryostat (ESR-9, Oxford 
Instruments) and a dual-mode X-band cavity (BrUker, type ER41 16DM). 
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2.15 Cytochrome P450cam 
Purified samples of cytocbrome P450cam were a generous gift from Dr. Luet Wong, 
Oxford University, and were used in the experiments outlined in Chapter 4. 
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Chapter 3: 
The role of phenylalanine 393 
Chapter 3: The Role of Phenylalanine 393 	 67 
The Catalytic Control of Fiavocytochron2e P450 BM3 
3 THE ROLE OF PHENYLALANINE 393 
3.1 Introduction 
Whilst the path of electron transfer through the NADPH-dependent P450-reductase 
can be rationalised by considering the close proximity of the NADPH, FAD and 
FMN cofactors (from examination of the crystal structure [93]), the formal route 
from the FMN to the heme in flavocytocbrome P450 BM3 has not been established. 
This is due in part to the absence of a crystal structure for the intact holoenzyme, and 
also due to controversy over the relevance of the recently reported Heme:FMN 
crystal structure complex [95]. 
Studies with the putidaredoxin reductase/putidaredoxinlP450cam ternary complex 
have demonstrated that the most likely interaction of putidaredoxin with P450cam to 
be electrostatic in nature [126,127], occurring at the proximal face of the heme [128]. 
Whilst the heme is buried within the hydrophobic core of P450cam, one of the heme 
proprionates and the cysteine ligand are partially exposed (Figure 3.1), allowing a 
plausible route for direct electron transfer between the ferredoxin and the heme. 
Modelling of P450cam with cytochrome b5 showed that the electrostatic association 
of a cluster of basic residues on the surface of P450cam with conserved acidic 
carboxylates of cyt b5, formed a convenient complex where the iron-to-iron distance 
was 18 A. The highly conserved phenylalanine residue Phe350 of P450cam was 
found to be located directly between the b5 (9 A) and P450cam hemes (4 A), 
implicating it in the mediation of electron transfer. Putidaredoxin contains a similar 
acidic binding surface and it is believed that the physiological association between 
P450cam and putidaredoxin occurs in the same fashion as that for the P450camlcyt 
b5 modelled complex. 
Although a number of basic residues are located in the vicinity of the proximal 
surface of P450 BM3, these do not appear to constitute a discernible patch, whereby 
an analogous (to P450cam) electrostatic interaction between the FMN- and heme-
domains could be formed. However, this type of interaction is likely to be less 
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Figure 3.1: Space-filled representation of the heme domain of P450 BM3 and of P450cam, 
showing the proximal surface of the enzymes. The heme (red) lies buried within the core of the 
P450s, and is only slightly solvent exposed. Also shown are the cysteine heme-liagand (green) 
and phenylalanine 393 (Phe350 in P450cam, blue). These residues are slightly more exposed in 
P450 BM3 than in P450cam. Darker grey regions highlight basic residues. These collectively 
form a patch in the vicinity of the heme in P450cam - the likely docking site for putidaredoxin. 
No analogous region is observed for the heme-domain of P450 BM3. This reflects the fact that 
electrostatic interactions between the reductase and the heme offlavocytochrome P450 BM3are 
less important (due to the arrangement of the redox cofactors in one continuous polypeptide) 
than for the formation of the ternary P450cam complex. 
important in forming the electron transfer complex in flavocytochrome P450 BM3, 
as the cofactors are pre-organised in a single protein. Despite these differences, the 
heme-proprionate and cysteine ligand of P450 BM3 are similarly exposed (Figure 
3.1) as those of P450cam, allowing a comparable path of direct electron transfer to 
be envisioned. 
Phenylalanine 393 of P450 BM3 is analogous to Phe350 of P450cam, and is one of 
the 4 highly conserved residues within what is termed the P450 heme-binding motif 
[129]. The high level of conservation of this residue implies its importance in the 
catalytic competence of P450s, mediation of electron transfer from the reductase to 
the heme is a likely candidate for its role. The results from mutagenesis studies 
designed to probe the role of this conserved phenylalanine in P450cam (F350), in rat 
P450 1A2 (F449) and rabbit P450 2E1 (F429) were inconclusive. In P450 1A2, F449 
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mutants showed diminished catalytic capacity and were affected in heme binding 
[130, 130a], whilst in P450 2E1, only an effect on heme binding was observed in 
F429 mutants [131]. None of these studies provided a satisfactorily comprehensive 
understanding of the role this phenylalanine plays in the P450 mechanism. 
Interestingly, the P450s in which this phenylalanine is not conserved (CYP 74: allene 
oxide synthase [132]; CYP 74: divinyl ether synthase [133]; CYP 8: prostacyclin 
synthase [134] and CYP 3: thromboxane synthase [135]) fall into a group which do 
not have to activate molecular oxygen. In all cases, the phenylalanine is substituted 
by either proline or tryptophan. Unlike typical P450s, these enzymes do not function 
as monooxygenases and do not require molecular oxygen or NAD(P)H dependent 
P450 reductase for activity. These examples catalyse rearrangement or isomerisation 
reactions, for which the activation of molecular oxygen is non-essential. This more 
subtle observation could be key to why a phenylalanine in close proximity to the 
heme ligand is necessary for conventional P450 monooxygenation. 
The aim of the research was to elucidate the role of phenylalanine 393 of 
flavocytochrome P450 BM3 by characterising both the kinetic and thermodynamic 
properties of a series of site directed mutants (F393A, F3931-I and F393Y). These 
were designed to probe how removal of steric bulk, aromaticity, hydrophobicity, 
introduction of charged residues and potential hydrogen-bonding interactions affect 
catalysis. 
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3.2 Results 
3.2.1 Overexpression and purification of mutant enzymes 
The successful overexpression and subsequent purification of the holoenzymes 
F393A, F393H and F393Y, along with the heme domains (HD) F393A HD and 
F393H HD and F393Y HD, immediately negated the previous assumption that 
phenylalanine 393 (Phe393) was essential for heme incorporation and stability. All 
mutant enzymes expressed to high levels, similar to wild-type, and remained stable 
when stored at —20°C. All of the enzymes generated a native-like P450 absorbance 
spectrum, with no P420 contribution. An absorption peak at 420 nm would indicate 
the presence of enzyme with non-cysteine heme ligation. 
3.2.2 Spectrophotometric analysis of carbon monoxide binding 
Typically, treatment of a sample of reduced P450 with carbon monoxide will 
generate the characteristic P450-CO Soret absorption at 450 run. This was the case 
for both wild-type P450 BM3 (Am = 449 nm) and the most conservative mutant 
F393Y. However, a -5 nm blue-shift in the P450-CO Soret absorption for mutants 
F393A (Amax = 444 nm) and F393H (Amax = 445 run) was observed (Figure 3.2). 
This shift in the Soret position of the F393A and F393H mutants relative to wild-type 
most likely reflects changes in the relative energies of the it and ir porphyrin 
molecular orbitals, caused by the mutations. This is likely to be to be due to change 
in the degree of iron it bonding to the porphyrin ligand. A blue shifted Soret 
absorption peak indicates stronger it bonding to the porphyrin ligand and weaker 
backbonding to ir molecular orbitals. Consequently the ir backbonding to the CO 
(Figure 3.3) molecule weakens in conjunction with the blue shift. Substitution of 
phenylalanine by either histidine or alanine appears to decrease the energy of the iron 
t2g orbitals, a suggestion which is supported by evidence that the ferrous-forms of 
mutants F393A and F393H are stabilised more so than in wild-type (ability to 
generate reduced spectra under aerobic conditions). The nature of the residue at 
position 393 appears to have an influence over this fundamental property of the 
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Figure 3.2: Comparison of the visible absorption spectra of the ferrous-CO complexes of wild-
type (black), F393A (red), F393H (blue) and F393 Y (green) P450 BM3. The spectra have been 
offset along the absorbance axis in the order indicated, for clarity. The Sores peak positions are 
blue-sh ifted by 4 nm (F393H), 5 nm (F393A) and 0 nm (F393Y) relative to that of wild-type 
(A = 449 nm, vertical line). 
heme. The most conservative substitution of phenylalanine (by tyrosine) does not 
appear to affect significantly the heme environment as its spectral properties are 
identical to wild-type. 
OFe1c :C0: 	 Fe
ll 	 :CO: 
00~ 0 
Fe" 	 Fe" 	:CQ: 
Figure 3.3: Schematic representation of the a-acidl,r-base character of carbon monoxide when 
ligated to ferrous iron. Back-donation (r) from the iron into the ,r  anti-bonding CO orbital 
destabilises the CO bond. A blue shfl in the Soret absorption, as observed for the F393A and 
F393H mutants, is indicative of a strengthening of the CO bond. This is a consequence of a 
decrease in the degree of it-back donation from a less electronegative heme than wild-type. 
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3.2.3 Fatty acid binding 
The values for the dissociation constants for arachidonate and laurate binding to 
wild-type P450 BM3 and the mutant enzymes F393A, F393H and F393Y are shown 
in Table 3.1. The major observation is that changing the nature of the side chain of 
residue 393 does not significantly alter the fatty acid-binding properties of the 
enzyme. 
Table 3.1: Substrate Dissociation Constants ('percentage spin conversion in parentheses) 
wild-type F393A F393H F393Y 
Arachidonate 	3.6 ± 0.3 (100) 2.6 ± 0.3 (97) 7.6 ± 0.5 (96) 4.2 ± 0.3 (100) 
Laurate 	241 ±9(48) 230±11(60) 525±10(47) 520±9(54) 
This is intuitive considering the fact that the mutation is on the opposite side of the 
heme to the substrate-binding channel. Although mutations of Phe393 appeared to 
have little effect on substrate binding, differences in the degree of spin state shift 
(low- to high-spin) associated with the dehydration of the ferric iron centre are 
apparent. For wild-type P450 BM3, there is a correlation between the degree of spin-
state conversion and both the Kd and chain length of saturated fatty acid substrates 
(Figure 3.4). 
Fatty acids of chain length C 1 5 and C16 (pentadecanoic and palmitic acids) have the 
lowest Kd values, and induce the largest degree of spin-state change. However, these 
substrates are highly insoluble in water. Laurie acid has better solubility in aqueous 
media (to approximately 1.2 mM) and has a Kd of 250 jiM. A much better substrate 
for P450 BM3 than any of the saturated fatty acids is the C20, tetra-unsaturated 
arachidonic acid (Kd 4 j.tM), which also has acceptable water solubility. 
Arachidonate induces a much greater spin-state shift than laurate (>95% and <60% 
respectively). Comparisons between the mutants and wild-type P450 BM3 show 
differences in the degree of spin-state conversion with laurie acid. The arachidonate-
induced (33 j.tM) spin-state shift for wild-type and all mutants was >95%, whereas 
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Figure 3.4: Comparison of the effect of binding substrates of different chain length has on the 
heme iron spin-state equilibrium. Substrate binding causes a low- to high-spin shift in the 
electronic configuration of the iron. In P450 BM3, the extent of the perturbation is directly 
related to substrate chain length. The binding of laurate (C 12 saturated fatty acid, red line) 
induces only partial (< 60 %) conversion to the high-spin form, whereas the binding of 
arachidonate (C20  zetra-unsaturated fatty acid, green line) induces almost complete conversion 
(>90 %) to it high-spin form, under saturating conditions. 
the laurate-induced (1.0 mM) spin-state shift varies across the series 
F393A>F393Y>WT>F393H, with F393A giving -42 % higher proportion of the 
high-spin form than wild-type P450 BM3 (see Table 3.1). 
3.2.4 Kinetics of fatty acid oxidation 
Although binding of the fatty acids was essentially unaffected by the nature of the 
residue at position 393, steady-state kinetic analysis (as outlined in Section 2.7) 
shows significant differences in the rates of turnover of the mutant fiavocytochromes 
compared to wild-type (Table 3.2). The background rate of NADPH oxidation in the 
absence of substrate was less than 0.3 mol NADPHIsec/mol P450, for all enzymes 
studied. For both arachidonate and laurate oxidation, the observed trend in k was 
WT>F393Y>>F393H>F393A. The differences in turnover are most obvious when 
arachidonate is the substrate, with 14-, 8- and 2-fold decreases in k for F393A, 
F393H, F393Y, respectively, compared to wild-type P450 BM3. Although the 
magnitude of the difference between wild-type P450 BM3 and the mutants is smaller 
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when laurate is the substrate, the trend is the same. Clearly some step in the catalytic 
cycle, other than substrate binding, has been perturbed and has become rate-limiting 
in the mutant enzymes. 
Table 3.2: Steady-State NADPH Oxidation Kinetics 
Arachidonate 	 Laurate 
k 	 K, 1 (.LM) 	 k. 	 KM (.tM) 
(s) 	 (sd ) 
wild-type 285 ± 3 4.7 ± 0.3 86 ± 2 288 ± 15 
F393A 21±1 2.7±0.3 29±1 19±3 
F393H 33±1 3.8±0.5 37±1 60±5 
F393Y 	 143 ±8 	9.5± 1.1 	65±2 	274±20 
The coupling efficiencies for wild-type, F393Y and F393H (-90 %) for arachidonate 
hydroxylation are all within experimental error of each other (Table 3.3) and suggest 
near exclusive coupling of NADPH oxidation to product formation. Whilst the 
coupling of the F393A mutant is lower than the other P450s studied, this decrease 
cannot fully account for the order of magnitude difference observed between the 
steady-state parameters for the F393A mutant with respect to wild-type. 
Table 3.3: Coupling efficiencies 
[Unreacted substrate] 	[Product] (jiM) 	% coupling 
(jiM) 
Wild-type 	 43 ± 3 	 89 ± 7 	 91 ± 11 
F393A 	 77±6 	 55±5 	 56±8 
F393H 	 53±4 	 79±6 	 81±10 
F393Y 	 39±3 	 93±7 	 95±11 
This indicates that all enzymes are catalytically functional, and that the lowered 
catalytic activity observed for all the F393 mutants is due to decreased rate(s) of 
steps in the catalytic cycle subsequent to substrate-binding and not as a result of the 
uncoupled reduction of oxygen. 
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3.2.5 Product characterisation (with Dr. A.J. Fulco) 
It is well established that wild-type P450 BM3 displays strict substrate-specificity for 
long-chain fatty acids, performing hydroxylation in a highly regio-specific manner. 
For wild-type enzyme, the sole hydroxylation products of palmitic acid are the co-1, 
o-2 and o-3 hydroxy derivatives [136,137]. The same trend has been demonstrated 
here for the hydroxylation of myristate (Table 3.4) by wild-type and the F393H 
mutant P450 BM3. 
The F393H mutant shows comparable affinity toward laurate and arachidonate as 
wild-type (Kd = -'250 j.tM and --'4 F.LM respectively). Characterisation of the F393H-
mediated turnover of myristate reveals an identical product profile to wild-type, 
Table 3.4: Product Characterisation 
Product Distribution (%) 
o)-2 	 o)-2 	 unreacted 
Wild-type 	 53.6 	 24.5 	 20.0 	 1.9 
F393H 	 57.7 	 22.5 	 15.0 	 4.8 
indicating that both the substrate specificity and the regiospecificity of hydroxylation 
is unaffected by the F393H substitution. There is a virtually identical product profile 
to wild-type, although there appears to be a slightly higher proportion of the 00-I 
metabolite with respect to the cD-3 product for F393H compared to wild-type. 
Notwithstanding this, the trend in regiospecificity between wild-type and the F393H 
mutant is the same (o)-l:0)-2:w-3:unreacted = 28:13:11:1 (12:5:3:1) respectively). 
There is a slightly higher proportion of unreacted myristate in the case of F393H 
turnover, resulting from the lower overall catalytic activity in this mutant, i.e. the 
F393H mutant turns over less myristate in the same time period as wild-type. 
The important result is that the substitution of phenylalanine 393 by histidine results 
in a mutant-form that retains the same selectivity for long-chain fatty acids and 
displays the same regiospecificity of hydroxylation as wild-type P450 BM3. 
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Similar product analyses were not conducted for the F393A or F393Y mutants, in 
light of the results from the F393H mutant and their similarity with the product 
profile of wild-type. 
3.2.6 Kinetics of heme reduction 
Stopped-flow experiments were undertaken to investigate whether the kinetics of 
flavin-to-heme electron transfer in the F393 mutants was affected. The rate of the 
first electron transfer step from the reductase FMN to the substrate-bound P450 BM3 
heme can be conveniently measured using CO-saturated buffer and monitoring the 
formation of the ferrous iron-CO adduct at 450 nm (as described in the Section 2.8). 
The observed initial fast-phase rate constants (kobs) for heme reduction were plotted 
against substrate concentration and fitted to a rectangular hyperbola (Figure 3.5). 
From these data, maximal apparent rates of first electron transfer to the heme iron 
(kiim) and apparent dissociation constants for the substrates (Kd) were obtained, and 
are shown in Table 3.5. The observed trend in k1j. F393A>F393H>>F393YWT 
was the reverse of that obtained from the steady-state turnover of both laurate and 
arachidonate. Thus, although steady-state experiments suggest an overall decrease in 
Table 3.5: Pre-Steady State Kinetics of Heme Reduction 
Arachidonate Laurate 
k, (s1) 	 JQ(M) k 	(s) KdQM) 
Wild-type 348 ± 17 	13.8 ± 2.0 172 ± 14 300 ± 65 
F393A 1176±78 	19.3±3.5 468±11 124±13 
F393H 832 ± 53 	13.3 ± 2.9 439 ± 20 291 ± 37 
F393Y 366± 11 	6.4±0.8 215± 10 400±42 
the turnover rates of these F393 mutant enzymes, the first flavin-to-heme electron 
transfer reaction is actually faster in all the mutant enzymes than in wild type. In the 
wild-type P450 BM3, the apparent rate of flavin-to-heme electron transfer (as 
measured by the formation rate of the ferrous-CO adduct) is 348 s', where the 
overall turnover rate of the enzyme is 285 s' (in the presence of arachidonate). 
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Figure 3.5: Example stopped-flow traces for the pre-steady-state heme reduction kinetics. 
Panel A shows an example slopped-flow trace for wild-type P450 BM3 in the presence of 980 
pM laurate, from which values of were obtained A plot of k,,,,s at different substrate 
concentration is shown in Panel B, from which ki, m  (the rate of heme reduction), was evaluated. 
See Section 2.8 for details. 
Clearly this microscopic rate is the major determinant of catalytic turnover rate, as 
observed previously [112]. However, with the F393A and F393H mutants, the 
situation is markedly different. For instance, in F393A, the flavin-to-heme rate is 
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1176 s' but the steady-state rate is only 21 s. Evidently, a step subsequent to the 
first electron transfer to the heme iron has become rate-limiting in these mutants. 
3.2.7 Generation of the oxy-ferrous complex 
Binding of oxygen to the ferrous wild-type heme domain and F393Y-HD was too 
transient to be monitored on a macroscopic time-scale, no absorbance spectrum for 
an oxy-ferrous species could be obtained for either of these enzymes. Addition of 
oxygenated buffer to the pre-reduced protein led to immediate oxidation to the ferric 
resting state, without noticeable formation of any oxy-ferrous intermediate. This was 
unsurprising considering that the oxy-ferrous intermediate has only been transiently 
observed for wild-type P450 BM3 at cryogenic temperatures [138]. However, the 
formation of the oxy-ferrous complex for the F393A-HD and F393H-HD were 
observed (Figure 3.6), in both the substrate-free and arachidonate-saturated (66 tM) 
forms. This result provides evidence of an increase in the stability of the ferrous-
form of the F393A and F393H mutants with respect to wild-type, i.e. the stable 
binding of oxygen to the heme for a appreciable period prior to eventual reoxidation 
of the heme. This supports the idea that the substitution of phenylalanine 393 alters 
considerably the reactivity of the P450 heme with molecular oxygen. 
3.2.8 Kinetics of oxy-ferrous decay 
Although the lifetime of the oxy-ferrous complex of wild-type and F393Y enzymes 
was too transient to record an absorbance spectrum, the pre-steady-state kinetics of 
the decay of the complexes (as well as those for F393A and F393H) could be 
comfortably measured using stopped flow sectrophotometry (as outlined in Section 
2.8). At the chosen wavelengths, the rate of decay (k 0ff) was exponential with time 
indicative of the first-order dissociation of superoxide from ferric heme (Table 3.6). 
Example traces for the decay of the oxy-ferrous complex of wild-type P450 BM3 are 
shown in Figure 3.7.The rate of formation of the oxy-ferrous complex was too fast 
for accurate evaluation, occurring within the dead-time of the stopped-flow. The 
results show that the stability of the oxy-ferrous complex of the F393Y mutant in 
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Figure 3.6: Visible absorbance spectra for the oxy-ferrous complex (black line) for substrate-
free (Panel A, A = 420 nm) and substrate-saturated (Panel B, A, = 424 nm) forms of the 
F393A mutant of P450 BM3. Inset is a 5x magnification of the a//i region for clarity.. 
wild-type. Yet F393A and F393H display considerably more stable oxy-ferrous 
complexes (between 18 to 40-fold) than wild-type. The complexes are also more 
stable in the presence, than in the absence, of substrate. Both of these observations 
correlate with the changes in reduction potential observed as a consequence of 
mutating F393 or the binding of substrate. The magnitude of the difference in /i0' 
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Table 3.6: Pre-steady stale kinetics of oxy-ferrous decay 
Substrate-free (A3 ) 	Substrate-saturated (A 424 ) 
k0ff(S) 	 k0ff(S') 
Wild-type 	 0.17±5.9x 10 	 0.12 ±4.5 x 10 
F393A 	 6.4 x 10-'± 1.9 x 10 -5 3.0 x IO ± 2.6 x io 
F393H 	 9.4 x 10-3±  7.7 x 10 -5 2.6 x 10 ± 1.3 x 10 
F393Y 	 0. 12 ± 4.2 x 104 	 0.10±1.2x10 
between wild-type and the F393A or F393H mutants in the presence of substrate is 
twice that in the absence of substrate, whilst the difference between their reduction 
potentials (hence driving force) is essentially constant (Figure 3.8). This suggests that 
the stability of the oxy-ferrous complex is not dictated solely by thermodynamic 
factors and that the physical presence of substrate plays an important role in the 
stability of this complex. This could be due to differences in the hydrophobicity or 
conformation of the active site induced upon substrate binding. 
3.2.9 Heme domain potentiometric titrations 
The substrate-free and arachidonate-saturated (33 tiM) reduction potentials of 
WT-HD, F393A-HD, F393H-HD and F393Y-HI) were measured in an attempt to 
establish effects of the mutations on the thermodynamic properties of these variants. 
Figure 2.5 shows the spectral shifts observed during the course of these 
potentiometric titrations. At the high P450 concentration (-•' 20 .LM) required for 
efficient communication between the P450/mediators/electrode, the absorption at the 
Soret maximum is much too high for accurate spectrophotometric measurement. A 
convenient part of the spectrum that reflects accurately the change in reduction state 
of the heme iron at this P450 concentration is the region between 460 nm and 470 
irni. Therefore, data for the substrate-free titrations at 465 nm were plotted against 
measured potential (mV vs SHE). Due to the spectral differences generated upon 
addition of substrate to the enzymes, substrate-saturated titrations were evaluated 
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Figure 3.7: Example stopped-flow traces for the time-dependent decay of the oxy-ferrous 
complex of wild-type P450 BM3 in the absence (Panel A) and presence (Panel B) of substrate. 
At the wavelengths monhtorea the data fits well to a single exponential (red line). 
potential (Figure 3.9). Data were fitted to a one-electron Nernst function, and values 
obtained are presented in Table 3.7. 
The first observation is that the reduction potential of the wild-type P450 BM3 heme 
iron has been more accurately re-determined in light of improved experimental 
techniques. The more negative reduction potential determined fits better to the 
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Figure 3.8: Comparison of the thermodynamic and kinetic factors effecting the stability of the 
oxy-ferrous complexes of the F393A and F393H mutants, and their comparison with wild-type 
P450 BM3. 
proposed redox organisation within P450 BM3. At this potential, the substrate-
induced redox switch [139] can still operate, since binding of substrate increases the 
reduction potential by 138 mV (to —289 mV) allowing electron transfer from 
NADPH, through the reductase and ultimately to the heme. 
Table 3.7: Heme Reduction Potentials 
E. (mV vs SHE) 
Wild-type HD 	F393A HD 	F393H HD 	F393Y HD 
Substrate-free 	-427±4 	-312±4 	-332±6 	-418±6 
Arachidonate-sat4 (331.LM) 	-289 ± 5 	-151 ± 4 	-176 ± 4 	-295 ± 6 
However, there is tighter control than previously imagined over uncoupling by virtue 
of the fact that the substrate-free heme potential is considerably more negative than 
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Figure 3.9: Heme-domain reduction potentials of wild-type and mutant P450s BM3. Overlaid, 
normalised one-electron Nernst curves showing the changes in the proportion of reduced 
species with reduction potential (vs. standard hydrogen electrode) are presented. The data for 
F393 Y-HD is essentially identical to WT-HD, and has been omitted for clarity. From these, the 
mid-point potentials of the substrate-free (Panel A) and arachidonate-saturated (Panel B) wild-
type heme domain (black), F393A-HD (red) and F393H-HD (blue) were determined (see Table 
3.7). The measured heme reduction potentials of both the F393A-HD and F39311-11D 
(substrate-free and substrate-saturated) mutants are considerably more positive than wild-type 
heme domain (between 95 and 138 m 0 suggesting stabilization of their ferrous forms. The 
substrate-induced redox shift, observed for wild-type, still operates in the F393A, F3931-! 
mutants as observed in wild-type. The nature of the residue at position 393 appears to control 
the thermodynamic properties of the heme. 
that of the physiological electron donor NADPH (E 0 = -320 mV) in the low-spin 
ferric form of wild-type P450 BM3. The midpoint potentials of the two mutants 
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F393A and F393H are considerably more positive than wild-type (E 0 = —312 and 
-332 mV respectively) and both display similar magnitudes of reduction potential 
shift upon substrate binding to wild-type (-140 - 160 mV shift). The more positive 
heme reduction potentials of these two mutants are also consistent with the higher 
rates of flavin-to-heme electron transfer observed. A thermodynamic consequence of 
the more positive reduction potentials of the heme iron is an increase in the 
stabilization of the ferrous form. 
This is borne out by the ability to generate the ferrous form (A = 410 nm) for the 
F393H and F393A mutant P450s aerobically, whereas this is achievable only under 
strictly anaerobic conditions for the wild-type P450 BM3. It is notable that the 
increase in reduction potential correlates to the relative size of the sidechain at 
position 393. As the steric bulk is decreased (Phe/Tyr -+ His - Ala), the reduction 
potential increases accordingly (E0 = 427/418 -+ -332---- -312 mV). 
3.2.10 Electron Paramagnetic Resonance 
Figure 3.10 shows the perpendicular-mode X-band EPR spectrum of F3 93 H, 
recorded at 10 K using 2.01 mW microwave power. The g-values of features 
discussed are indicated on the figure. Minor signals at g - 5.8 and 4.3 are due to trace 
amounts of high-spin ferric heme and adventitious Fe" ion respectively. The three 
major features at g = 2.43, 2.25, 1.92 are characteristic of a low-spin ferric heme and 
are virtually identical to those for the F393A and F393Y mutants and previously 
reported for the wild-type protein [140,141]. These g-values are typical of native 
low-spin ferric P450s and nitric oxide synthases (NOS) in which the heme is bound 
axially by cysteinate and water and also match those of adducts in which the water is 
displaced by a range of oxygen-donor ligands [42,142-144]. The position of these 
bands was the same for all of the mutants. 
3.2.11 Crystallography (with Dr. C.G. Mowat) 
The crystallographic results will not discussed in detail, as the solution to the 
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Figure 3.10: EPR spectrum of ferric P450 BM3 F393H heme domain. The spectrum was 
recorded at 10 K, using a 1 m T modulation and 2.01 m W microwave power. Sample 
concentration was 218 1uti4. The g-values of 2.43, 2.25 and 1.92 are typical of low spin, ferric 
heme. Signals at g - 5.8 and 4.3 are due to small amounts of high spin ferric heme and 
adventitious iron. 
pertinent features of the structures are referred to. Detailed results for the solution of 
the F393H HD are reported in Ost et a! 2001 (PDB: liME) [125], the structures of 
F393A and F393Y are as yet unpublished. 
The substrate-free crystal structures of the F393 mutants (all solved to 2.0 A) 
clearly shows the substitution of the six membered phenyl sidechain of phenylalanine 
by either methyl (F393A-HD), imidazole (F3931-I-HD) or phenol (F393Y-HD), 
Figure 3.11. In the case of the F393H-HD and F393Y-HD mutants, the side-chain of 
residue 393 adopts a very similar position to the phenylalanine of wild-type, 
sandwiched between the side-chains of Pro392 and Gln403, with no major 
conformational changes of surrounding residues as a result of the mutation. In the 
F393H-HD structure, a solvent water molecule positioned on the opposite side of 
His393 to the heme, is hydrogen-bonded to N61 of the histidine side-chain (N ... O = 
2.77 A). The apparent protonation state of this histidine and the presence of an 
intermolecular hydrogen-bond to water, appears to preclude the formation of an 








Figure 3.11: Panels A-D show the crystal structure of the heme and the backbone chain of the 
heme-binding loop (residues 393-400) of (a) P450 BM3 wild-type, (b) F393A, (c) F393F1, 
(d) F393 Y mutants. The dotted circle highlights residue 393. The two different views indicate 
the position and orientation of the sidechain of residue 393 relative to the heme and the 
cysleine ligand 
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electron density for the G1n403 residue suggests that it is conformationally flexible, 
capable of adopting one of two possible orientations with the amide group pointing 
toward or away from the heme. Refinement of the structure favoured adoption of the 
former conformation, with an estimated occupancy of Ca. 85 %, whereby the amide 
head of G1n403 moves to accommodate the space created by the substitution of 
phenylalanine393 by alanine (Figure 3.12). 
Table 3.8 lists key structural parameters of the substrate-free wild-type HD and 
F393X HD (X = A, H or Y) mutant crystal structures. 
Table 3.8: Key Structural Parameters 
Structural Feature 
Fe ... S (A) 	F393X ... Cys400 F393X ... heme (A) 	L Fe-S-Cys (°) 
(A) 
Wild-type HD 2.05 3.67 3.57 111.70 
F393A14D 2.22 3.94 5.29 104.34 
F393HHD 2.13 3.50 3.45 109.17 
F393Y HD 2.26 3.69 3.57 107.08 
3.3 Discussion 
3.3.1 The concequence of mutating Phe393 
Certain parallels can be drawn between these data and those reported previously for 
mutants of P450 1A2 (e.g. similar blue-shifts in the ferrous-CO spectra) [130] and 
P450 2E1 (slower turnover kinetics) [131]. However, in the light of this study, it is 
clear that previous assumptions made as to the role of the phenylalanine (decreased 
enzyme stability and alteration of electron flow) are unlikely to fully account for the 
observed decreases in catalytic activity. 
The successful overexpression of F393A, F393H and F393Y mutants demonstrates 
the lack of a requirement for a phenyl ring to stabilise heme binding. Also, the 
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Figure 3.12: Superposition of the heme and residues Phe393 and G1n403 of P450 BM3 wild-
type (yellow), F393A (red), F393H (blue) and F393 Y (green) mutants. The sidechain of residue 
G1n403 is in the same orientation in the F393H and F393  mutants as in wild-type, but moves 
to accommodate the space created by the F393A substitution. In the F393A mutant, it is 
proposed that an intramolecular hydrogen bond is formed between the cysteine ligand and the 
amide nitrogen of Gln403 in this new conformation. 
kinetic profiles of these mutant enzymes dismisses the argument that this residue is 
essential in facilitating electron transfer to the heme. It has been demonstrated that 
whilst the F393A and F393H enzymes are less catalytically competent (lower 
turnover rate), the study of individual steps in the catalytic cycle reveals that the rate 
of heme reduction is actually faster for these mutants than for wild-type. Thus, 
replacement of the phenylalanine can actually elevate the rate of heme reduction. 
Contrary to previous suggestions, the residue is non-essential for mediation of 
electron transfer, either directly or indirectly, to the heme. It is not required 
absolutely for electron transfer, but instead plays a vital role in the control of the 
process. The question is then one of how this control is achieved. The most 
convenient starting point for discussion is with the thermodynamic data obtained 
from the potentiometric titrations. All other results are consistent with, and can be 
explained in light of, data from these experiments. 
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Substitution of phenylalanine 393 by either histidine or alanine results in an increase 
of the heme iron reduction potential with respect to wild type P450 BM3, whereas 
the reduction potential is unchanged upon substitution by tyrosine. This explains the 
apparent contradiction in effects on steady-state (decreased) and heme-reduction 
(increased) kinetic rates observed for the mutants relative to wild-type P450 BM3. 
Creating a large positive gap in reduction potential between the electron donor 
(NADPH at E. = —320 mV ultimately providing the electron(s) to the FMN 
semiquinone at E0 = -213 ± 5 mV) and the substrate-bound heme (e.g. E 0 = - 151 ± 4 
mV for F393A) increases the driving force (AG) for heme reduction in this system 
(Figure 3.13). The observed increase in pre-steady state flavin-to-heme electron 
transfer kinetics (ki im = 1180 s- ' (F393A) cf. 348 s_ I (WT)) is totally consistent with 
the more positive reduction potentials of heme iron (suggesting stabilization of the 
ferrous form) in the F393A and F393H mutants. However, the fact that F393A and 
F393H mutants give much lower steady-state rates of fatty acid-dependent NADPH 
oxidation suggests that some step, other than substrate-binding or first electron 
transfer, has become rate limiting in these mutants. The increased stability of the 
oxy-ferrous intermediate of these mutants with respect to wild-type infers that a step 
subsequent to oxygen binding is likely to be responsible for the steady-state 
discrpeancy. 
Product analysis of the F393H mutant-catalysed myristate-turnover was essentially 
identical to wild-type, with 0)-i hydroxylation predominating [125]. No unusual 
oxidation products, suggestive of a change in the specificity of the mutant, were 
observed. From this we can conclude that F393 does not significantly influence 
either the regio- or substrate-specificity of the enzyme. This is an important 
observation, confirming that F393H is able to act as a P450, yet is catalytically 
impaired relative to wild-type. 
For wild-type P450 BM3, the rate of first electron transfer to the ferric heme (348 s_ I 
with arachidonate) is similar to the steady-state k for turnover of this substrate 
(285 s'), indicating that the sequence of events leading to the first electron transfer to 
the heme plays a major role in the rate limitation of turnover. By contrast, in the 
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F393A and F393H mutants, not only are the rates of heme reduction elevated 
(1176 s_ I  and 832 s, respectively, with arachidonate), but the steady-state turnover 
rates are diminished (21 1  and 33 s 1 , respectively). Obviously, there is a new major 
factor in overall rate limitation that occurs subsequent to the first heme reduction 
and, presumably, does not involve substrate binding (as the binding characteristics of 
the mutants are essentially identical to wild-type). This factor almost certainly 
reflects the increased stability of the oxy-ferrous form in the mutants. The elevated 
reduction potential of their hemes results in the stabilisation of the oxy-ferrous form 
to a greater extent than that observed for wild-type. The change in the reduction 
potential does not significantly alter the rate of oxygen association to ferrous heme 
(presumably due to the high affinity of ferrous heme for oxygen), but does effect the 
rate of decomposition of the oxy-ferrous complex. The dissociation of the oxy-
ferrous complex in wild-type is 27- and 18-fold faster than either F393A or F393H 
respectively, providing conclusive evidence for the increased stability of the ferrous-
forms of the F393A and F39311 mutant enzymes. A more pronounced difference in 
the stability of the oxy-ferrous complex is observed when substrate is bound, as 
oxy-ferrous dissociation is 40- and 46-fold slower for F393A and F393H mutants 
than wild-type. Substrate participates in the stabilisation of the oxy-ferrous complex 
in a manner which is currently unresolved, but which is likely to be the result of an 
increase in the hydrophobicity or a conformational change in the active site. 
The consequence of the elevated heme reduction potential in F393A and F393H is 
that oxygen activation is disfavoured, and that the stabilized oxy-ferrous intermediate 
becomes a thermodynamic trap, which decreases the rate of overall catalysis. 
Speculation as to the actual step perturbed can be made based on the evidence 
compiled. Of the remaining steps in the catalytic cycle, changes in i) the rate of 
second electron transfer, ii) 0-0 bond scission and iii) the reactivity of the oxy-ferryl 
moiety could all be responsible for rate limitation. Any significant alteration to steps 
involving dioxygen cleavage or oxygen atom insertion would be expected to change 
the extent of uncoupling via either the peroxide or oxidase pathways respectively. A 
change in the specificity of reaction may also have been expected if a modification of 
oxy-ferryl reactivity had occurred. The results do not support these possibilities as 
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neither mutant is extensively uncoupled and the product profile for the F393H 
mutant was essentially identical to wild-type. Although experimental verification is 
still required, it appears likely that in these mutants, the rate of second electron 
tranfer replaces the rate of heme reduction as the overall rate limiting step. 
3.3.2 The cause of the thermodynamic control 
The two dominant factors which influence reduction potentials in proteins are a) the 
dielectric environment, and b) bonding interactions at, and to, the redox centre [146]. 
Whilst the effects on the kinetic and thermodynamic properties have been 
experimentally substantiated, the results from the spectroscopic and structural 
analysis of wild-type P450 BM3 and the F393 mutants allow a qualitative discussion 
regarding the physical process (i.e. the precise cause) by which these differences 
have occurred. The F393Y mutation is so conservative, that only minor deviations 
from the characteristics of wild-type P450 BM3 were observed. Concequently, the 
discussion will concentrate of the factors responsible for the dramatic differences 
between the F393A and F393H mutants with respect to wild-type. For the purpose of 
the discussion, the F393Y mutant is regarded the same as wild-type, unless otherwise 
stated. 
The EPR spectrum of each of the F393 mutants is identical to that of the wild-type 
enzyme. This infers that the iron in the ferric form is in a similar environment (no 
change in g values) in both enzymes, and that they share a common ferric resting 
state. The form of the EPR spectrum is determined mainly by the relative splitting of 
the ferric d-orbitals, if all five are moved in energy together by a process that does 
not substantially alter the iron geometry, then the spectrum would remain the same. It 
is surprising, therefore, that the elevation in the reduction potential of the heme does 
not induce a significant change in the EPR spectrum. This observation implies that 
the positive shifts in reduction potential of the F393A or F393H mutants relative to 
wild-type (reported previously [125]) are due to differences in the energy of their 
ferrous-forms, relative to the observed, common ferric ground state (Figure 3.13). 
Electrons are more easily introduced to the iron frontier orbitals of the F393A and 
F393H mutants as a consequence of the difference in the energy (AE) between the 
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Figure 3.13: Diagrammatic representation of the proposed perturbation in the iron d-orbital 
energies between the ferric-resting stale (A), the substrate-bound state (B) and the one-electron 
reduced forms of wild-type (C) and F393H mutant (D), caused by the substitution of 
phenyla/anine 393 by histidine. The energy difference (4E) between the ferric- and ferrous-d-
orbitals (related to the Fe"/Fe" reduction potential by the Nernst equation, AG = -nF4E) is 
smaller for the F393H mutant (AEFy) than wild-type (2IE wi). This is consistent with the 
elevated reduction potential of the F393H mutant compared to the wild-type enzyme. The 
similarity of the ferric-EPR spectra for the F393H and wild-type enzymes suggest that the 
magnitude of the cryst a/field splitting parameter (4) is unchanged by the mutation. 
ferric- and ferrous-forms being smaller than for wild-type. This is reflected in the 
Fell '/Fe ll  couple for the F393A and F3931-1 mutants being more positive than 
wild-type (reduction requires less energy). Whilst this is an unusual observation, it is 
not unique. It has been demonstrated that loading the core of the bacterioferritin from 
Azotobacter vinelandii drops the reduction potential of its heme group by —250 mV, 
without changes being observed in the EPR spectra of the loaded and unloaded forms 
[147]. 
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Changes in the dielectric environment of the heme 
The study of the F393X mutant structures allows us to qualitatively evaluate how, or 
even if, changes in size, hydrophobicity and electrostatics affect the heme reduction 
potential and provides a useful context for discussion. 
Neither the F393A, F393H nor F393Y substitutions grossly increase the exposure of 
the heme to solvent, or dramatically change the hydrophobicity of the heme binding 
pocket relative to wild type. Whilst the N1 of the His393 is solvent exposed 
(formation of a His. . . H 20 H-bond (Figure 3.14)), the steric bulk of the histidine 
residue is sufficient to prevent the penetration of water which would alter the 
dielectric environment at the iron, and hence the redox properties, of the heme. The 
movement of G1n403 toward the heme in the F393A structure also serves to 
minimise heme exposure, which may have been predicted by the significant steric 
effect of replacing a phenyl ring by a methyl group. 
The crystal structure of the F393H HD was determined at pH 6.5, a pH at which His 
/ 
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Figure 3.14: A stereo view of the heme binding region of the F393H mutant. Electron density is 
shown in cyan, whilst the heme macrocycle and peptide are shown in atom-type colours (red = 
oxygen; blue = nitrogen and green = sulfur), the heme iron is depicted in orange. This figure 
clearly shows electron density for water molecule X and the likelihood of an intermolecular 
hydrogen-bond to histidine 393. The electron density map was calculated using Fourier 
coefficients (2Fo Fc.), where F0 and F are the observed and calculated structure factors 
respectively. The contour level is 1.5a, where a is the rms electron density. This diagram was 
generated using TURBO-FRODO. 
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may be expected to be partially protonated, with the resulting imidazolium 
interacting with Cys400. Redox titrations of both wild-type and the F393H mutant 
have been performed over a pH range 6 - 8 (data not shown) and neither show a 
significant (< 15 mV) deviation from the value of the reduction potential determined 
at pH 7.0. Since the redox potential of the F393H mutant is not pH dependent, one 
must conclude that His393 remains in the same protonation state through the pH 
range 6-8. How the His-water hydrogen-bond affects the pKa of this residue is 
unquantifyable, but if, for example, it is dramatically increased (i.e. toward the pKa 
of free imidazole, pKa = 9), it is plausible that the residue would have mainly 
imidazolium character within the range pH 6 - 8. The presence of a positive charge 
so close to the heme-ligand would introduce a significant electrostatic interaction 
between His393 and Cys400. This increase in Lewis acidity would destabilize the 
Fe-S bond, by drawing electron density away from the iron and toward His393, with 
a possible concomitant effect of lengthening, hence weakening, the Fe-S bond. 
It seems unlikely that any of the single point mutations discussed would cause a large 
enough change in the hydrophobicity or dielectric environment of the heme to 
account for the dramatic differences observed in the reduction potentials. The 
comparison of cytochrome c with the octapeptide (methionine) complex (formed by 
the hydrolysis of cytochrome c) is the classic study of how heme solvation and the 
change in the dielectric environment of the heme affects redox properties [148]. Here 
a heme reduction potential shift of 300 mV is observed between the semi-exposed, 
partially solvated heme of cytochrome c, with the fully exposed and solvated heme 
of the octapeptide (hence, the difference in solvation being substantial and 
influential). It is also interesting to note that the reduction potential in a series of F82 
mutants of cytochrome c (a highly conserved phenylalanine in cytochrome c, in a 
similar environment to F393 in P450 BM3) shift only slightly (by 43 mV) upon 
substitution of phenylalanine by glycine [149]. Previously, the minor redox potential 
changes of these cytochrome c Phe82 mutants had been rationalized by assuming the 
removal of the steric bulk of phenylalanine was compensated for by a refolding of 
the peptide. Whilst this resulted in a change in the dielectric environment of the heme 
(increased the number of polar amide backbone groups in the hydrophobic heme 
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pocket, due to the refolding) no overall increase in the degree of heme solvation was 
observed compared to wild-type cytochrome c [150,151]. The fact the F393 
mutations involve such a slight steric substitution suggests that the changes in 
hydrophobicity and heme-exposure, would be minimal. 
Distortions to the heme-plane would cause perturbations in the energy levels of the 
porphyrin macrocycle, leading to modifications of the thermodynamic properties of 
heme. Residue 393 is within van der Waals contact of the heme plane, so any 
increase or decrease in steric bulk at this position would have an impact on the 
degree of this interaction. Direct structural comparison of heme planes is difficult, as 
the degree of distortion depends highly upon the constraints placed on the heme 
during refinement of the X-ray structure. However, none of the hemes look 
particularly distorted with no significant difference in the B-factor of the hemes 
between the structures. 
Bonding interactions to the redox centre 
More plausible reasons for the modification of the redox properties observed, are the 
factors affecting the bonding interactions of the redox centre. The iron-cysteine bond 
is central to the reactivity of P450s. It has been suggested that the cysteinate ligand 
provides a 'push' effect, whereby the strong electron donating nature of the thiolate 
pushes electron density toward the heme iron. This increases the electron-rich nature 
of the heme [65,152], facilitating the stabilisation of high iron oxidation states, and 
also helping the heterolytic cleavage of the 02 bond. Therefore, it is likely that 
factors affecting the nature of the Fe-S bond are likely to have significant 
implications on the P450 catalytic cycle. In nitric oxide synthases (NOSs), there is a 
highly conserved tryptophan residue six residues downstream of the cysteine ligand, 
which forms an intramolecular hydrogen-bond with the heme ligand [153] (Figure 
3.15). Mutation of Trp409 of nNOS to either phenylalanine or tyrosine, results in 
mutant forms in which heme reduction is slowed relative to wild-type [154]. This 
decrease in rate was attributed to the removal of the hydrogen-bond, resulting in a 
decrease in the heme reduction potential. By analogy, the formation of a hydrogen 
bond with the cysteine ligand of P450 BM3 could cause an increase in the heme 
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Figure 3.15: Illustration of the heme binding region of inducible nitric oxide synihase (1NOS). 
Shown are the heme (red) and residues the residues which constitute an analogous cysteine 
ligand loop to that observed in P450s (from Trp188-Cys194). Tryptophan 188 (atom type 
colours) forms an intramolecular hydrogen bond (dotted line, 3.74 A) to the heme ligand 
Cys 194 (green). The presence of this hydrogen bond serves to modulate the heme 
electronegativity, and acts as a feedback control mechanism in the reaction of NOS with oxygen 
and nitric oxide. 
reduction potential, which would account for the effects observed for the F393A and 
F393H mutants. The formation of an intramolecular hydrogen-bond would remove 
electron density from the Fe-S bond, reducing the ability of the thiolate to stabilize 
high oxidation states. Alternatively, this thiolate can be considered as being more 
highly tuned to stabilising low oxidation states (e.g. nNOS, E 2 = -239 mV [155]). 
From inspection of the F393H mutant alone, it is impossible to decide categorically 
whether or not H393 hydrogen bonds to the cysteine for several reasons: i) His393 
forms an intermolecular hydrogen bond with a solvent water molecule; ii) the 
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relative orientations of 11393 and Cys400 are incorrect; and iii) the F393A mutant 
(without the functionality to form a hydrogen bond) displays a similar pronounced 
effect on the heme reduction potential. 
In the structures of wild-type, F393H and F393Y, the residue sidechain is 
sandwiched between G1n403 and Pro392, with the amide group of G1n403 pointing 
toward the solvent. In the structure of the F393A HD, G1n403 moves ca 1800  to 
accommodate the space created by substitution of phenylalanine393 by alanine 
(Figure 3.12). The new conformation adopted by G1n403 brings the amide nitrogen 
within hydrogen bonding distance of Cys400. This hydrogen-bond rationalises the 
observed increase in the heme reduction potential of the F393A mutant according to 
the reasoning discussed above. 
A similar argument can be made for the F393H mutant. Interpretation of crystal 
structures can often be misleading as they are static representations of dynamic 
molecules. Consequently, it is conceivable that the intermolecular His393 ... water 
hydrogen bond observed in the F393H crystal structure is an artefact of 
crystallisation, with the orientation of the His393 not being a true reflection of its 
solution conformation. If rotated, the imidazole head of histidine can adopt an 
orientation allowing the formation of the desired intramolecular His393 ... Cys400 
hydrogen bond, analogous to that observed for the tryptophan residue of NOS. In 
fact, the proposed hydrogen bonding distance (3.7 A) in F39311 is identical (within 
crystallographic error) to that determined for NOS. 
33.3 Re-evaluation of the mechanistic control exerted by substrate-binding 
Substrate binding to P450s is believed to act as a thermodynamic switch, a control 
mechanism which prevents the futile uncoupled oxidation of NADPH. Displacement 
of the weakly ligated water molecule from the heme iron induces a change in the iron 
coordination geometry which is accompanied by an increase in the heme reduction 
potential. This redox shift is generally accepted to be the factor that prevents heme 
reduction in the absence of substrate. Little or no consideration is given to the 
physical significance of the change in coordination geometry of the iron. The 
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behavior of the F393A mutant appears contradictory, and challenges these ideas. The 
substrate-free heme reduction potential of the F393A mutant (E 0 = -312 mV) is 
comparable to the reduction potential of substrate-saturated wild-type (E 0 = -289 
mV). The thermodynamic driving force for the reduction of substrate-free F393A 
mutant is roughly equivalent to that of substrate-bound wild-type. If substrate-
binding exerted only thermodynamic control, then electron transfer to the heme of 
the F393A mutant would be expected in the absence of substrate, at an appreciably 
higher rate than substrate-free wild-type (resulting in the uncoupled reduction of 
oxygen). This is not the case, as the background (substrate-free) rate of NADPH 
oxidation is the same for the F393A mutant as for wild-type. 
This shows that the spin-state change is more important in activating electron 
transfer in the wild-type enzyme, and that the change in the driving force associated 
with substrate binding is much less important. Conversely, electron transfer in the 
F393A mutant is therefore limited by the requirement for a simultaneous change in 
the ligand coordination sphere (Figure 3.16), so to achieve heme reduction either the 








Cys-S-- 	OH2 	 [CYsS OH2] ----- 10- CysS 
Figure 3.16: Schematic describing the sequence of events leading to P450 heme reduction in 
the presence and absence of substrale. The porphyrin macrocycle is denoted by the red box. In 
the absence of substrate, the heme must undergo a redox-induced geometry reorganisation 
before iron reduction can take place. This reorganisation energy is a kinetic barrier for heme 
reduction, a scenario that is avoided when substrate is present. The act of substrate binding 
induces an analogous geometry change, avoiding the requirement for a redox-induced 
geometry reorganisaliOn. 
additional step acts as a kinetic barrier. In P450s, substrate binding exerts kinetic 
control by preorganising the iron geometry prior to reduction. The shift in heme 
reduction potential is therefore less important than the change in spin-state induced 
by substrate binding. This provides the first piece of experimental evidence to 
support previous assumptions [155b] that the change in driving force for heme 
reduction is not the primary control mechanism in operation induced by substrate 
binding. 
The previous conclusion that substrate-binding exerted purely thermodynamic 
control was a logical conclusion, with no requirement to invoke a kinetic argument, 
as the reduction potential of substrate-free P450 BM3 was considerably more 
negative than that of NADPH. In light of the observations for the F393A mutant, it is 
more applicable to consider substrate binding as exerting kinetic control over heme 
reduction. 
3.4 Conclusion 
It has been established for flavocytochrome P450 BM3 that the highly conserved 
phenylalanine residue F393 has an fundamental role in the P450 catalytic mechanism 
- it exerts thermodynamic control over the heme. The use of site directed 
mutagenesis has shown that the nature of the residue at position 393 is critical for 
competent monooxygenase activity. The bulky, aromatic, hydrophobic, chemically 
neutral character of phenylalanine are features which are required to maintain the 
hydrophobic environment of the heme and to prevent any intermolecular (solvation) 
or intramolecular (hydrogen-bond) interactions with the heme ligand. It is by virtue 
of these influences that phenylalanine exerts its thermodynamic control. The nature 
of the heme environment imposed by the presence of phenylalanine poises the heme 
reduction potential such that a likely trade-off is established between NADPH 
oxidation and oxygen activation. Although this remains speculative and does not rule 
out possible changes to subsequent steps, e.g. second electron transfer, perturbation 
of such a balance could result in a considerable loss of enzymatic efficiency. 
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Furthermore, this study highlights the electronic influence the cysteine ligand has in 
dictating the characteristic reactivity of P450s, and its sensitivity to its chemical 
environment. Modulating the electron density of the Fe-S bond (introduction of 
intramolecular hydrogen bonds) has a direct effect on the ability of P450s to bind and 
activate molecular oxygen. This point is key to the high degree of conservation of 
this residue throughout the P450 superfamily - monooxygenation requires oxygen 
activation. This phenylalamne is conserved in every member which needs to perform 
this activation, for the small number that do not, the nature of this residue varies. 
( lI.I 	 . 	 101 
Chapter 4: 





One contentious and unresolved issue regarding the general P450 mechanism is the 
effect heme-reduction has on the affinity of substrate binding. 
Although the effect of heme-reduction on substrate binding can be tentatively 
evaluated by considering the difference between the substrate-free and substrate-
bound heme reduction potentials (-RT1nK4j = -nFAE 0), substrate dissociation 
constants have not been formally quantified for the ferrous-form of the enzymes. It 
is, however, believed that the affinity of the enzyme for substrate increases 
dramatically upon reduction (possibly by an order of magnitude) in preparation for 
reactions between the heme and the substrate in subsequent steps of the catalytic 
cycle [156,45]. 
The method by which ferric dissociation constants are determined relies on the 
visible spectral shifts associated with the low-spin (419 run) to high-spin (390 rim) 
conversion of the heme-iron induced upon addition of substrate [157-159]. Binding 
of substrate to P450s displaces a weakly ligated water ligand that occupies the sixth 
coordination site of the heme-iron, hence the iron geometry changes from octahedral 
(low-spin) to square-based pyramidal (high-spin)[160]. Although substrate must bind 
to the ferric P450 before reduction (hence Fe 3+  Kj KM), quantitation of the 
substrate dissociation constant for the reduced, catalytically relevant form of the 
enzyme is of particular interest. Unfortunately, this value cannot be determined in an 
analogous manner to the oxidised enzyme, as the substrate-free- and substrate-
bound-ferrous absorption spectra are identical (A m 410 nn). 
It is generally accepted that P450s are mechanistically regulated at the level of 
substrate binding. A redox switch operates whereby the iron spin state conversion 
induced upon substrate binding is accompanied by a positive shift in the heme 
reduction potential [41,91]. This redox shift gates the flow of electrons from the 
reductase to the heme, only allowing transfer of the first electron to the heme when 
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substrate is bound. This regulatory mechanism discourages uncoupling (the 
unfavourable reduction of oxygen to superoxide or peroxide) and conserves precious 
reducing equivalents (NAD(P)H). Quantification of P450 heme reduction potentials 
is therefore a highly desirable outcome, yet is experimentally complicated for several 
reasons. The inherent reactivity of P450-heme with molecular oxygen means that 
potentiometry has to be performed in strictly anaerobic conditions, often requiring 
the use of sophisticated cells or glove boxes [91,155]. The logistics of performing 
such experiments makes the technique inherently awkward and prone to systematic 
errors. The technique also requires soluble protein of high concentration (to achieve 
efficient electrical communication with the electrode) and long equilibration periods 
which is why such data has been almost exclusively restricted to P450s from 
bacterial sources. The majority of physiologically relevant (i.e. mammalian P450s) 
P450s are membrane-bound and the problems of insolubility, protein precipitation 
and insufficient protein concentration make them inaccessible to be studied by this 
technique. Direct electrochemical methods are also inappropriate due to poor 
electrical communication between P450s and electrodes, mainly as a consequence of 
the well insulated, buried heme (in the case of P450 BM3 heme domain, although a 
monolayer film could be generated on the surface of a PGE electrode, direct 
electrical reduction was not observed, K.L. Turner, personal communication). A 
spectroscopic method for predicting the midpoint potential of such hemoproteins "on 
the bench" would be of considerable usefulness, and would circumvent many of 
these disadvantages. 
This chapter describes the development of such a method using the novel heme 
ligand 4-cyanopyridine as an extremely useful spectroscopic tool. 
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4.2 Results 
4.2.1 Purification of 4-cyanopyridine 
Crude 4-cyanopyridine (4CNPy) was purchased from Sigma (-80 % purity) and was 
purified by vacuum sublimation. Purified 4CNPy was stored in a dessicator at room 
temperature, and used within 1 month of manufacture. The use of crude 4CNPy was 
avoided as it contains a significant amount of free cyanide, the ligation of which 
(submicromolar Kd) to P450 is irreversible, and preferential to the binding of 4CNPy. 
Vacuum sublimation liberates sufficiently pure 4CNPy (spectrum of ferrous P450-
4CNPy has no trace of ferrous P450-CN) for the purpose of these experiments. The 
aqueous 4CNPy stocks were prepared using assay buffer (100 mM MOPS, pH 7.0). 
Fresh stocks ([4CNPy] = 180 mM) were used for each experiment. 
4.2.2 The mode of 4-cyanopyridme binding to P450 heme. 
The mode of binding of 4CNPy to P450 heme was determined to be through the 
pyridine ring nitrogen, as opposed to the cyano-nitrogen. This was deduced by 
comparing the 4CNPy-bound spectrum to the CN-bound and pyridine-bound spectra 
(Figure 4.1). These two adducts have characteristically different absorption spectra. 
The absorption spectra of the ferrous-4CNPy complex and ferrous-pyridine complex 
are essentially identical. Subtle differences are observed in the spectra and will be 
discussed in detail later, but the major observation is that the ferrous4CNPy spectra 
is more ferrous-pyridine-like than ferrous-cyanide-like. The ferrous-pyridine spectra 
of P450 BM3 are comparable to those shown previously for pyridine-binding to 
P45Ocam by Griffin et al [161]. 
4.23 4-cyanopyridine binding to cytochromes P450. 
Visible absorption spectra showing the typical shifts associated with the binding of 
4CNPy to the oxidised and reduced forms of P450 are shown in Figure 4.2, 
exemplified by the binding to P450cam (the same observation was made for P450 
BM3 and the F393 mutants). The visible spectra of the ferric P450-4CNPY 
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Figure 4.1: Comparison of the binding ofpyridine (green), cyanide (blue), and 4CNPy (red) to 
A: ferric and B: ferrous P450. Absolute spectra offerric and ferrous forms are shown as solid 
black lines in both panels. 
complexes are essentially the same as their respective ligand-free, ferric forms. 
Reduction of ferric P450-4CNPy complexes yielded the ferrous P450-4CNPy 
complexes, which was accompanied by a dramatic change in the absorption spectra 
(shift in the Soret absorption from 419 nm (ferric) -), 440 nm (ferrous-4CNPy)). 
Similar shifts were observed for all proteins studied. 
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Figure 4.2: Absorbance spectra showing the ligation of 4CNPy to A: ferric and B: ferrous 
P450cam. Difference spectra are shown inset. 
The dissociation constants for 4CNPy with wild-type P450 BM3 and P450cam were 
determined by titrating small aliquots of aqueous 4CNPy (180 MM stock) into 
samples of either oxidised or reduced protein (Ca. 5 pM) and recording the resultant 
visible absorption spectrum after each addition. Difference spectra were generated by 
subtraction of the absolute oxidised (or reduced) protein spectrum from each 4CNPy-
bound spectra. Dissociation constants were calculated by plotting the maximum 
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absorbance change in the difference spectra versus [4CNPy], and evaluated as 
outlined in Section 2.6. 
Two noteworthy observations are: the formation of a new metal-to-ligand charge 
transfer (MLCT) absorption band (assigned MLCT due to 4CNPy being a good it-
acceptor (it-acid) with low lying ir anti-bonding orbitals [162,163]) in the blue-
region of the spectrum (Am = 620 - 650 rim); and the increase in affinity for 4CNPy 
for ferrous-heme (Table 4.1). 
Table 4.1: 4CNPy dissociation constants for ferric and ferrous P450 
4CNPy Kd (j.tM) 
P4500,, 	 P450 
Wild-type P450 BM3 	 1130±45 	 11.3 ± 0.7 
Wild-type P450cam 	 845 ± 70 	 0.9 ± 0.1 
The affinity of 4CNPy for reduced heme is - 2-3 orders of magnitude greater than 
for oxidised heme, this has implications for the competitive binding studies which 
will be discussed in detail later. 
4.2.4 Competitive inhibition of 4-cyanopyridine binding by substrate. 
The ferrous-form of both wild-type P450 BM3 or P450cam displayed competitive 
ligation between 4CNPy and substrate, enabling the Kd of the substrate for the 
ferrous-form (Ka(red)) to be calculated. The apparent dissociation constants for the 
competitive binding of 4CNPy to reduced P450 (Kd) were determined essentially 
as described above (Section 4.2.3), but in the presence of varying concentration of 
substrate. For P450 BM3, the substrate was laurate (Kd( ox ) = 241 JIM; [laurate] used = 
25, 50, 100 and 200 pM), for P450cam, the substrate was fenchone (Kd(0) = 52 1.tM; 
[fenchone] used = 4, 21, 42 and 84 pM). Titration of 4CNPy into substrate-bound, 
ferrous P450 competitively displaces substrate as it ligates the heme. Sub-optimal 
substrates were chosen for the two P450s as their Kd values for the oxidised protein 
were in the range 50-250 pM, which was found to be sufficient to be displaced by a 
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modest concentration of 4CNPy. Optimal substrates bound too tightly and thus did 
not display competitive binding with 4CNPy. 
In the case of both wild-type P450 BM3 and P450cam, the apparent 4CNPy K,j 
(y/PP) increased with increasing substrate concentration. In this respect, substrate 
can be considered as acting as an inhibitor of 4CNPy ligation (in this context, 
substrate will be referred to as the 'inhibitor' of 4CNPy binding). Kd"  was evaluated 
by plotting the maximum absorbance change induced upon 4CNPy ligation to the 
ferrous heme, versus [4CNPy] at each inhibitor concentration (Table 4.2). 
Table 4.2: Competitive inhibition of 4C'NPy binding by substrate 
[substrate] 	Kd" 	Gradient 	Intercept 	K1 (riM) 
(pM) (units) (lAM) 
P450BM3 	 25±2 	27±2 
(substratelaurate) 	
50±3 	49±4 	21.7±5.5 	0.46±0.1 	47±6 
100±4 	72±8 
200±6 	111±5 
P450cam 	 4 ± 0.4 	32 ± 2 
(substrate = fenchone) 	I 21 ± 1 	169 ± 3 1 11.3 ± 7 	7.2 ± 0.1 	1.5 ± I 
42±3 	317±10 
84±4 	610±28 
The double reciprocal plots (I/AA.,,, vs 1/[4CNPy] at each [inhibitor]) for P450 
BM3 (laurate) and P450cam (fenchone) are shown in Figure 4.3 and confirm the 
nature of the inhibition to be purely competitive [164]. By plotting K/' versus 
inhibitor concentration, a linear relationship was observed (Figure 4.4), from which 
the inhibitor constant (Kj = intercept/gradient) was determined (Table 4.2) by 
applying a variation of the Michaelis Menten equation in the presence of inhibitor 
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Figure 4.3: Double reciprocal plots, demonstrating the competitive inhibition of 4CNPy 
binding to A: P450 BA'f3 in the presence of laurate and B: to P450cam in the presence of 
fenchone. 
As the substrate is acting as the inhibitor in this situation, Kd(red) can be simply 
evaluated (since under these circumstances K1 = Ka(red)). For P450 BM3, Ka(red) 
(laurate) = 47 ± 6 1.tM, for P450cam, K(red) (fenchone) = 1.5 ± 6 iM (this in 
comparison to the oxidised dissociation constants P450 BM3, Kj(ox) (laurate) = 241 
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Figure 4.4: The linear variation of K7"  (4CNPy) with increasing substrate concentration 
(Panel A, P450 BM311aurate, Panel B, P4SOcam/fenchone). From this, K 1 can be evaluated. 
in K1 (hence Kd(red))  are large, this is to be expected due to the large variation in the 
affinity of 4CNPy in the presence of modest concentrations of substrate, this is 
especially true for P450camlfenchone. Substrate binding affinity to the ferrous form 
of both P450 BM3 and P450cam is 5- and 35-fold increased (respectively) with 
respect to their ferric forms. Here, the effect is more pronounced for 
P450camlfenchone than P450 BM3flaurate, as fenchone is not as poor a substrate 
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analogue for P450cam, as laurate is for P450 BM3. Reduction is therefore 
accompanied by a substantial increase in the affinity of the enzyme for the substrate. 
Equation 4.1: Variation of the Michaelis-Menten equation to calaculate K 1 for 
4CNPy in the presence of substrate 
L\A[E 1 ][S] 	 AA [E 1 ][S] 
A = 	 which approximates to A = 	 when [I] = 0 
[S]+K d +(Kd[j/K) 	
+[S] 
therefore, L'  d' 
	d +(Kd[h) 
K 1 
where Kd = Kd (4CNPy) when [ii = 0, 	Kd (4CNPy) when [I] > 0; S = 4CNPy; 
I = laurate/fenchone 
4.2.5 Prediction of P450 heme reduction potentials 
The position of the new MLCT absorption (XMLCT) generated upon ligation of 
4CNPy to ferrous heme was seen to vary with the proteins studied (Figure 4.5). The 
wavelength of this absorption band for the P450s studied is shown in Table 4.3 
alongside their respective substrate-free reduction potentials. The F393 mutants of 
P450 BM3 provided a convenient set of proteins to study, as the mutation causes the 
redox potential to shift without a change in the affinity for substrates or ligands [40]. 
Table 4.3: Position and energy of the ferrous P4504CNPy MLCT 
Parameter 
XM.LCT (rim) 	 EML (cm- ') 	E0 (mV vs SHE) 
P450BM3WT 	 647±1 	 15456 	 427 
P450BM3F393A 628± 1 15924 -312 
P450BM3F393H 632± 1 15823 -332 
P450BM3F393Y 644±1 15528 420 
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Figure 4.5: Expansion of the a/fl region (500-800 nm) of the ferrous-4CNPyadducts of 
P450cam (black), P450 BM3 F393A (red), F393H (green), F393 Y (blue) and wild-type (cyan), 
showing the shift in the newly formed MLCT between proteins. 
When the energy of the absorption band (EMLCT,cm) is plotted versus substrate-free 
reduction potential (E 0, mV) a linear relationship is observed (Figure 4.6), 
where, EMLCT = (3.86 x E0) + 17122 cm 
The standard deviation of the line (0.9966, n=5) confirms the accuracy of the linear 
relationship. This suggests that the origin of the absorption is sensitive to the redox 
nature of the heme iron, and hence can be used as a method for accurately estimating 
substrate-free P450 reduction potentials. The correlation between charge transfer 
bands and reduction potentials is a well recognised practise for inorganic 
coordination complexes [165-169], and seems equally applicable in this 
circumstance. 
Interestingly, this phenomena was not restricted solely to P450s, as treatment of 
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Figure 4.6: The linear variation in EML(7  with P450 reduction potential. 
MLCT, whose absorption maxima fits the same linear relationship observed for the 
P450s. It seems as though this relationship could hold for all P450-like, thiolate 
ligated hemoproteins. 
4.3 Discussion 
The two features of 4-cyanopyridine which make it an ideal ligand for the type of 
studies outlined previously are, firstly, its essentially exclusive, tight reversible 
binding to ferrous heme (with little affinity for ferric heme) and secondly, the 
unusual spectral properties of the 4CNPy-ferrous heme adduct. Therefore, we have: a 
ligand with strict selectivity for ferrous heme; a convenient spectroscopic handle; and 
completely reversible ligand binding. The methodology outlined to calculate the 
substrate dissociation constants for reduced P450 exploits these observations. 
The specificity of 4CNPy for reduced P450 allows the evaluation of substrate 
dissociation constants for purely the reduced enzyme and eliminates interference 
from binding of 4CNPy/substrate to ferric heme. Previously, pyridine had been used 
in an analogous manner to estimate Kj(red) [161,170], the magnitude of which (4.5 
nM) is likely to be inaccurate for a number of reasons. Pyridine has a high affinity 
for both oxidised and reduced P450 (so interference from binding to the ferric form 
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cannot be discounted), the quoted value was an average of only 5 single absorption 
measurements in the presence of camphor (as opposed to full titrations at each 
camphor concentration), and thirdly, high concentrations of pyridine were used (:! ~ 19 
mM) which could have a detrimental effect on the integrity of the P450. The highest 
concentration of 4CNPy added to a P450 sample in any given experiment was 1.5 
mM, the integrity of the protein was checked by bubbling CO through the samples 
subsequent to titration. In every case, full conversion to the characteristic P450 
complex was observed, synonymous with intact non-denatured P450. For these 
reasons, 4CNPy is a much more applicable ligand for these types of study than 
pyridine, combined with its additionally useful absorption properties when bound to 
ferrous heme. 
An increase in substrate binding affinity upon heme reduction, is key to the 
mechanism of action in the P450s. This is inferred by the difference between the 
substrate-free and substrate-bound heme reduction potentials. Introduction of 
substrate into the active site increases the heme-reduction potential and thus 
thermodynamically controls electron transfer from the reductase. Consideration of 
the Gibbs' Free Energy equation (G = -RT1nK) suggests that this increase in 
reduction potential must be due to a decrease in the magnitude of the equilibrium 
constant, K - in this situation, K can be considered as the substrate dissociation 
constant (K). Theoretically, Id should decrease upon protein reduction. It is widely 
accepted that there is considerable peptide motion upon substrate binding associated 
with dehydration of the active site [171,88] of P450 BM3. A similar conformational 
contraction may be expected upon reduction, to bring the substrate closer to the heme 
to facilitate oxygenation. This is substantiated by NMR relaxation experiments on 
P450 BM3, which show a dramatic 6 A movement of the substrate toward the heme 
upon reduction [45]. The active site contraction probably serves two purposes, to 
ensure dehydration of the active site and also to stabilise the Michaelis-complex. 
This movement can be interpreted as an increase in affinity of the reduced heme for 
the substrate, hence one would expect a concomitant decrease in the substrate 
dissociation constant for this form of the enzyme. Inspection of the crystal structure 
of the palmitoleate-bound, ferric P450 BM3 heme domain [87] (PDB:1FAG), shows 
Chapter 4: 4-cyanopyridine as a Spectroscopic Ligand 	 115 
r .......... t­t­ - JEox + S1 






- 	 AGrj(SB) \GSUb(red) 
[ES] 	.iJ .......... 
Figure 4.7: A schematic showing the dissection of the total Gibbs 'free energy for substrate- 
binding and reduction to a P450, into its components. Eox  = oxidised P450, Ea = reduced 
P450, ES = oxidised P4501substrate complex, 	= reduced P4501substrate complex, 
L1G JSF and 	are the free energies of reduction for the substrate-free and substrate- 
bound P450 (respectively), 4G 5b(ox) and /iG3 b(red) are the free energies of substrate binding 
to oxidised and reduced P450 respectively. 
that the substrate terminus is - 8 A away from the heme, too far for hydroxylation, 
suggesting that a movement of the substrate must occur in order for reaction to take 
place. For the first time, we report the determination of substrate dissociation 
constants for ferrous P450 BM3 and P450cam. These concentrations are 
considerably lower than those determined for the ferric enzymes (-- 5-35-fold) and 
quantify the degree to which substrate is bound tighter to the active site in the 
enzymes catalytically relevant, ferrous-form. Whilst the effect of reduction seems to 
only have a modest effect on substrate binding, it has to be reiterated that the values 
were determined for sub-optimal substrates for the particular P450s (laurate and 
fenchone for P450 BM3 and P450cam respectively). It can be expected that the 
increase in affinity for physiological substrates for the ferrous form to be more 
pronounced. 
The importance of determining K<j(red) cannot be understated. Once determined for a 
particular substrate, a wealth of (otherwise unquantifyable) mechanistic data can be 
calculated, enabling the deconvolution of important steps in the P450 catalytic cycle. 
Figure 4.7 illustrates the dissection of the substrate binding equilibrium into its 
constitutive components and the Gibbs free energy (AG) terms associated with each 
transition (the terms AG SUb(ox), itGSUb(red) AGSF and AGSB are defined in the figure 
legend), the magnitude of which are given in Table 4.4. The most important 
parameter is MG - this is a measure of the relative stability of the ferric-substrate-
bound P450 compared to the ferrous-substrate-bound P450, determined by the 
4CNPy competitive inhibition titration (determination of Kj(red)). 
The sign of MG demonstrates that the ferrous-substrate complex is more stable 
(lower in energy) than the ferric-substrate complex. Interestingly, although the MG 
values for arachidonate- and camphor-bound P450 BM3 and P450cam respectively 
were not measured directly (rather, calculated from the known, measured reduction 
potentials [40,172] by assuming -nFM = -RTInK d(red)), they are of greater 
magnitude than for the sub-optimal substrates - an intuitive interperetation. By 
definition, the best substrates bind tightest, hence forming the most stable Michaelis-
complexes (largest MG). The fact that MG = AGSB allows estimation of the 
substrate-bound heme reduction potential for a sub-optimal substrate (i.e. by 
caleulating K j(red} and affi 	the-aeeuraeyothe-estimation-ofKred) f-a----- 
physiological substrate from the energy difference (AE.) between the substrate-free 
Table 4.4: Thermodynamic parameters for substrate binding to ferric and ferrous 
P450 
Thermodynamic parameters (kimor') 
AG (ox) 	AG,.b (red) 	AAG 	AGSB 
P450 BM3 + laurate 	 20.5 	24.7 	-4.2 	 - 
P450 BM3 + arachidonate 	30.8 	42.7* 	 - 	 -13.2 
P450cam + fenchone 	 24.3 	33.2 	-8.9 	 - 
P450cam + camphor 	 32.8 	453* 	 - 	 -12.4 
'Calculated from AE0 
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and substrate-bound heme reduction potentials. Sub-optimal substrates tend to only 
induce a partial spin-state shift [125] (e.g. for P450 BM3, laurate induces -60 % spin 
state shift, whereas arachidionate > 95 %) and this limits the range of substrates 
available to study by redox potentiometry. Substrate-bound heme reduction 
potentials can be significantly underestimated if the conversion from low-spin to 
high-spin is incomplete [91]. The determination of Kj(red) allows the prediction of 
these substrate-bound reduction potentials for these sub-optimal substrates. This can 
be illustrated in the case of either P450 BM3 with laurate (predicted E 0 = -383 mV), 
or P450cam with fenchone (predicted E 0 = -208 mV) - the substrate-bound potentials 
for either case have not previously been evaluated. Although the dissociation 
constants for sub-optimal substrates with ferrous P450 were only modestly decreased 
with respect to their ferric counterparts, calculation of Kd(red)  for the physiological 
substrates suggests a significantly more pronounced increase in affinity, such that the 
K(red) for these substrates is in the nanomolar region (32 nM P450 
BM3/arachidonate; 11 nM P450cainlcamphor). 
It has also been demonstrated that 4-cyanopyridine can be exploited to predict the 
substrate-free P450 heme reduction potentials. This feature makes 4-cyanopyridine a 
fundamentally important mechanistic probe. The energy of the MLCT absorption 
band (upon formation of the 4CNPy-ferrous adduct) varies linearly with heme 
reduction potential. This is an observation which has been used effectively in 
studying the correlation of absorption band energy of simple inorganic complexes 
with reduction potential [165-169]. This provides a convenient route by which heme 
reduction potentials can be accurately estimated for P450s for which such 
information has been previously unobtainable (due to either purification/extraction or 
stability problems). The versatility of such a ligand may even allow the evaluation of 
heme reduction potentials of P450 in crude microsomal fractions. The data presented 
here could act as a calibration chart, against which subsequent P450 reduction 
potentials can be estimated. The relationship shown in Figure 4.6 (EMLCT = (3.86 x 
E0) + 17122 cm) allows the evaluation of a P450 heme reduction potential, simply 
by knowing the energy of the MLCT absorption of the ferrous4CNPy adduct. The 
advantage of the 4CNPy MLCT is that the shift from P450 to P450 occurs over a 
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large wavelength range (- 20 nm, WT —* F393A), allowing accurate estimation of 
reduction potential when EMLCT is plotted against reduction potential. 
Whilst the number of P450s tested in this study is relatively small, the inclusion of 
data for P450s with distinctly different catalytic sites (P450 BM3 versus P450cam), 
suggests that this trend could be applicable to all heme-thiolate proteins. However, a 
larger sample of proteins needs to be considered before such a hypothesis can be 
justified. 
4.4 Conclusion 
4-cyanopyridine has been demonstrated to be a ligand that can be expolited as an 
invaluable mechanistic tool for cytochromes P450, and even heme-thiolate proteins 
in general. Its strict selectivity for ferrous-heme and the unusual spectral properties 
of the ferrous-4CNPy adduct have enabled the quantification of previously 
unmeasurable properties. It provides a quick, convenient and accurate method of 
determining substrate dissociation constants for reduced P450s, for predicting heme 
reduction potentials of P45 Os bound with sub-optimal substrates, and can even be 
used to estimate the reduction potential of P450s for which conventional 
experimental techniques, such as redox potentiometry, are unsuitable. 
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APPENDIX II 
DERIVATION OF KINETIC EQUATIONS 
1 	The Michaeis-Menten equation 
The Michaelis-Menten equation applies for an enzyme catalysed reaction in which 
substrate binding is rapid and reversible and when product formation is rate 
KM 	 kcat 
E + S - ES -> EP Equation 1 
determining, e.g. 
Where E, S, ES and P are, the enzyme, substrate, enzyme-substrate complex and 
product respectively. From this, the substrate-binding equilibrium constant (Km) and 
initial rate (v) can be evaluated (Equation 2 and 3): 
	
K 




v = kt[ES] 	 Equation 3 
The total concentration of enzyme present, [E T], is equal to the sum of the free 
enzyme, [E], and the bound enzyme, [ES]. The concentration of free enzyme, [E], 
can therefore be represented as in Equation 4. 
[E] = [ET] - [ES] 	 Equation 4 
Substitution of equation 4 into equation 2 gives: 
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Km= (JE T ] - IESDISI 	
Equation 5 
IESJ 
Which simplifies to Equation 6: 
IESI= 1E
1  I  IS1k 
K M  +SJ 
Equation 6 
Substitution of Equation 6 into Equation 3 gives the Michael is-Menten equation 
(Equation 7). 
	
V=IETIISIkCIt 	 Equation 7 
K M +ISJ 
2 	The Lineweaver-Burk equation 
To analyse data graphically, the Michaelis-Menten is often transformed into a linear 
form (Equation 8). The most common method is the double-reciprocal or 
Lineweaver-Burk plot (Figure Al .1). This is obtained by inverting both sides of 
Equation 7 and substituting v na,, for k[Eo],  where v is the limiting velocity. 
1 	K M + 1 
	 Equation  -=  
V Vms1  IS] V msx 
One disadvantage of this method is that data points at low concentrations are 
ephasised, whereas those at high concentrations are compressed. Departure from 
linearity for a particular enzyme catalysed reaction indicates that the assumptions 





xintenept= -l/KM 	- 
\ZZ 	y intercept = INmw  
1 / [S] 
Figure A2.1 
3 	Competitive Inhibition 
Competitive inhibitors often closely resemble in some respects, the substrates whose 
reactions they inhibit, and because of this structural similarity they may compete for 
the same binding site of the enzyme. In terms of the Michaelis-Menten mechanism, 
an additional equilibrium must be taken into consideration (Equation 9) and 
S, KM 
	 kcat 
E - ES 	> EP 
I, K1 	 Equation 9 
El 
described by Equations 10 to 16. Here, I is the inhibitor and El is the enzyme-











In this case, the total concentration of enzyme must take into account the 
contribution from El, hence equation 12: 
[E T  I=IEJ +IESJ+  [Ell 
	
Equation 12 
Expressing Equation 12 in terms of [El] and substituting into equation 4 gives: 
IE T I= [El +EESI+ [El [I] 
	 Equation 13 
K 1 
	
- [E T I - [ES] 	 Equation 14 
(1+111/
/'iK 
Expressing Equation 11 in terms of [E] and substituting into equation 15, gives: 




Finally, substituting [ES] = V/kcat into Equation 16 gives: 
lE T  I ISlkcat 	 Equation 16 
I 
V= IIV 
Equation 15 is expressed in the same form as the Michaelis-Menten equation and 
shows that for competitive inhibition, v is unchanged but KM is apparently increased 
by (1 + [I]/K,). A typical series of inhibited Michaelis plots are shown in Figure 
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APPENDIX III 
PEPTIDE SEQUENCE OF FLAVOCYTOCHROME P450 BM3 
The heme binding residue, Cys400, is shown in green. Heme Domain: 1 - 472; 
Reductase Domain: 473 - 1048. 
1 	10 	 20 	 30 	 40 	 50 	 60 
	
I 	 I 	 I 	 I 	 I 	 I 
TIKEHPQPKT FGELKNLPLL NTDKPVQALM KIADELGEIF KFEAPGRVTR YLSSQRLIKE 
70 	 80 	 90 	 100 	 110 	 120 
I 	 I 	 I 	 I 	 I 
ACDESRFDKN LSQALKFVRD FAGDGLFTSW THEKNWKKAH NILLPSFSQQ AMKGYF1PNMV 
130 	 140 	 150 	 160 	 170 	 180 
I 	 1 	 I 	 I 	 I 	 I 
DIAVQLVQKW ERLNADEHIE VPEDMTRLTL DTIGLCGFNY RFNSFYRDQP HPFITSMVRA 
190 	 200 	210 	 220 	 230 	240 
I 	 I 	 I 	 1 	 I 
LDEANNKLQR ANFDDPAYDE NKRQFQEDIK VMNDLVDKII ADRKASGEQS DDLLTHMLNG 
250 	 260 	270 	 280 	290 	 300 
I 	 1 	 I 	 I 
KDPETGEPLD DENIRYQIIT FLIAGHETTS GLLSFALYFL VKNPHVLQKA AEEAARVLVD 
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310 	 320 	 330 	 340 	 350 	 360 
I 	 I 	 I 	 I 	 I 	 I 
PVPSYKQVKQ LKYVGMVLNE ALRLWPTAPA FSLYAKEDTV LGGEYPLEKG DELMVLIPQL 
370 	 380 	 390 	 400 	 410 	 420 
I 	 I 	 1 	 I 
HRDKTIWGDD VEEFRPERFE NPSAIPQHAF KPFGNGQRAC IGQQFALHEA TLVLGMMLKH 
430 	 440 	 450 	 460 	 470 	 480 
I 	 I 	 I 	 I 	 I 	 I 
FDFEDHTNYE LDIKETLTLK PEGFVVKAKS KKIPLGGIPS PSTEQSAKKV RKKPIENAHNT 
490 	 500 	 510 	 520 	 530 	 540 
I 	 1 	 I 	 I 	 I 	 I 
PLLVLYGSNM GTAEGTARDL ADIAI'ISKGFA PQVATLDSHA GNLPREGAVL IVTASYNGHP 
550 	 560 	 570 	 580 	 590 	 600 
I 	 I 
PDNAKQFVDW LDQASADEVK GVRYSVFGCG DKNWATTYQK VPAFIDETLA AKGAENIADR 
610 	 620 	 630 	 640 	 650 	 660 
I 	 I 	 I 	 I 
GEADASDDFE GTYEEWREHM WSDVAAYFNL DIENSEDNKS TLSLQFVDSA ADMPLAKMHG 
670 	 680 	 690 	 700 	 710 	 720 
I 	 I 	 I 	 I 	 I 	 I 
AFSTNVVASK ELQQPGSARS TRHLEIELPK EASYQEGDHL GVIPRNYEGI VNRVTARFGL 
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730 	740 	750 	760 	770 	780 
I 	 I 	 I 	 I 
DASQQIRLEA EEEKLAHLPL AKTVSVEELL QYVELQDPVT RTQLRAMAA}( TVCPPHKVEL 
790 	800 	810 	820 	830 	840 
I 	 I 	 I 	 I 	 I 
EALLEKQAYK EQVLAKRLTM LELLEKYPAC EMKFSEFIAL LPSIRPRYYS ISSSPRVDEK 
850 	860 	870 	880 	890 	900 
I 	 I 	 I 	 I 	 I 	 I 
QASITVSVVS GEAWSGYGEY KGIASNYLPE LQEGDTITCF ISTPQSEFTL PKDPETPLIM 
910 	920 	930 	940 	950 	960 
I 	 I 	 I 	 I 
VGPGTGVAPF RGFVQARKQL KEQGQSLGEA HLYFGCRSPH EDYLYQEELE NAQSEGIITL 
970 	980 	990 	1000 	1010 	1020 
I 	 1 	 I 	 I 
HTAFSRNPNQ PKTYVQRVME QDGKKLIELL DQGAHFYICG DGSQMAPAVE ATLMKSYADV 
1030 	1040 	1048 
I 	 I 	I 
HQVSEADARL WLQQLEEKGR YAKDVWAG 
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Abstract Bacillus inegaterizim P450 BM3 is a fatty acid 
hydroxylase with selectivity for long chain substrates (C12— 
C20). Binding or activity with substrates of chain length <C 12 
has not been reported. Rational mutagenesis was used to re-
design the enzyme to encourage binding of short chain fatty acids 
(C4—C 1 0). We show that wild-type P450 BM3 has activity and 
weak affinity for substrates as short as butyrate (C4). However, 
turnover/binding of short chain substrates is dramatically 
increased by introducing a novel substrate carboxylate binding 
site close to the heme. Mutant LI8IK shows catalytic efficiency 
(k cat /KM) increased > 13-fold with butyrate, while the L75T/ 
L18IK double mutant has k ca,/Krj increased > 15-fold with 
hexanoate and binding (Kd) improved > 28-fold for butyrate. 
Removing the arginine 47/lysine 51 carboxylate binding motif at 
the mouth of the active site disfavours binding of all fatty acids, 
indicating its importance in the initial recognition of 
substrates. © 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved. 
Key words: Cytochrome P450; Substrate recognition; 
Rational mutagenesis 
1. Introduction 
Cytochromes P450 (P450s) are cysteirie-ligated haem-con-
taming monooxygenases widespread in nature [1]. They have 
important metabolic functions (including steroid syntheses 
and transformations), play roles in detoxification of drugs 
and xenobiotics, and catalyse breakdown of unusual com-
pounds as carbon sources for growth [2,3]. Their predominant 
reaction is the mono-oxygenation of organic molecules by the 
activation and insertion of an atom from molecular 02 
(Scheme I). However, other reactions (e.g. dealkylation) 
have also been reported [4]. 
RH +02+ 2H + 2e -* ROH + H 2 0 	 Scheme 1 
Analysis of soluble bacterial P450s such as the camphor 
hydroxylase from Pseudomonas putida and the fatty acid hy-
droxylase from Bacillus inegaterium have given insights into 
the structure and function of their membrane-bound eukary-
otic counterparts [5]. The X-ray crystal structures of bacterial 
*Corresponding author. Fax: (44)-141-5483727. 
E-mail: andrew.munro@strath.ac.uk  
P450s have allowed various aspects, key to their function, to 
be investigated by a rational approach. Bacterial structures 
also have important biotechnological roles as models for the 
eukaryotic P450s for e.g. design of new drugs, and have great 
potential to catalyse novel reactions inaccessible to conven-
tional chemistry. 
One of the most intensively studied of the bacterial P450s is 
the fiavocytochrome P450 BM3, a high activity fatty acid 
hydroxylase from B. megalerium [6]. P450 BM3 is a natural 
fusion of a P450 to a mammalian-like diflavin NADPH-P450 
reductase and is of great importance in understanding struc-
ture, function and electron transfer in this enzyme class. 
In this study, we have altered substrate selectivity in P450 
BM3. The substrate (palmitoleate)-bound P450 BM3 structure 
reveals several hydrophobic residues within van der Waals 
contact of the substrate [7]. Using rational site-directed muta-
genesis, we have replaced selected neutral residues with pos-
itively charged or more hydrophilic residues in attempts to 
pinpoint substrate binding determinants. We have also at-
tempted to copy the fatty acid carboxylate binding motif 
(R47IY51, found at the mouth of the active site) at positions 
further down the substrate binding channel to encourage 
binding of shorter chain fatty acids. To date, no research 
has successfully addressed reasons for the observed substrate 
selectivity profile of this important flavocytochrome, which 
only has reported activity for fatty acids of chain length 
C12—C20. Here we provide evidence that rational mutagenesis 
can be used to convert P450 BM3 to favour binding of shorter 
chain (C4—C10) fatty acids. 
2. Materials and methods 
All P450 BM3 substrates (arachidonic acid and sodium laurate 
(C12), decanoate (C10), octanoate (CO, hexanoate (C 6 ) and butyrate 
(C4)) were from Sigma (St. Louis, MO, USA). Oligonucleotide prim-
ers were from PE Biosystems. Restriction and DNA modification 
enzymes were from New England Biolabs. All other reagents were 
from Sigma. The arachidonic acid stock solution was 33 mM (approx-
imately 10 mg ml) in ethanol. All other substrates were prepared as 
aqueous solutions in the assay buffer for P450 BM3 reactions (20 MM 
MOPS, p1-I 7.4, plus 100 mM KCI). NADPH was prepared as a 20 
mM stock in ice-cold degassed assay buffer. 
Cloning of P450 BM3 and generation of mutants R47A and Y51 F 
has been described previously [8,9]. Site-directed mutagenesis of fla-
vocytochrome P450 BM3 and its haem (P450) domain was according 
to Kunkel [10.11]. Oligonucleotides used to construct the indicated 
mutants were as follows (plasmid nomenclature in parentheses, under-
lined bases indicate mismatches): LI8IK (pCM2I) - 5'-CATTGCTT-
CATCCflTGCACGGACCATAC-3' LI8IR (pCM22) - 5'-GCTT- 
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CATCCCGTGCACGGAC-3' L437K (pCM23) - 5'-GGTTTTAAC-
GTTUAGTrTAATATCC-3' L437R (pCM24) - 5'-GGTTVFAAC-
GTTçQAGTTTCTTTAATATCC-3' 1263K (pCM6I) - 5'-GTTTC-
GTGTCCCGCflTTAAGAATGTAAT-3' L75K (pCM59) - 5'-CG-
TACAAAmCTTCGCTTGACTTAAG-3' L181 KI1_75T (pCM60) - 
5'-CGTACAAATTfAGTCGCTTGACTTAAG-3' 
Double mutant R47A/Y5 IF was prepared by mutagenesis of exist-
ing clone pCM25 (R47A) [9] using primer 5'-GACTTGATAA-
GAAGCGCGTTAC-3'. Triple mutant R47AJY5IF/LI8IK was gen-
erated by digestion of the existing plasmid clones pCM28 (R47A/ 
Y5IF) and pCM2I (LI8IK) with SpeI and AflhI, followed by purifi-
cation of the smaller (1.5 kb) fragment from the pCM28 digest and 
the larger ('-6.5 kb) fragment from the pCM21 digest by elution after 
agarose gel electrophoresis. These fragments were re-ligated to gener-
ate clone pCM29 (R47AIY5IF/Ll81K). All mutations were verified 
by sequencing the complete gene. Plasmid preparations, transforma-
tions and dideoxy DNA sequencing (to verify mutations) were per-
formed by standard methods [12]. Esclzeric/zia co/i strain TGI was 
used for the expression of the enzymes [13]. 
Wild-type and mutant P450s BM3 were expressed under the control 
of the BM3 promoter system, which is highly active in stationary 
phase. Transformed E. co/i cells were grown in Luria—Bertani medium 
supplemented with 25 .tg ml— ' carbenicillin. Enzymes were purified 
following the reported protocol [8]. Pure proteins were concentrated 
to 200 1.tM by ultrafiltration, dialysed against 11 of storage buffer 
(50 mM Tris—HCI, 1 mM EDTA, pH 7.4) containing 50% (v/v) glyc-
erol, and stored frozen at —80°C. 
Steady-state kinetic assays were performed at 30°C in assay buffer. 
Substrate oxidation assays were performed as described previously [9], 
monitoring coupled oxidation of NADPH at 340 nm (es = 6210 M' 
cm'). Enzyme concentration was ! ~ 3 l.IM and substrate (carboxylic 
acids of differing chain length from butyric acid (C4) up to arachi-
donic acid (C20)) was added over a range of different concentrations, 
according to the enzyme affinity. The reaction was initiated by addi-
tion of NADPI-1 (200 l.tM). Initial rate of substrate oxidation was 
measured over the first minute. Specific enzyme rates were calculated 
and plotted against substrate concentration, and the data fitted to the 
Michaelis function to generate kcat and KM parameters. 
Substrate dissociation constants (K4 values) were determined by 
following the low- to high-spin perturbations of the ferric absorption 
spectra (absorbance shift from 419 to 390 nm) upon substrate-induced 
removal of the sixth (water) ligand to the heme iron. Titrations were  
performed either by addition of small (<0.5 Ill) volumes of alcoholic 
arachidonic acid using a Hamilton syringe (< 5 il total), or by mixing 
aliquots of substrate-free enzyme solution with substrate-saturated 
aqueous solutions containing enzyme at the identical concentration. 
By mixing substrate-free and substrate-saturated enzyme solutions in 
different ratios, the desired substrate concentration is obtained. Spec-
tra were recorded between 800 and 300 nm at each point in the titra-
tion. Difference spectra were generated and the maximum absorbance 
difference calculated. Differences were plotted against substrate con-
centration and fitted to a rectangular hyperbola to generate the Kd in 
each case. All data manipulations and non-linear least-squares curve-
fitting were performed using Origin (Microcal). 
Determinations of P450 integrity and concentration were achieved 
by generating the ferrous-CO adduct of each enzyme. Reduction was 
performed by addition of sodium dithionite to the enzyme (—'5 PM) 
in assay buffer, and carbon monoxide gas was bubbled into the solu-
tion slowly for 60 s to generate the characteristic P450 complex. In all 
cases, there was near complete (>95%) conversion to the ferrous-CO 
adduct at 450 nm ('P450'), indicative of active protein. Negligible 
amounts of the inactive ('P420') species were observed. P450 concen-
tration was determined from the reduced/CO-bound minus reduced 
difference spectrum, using E450-490 = 91 MM- 1 cm. 
3. Results and discussion 
Our mutagenesis strategy was based on examination of the 
active site of palmitoleate-bound P450. Residues in the central 
region of the long, hydrophobic channel in van der Waals 
contact with the substrate and less than 10 A from the 
heme were selected as mutagenesis targets (Fig. I). Since the 
Arg47, Tyr5l motif at the active site mouth is essential both 
for binding carboxylate groups of long chain substrates and 
transition state stabilisation [7,9], we constructed a series of 
mutants in which the selected hydrophobic amino acids 
(Leu75, Leul8l, 11e263 and Leu437) were altered. These 
were changed to residues capable of forming hydrogen bonds 
or salt bridges to the carboxylate group of shorter substrates 
(C4 —CIO). We also examined the effects of removing the R471 





Fig. I. Important amino acids in the X-ray atomic structure of palmitoleate-bound P450 BM3. Several amino acids have key roles in substrate 
association (R47, Y51, F42 [9]), regioselectivity of substrate oxidation (1787 [211), haem incorporation and haem iron spin -state regulation (W96 
[22]) and coordination of the haem iron (C400). Other residues within the substrate binding pocket are in van der Waals contact with substrate, 
and were targets for mutagenesis in this study. 
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Table I 
Catalytic parameters for wild-type and mutant P450s BM3 
175 
Enzyme Substrate 
C4 C6 C8 C10 C2 C20 
Wild-type kcat (min) 88 ± 6 229 ± 26 1364 ± 153 6393 ±486 5140 ± 90 17100 ± 190 
KM 387±66 mM 243±49 mM 39±9 mM 6±1 mM 290±20 IIM 4.7±0.3 l.tM 
keat/KM (mM min') 0.23±0.065 0.94±0.35 35± 15.5 1066±310 17700 ± 1700 (3.64±0.29)x 10 
R47A/Y51F kcal (min) 142±16 156±31 692±61 1654±88 2095±88 3234± 199 
KM 463± 123 mM 480±134mM 46±10mM 4.6±0.6mM 514±48 iM 33±4 jiM 
kcai/KM (mM min) 0.307±0.154 0.325±0.215 15.0±5.9 360±75 4080±600 98000±20400 
L181  kcat (min) 353±7 166± 10 747±20 547±35 693±27 3073 ± 174 
KM 116±8mM 121 ± 14 	m 4.0±0.3mM 3.8±0.6mM 134±20 jiM 6.3±0.7 p  
kcat/KM (mM min) 3.04 ± 0.29 1.37 ± 0.27 187 ±20 144± 38 51700 ± 11500 (4.88 ±O.92)x 10 
L181K/L75T kc .at (min) 205± 17 2590±212 3256 ± 128 116±7 269 ± 13 14006±624 
KM 602±79.5 mM 177±32.5 mM 19.7±2.1 mM 2.67±0.36 mM 316±38 jiM 9.3± 1.4 jiM 
kcat/KM (mM min) 0.34±0.08 14.6±4.8 165±27 43±10 850± 160 (1.51 ±0.35)x 106 
The 	and KM values were determined as described in Section 2. Catalytic efficiency of wild-type and mutant P450s was calculated as the 
kcat/KM ratio. ND = 'not determinable', and indicates that catalytic rate was not significantly higher than background, preventing accurate deter-
mination of the kcat and KM values. 
capable of diffusing further into the active site without becom-
ing tethered in a position unfavourable for catalysis. 
All mutant enzymes had a full complement of fiavin and 
heme, indicating the mutations did not cause major disruption 
to the tertiary structure. Catalytic (kcat and KM) and substrate 
binding (Kd) studies of wild-type P450 BM3 showed there was 
modest binding (KM, Kd in mM range) of substrates with 
chain length shorter than laurate (Tables I and 2). However, 
mutants LI8IR, L437K, L437R and R47AIY51F/LI8IK 
showed weaker binding and lower catalytic activity than 
wild-type P450 BM3 with all substrates. The L437K and 
L437R mutant enzymes were particularly severely affected. 
L437R had rates of < 10 min -] with all substrates, and max-
imal activity obtained with L437K was only 120±4 min 
with arachidonate, almost 150-fold lower than wild-type 
P450 BM3. 
Mutants 1263K and L75K retained considerable activity 
(kcal, min- ') with laurate (10 14 ± 14 and 1090 ± 34, respec-
tively cf 5140±90 for wild-type P450 BM3) and arachidonate 
(1443±73 and 1395±54 cf 17100±190 for wild-type P450 
BM3), but showed no activity improvement (kcat ) with short 
chain substrates. However, KM values (mM) for 1263K and 
L75K were lower for hexanoate (49 ± 7.6 and 114 ± 18, respec-
tively, cf 243±49 for wild-type), octanoate (14.6±1.1 and 
9.8 ± 1.3 cf 39 ± 9.0) and decanoate (0.85 ± 0.06 and 2.5 ± 0.3 
cf 6 ± I). These KM improvements lead to small increases in 
efficiency (kcai /KM) over wild-type for 1263K with hexanoate 
(4.3-fold) and octanoate (1.9-fold), and for L75K with octa-
noate (2.7-fold). Spectral measurements also indicated im-
provements in hexanoate and decanoate binding for L75K 
(Kd values = 79 ± 19 mM and 0.63 ± 0.09 mM, respectively). 
A feature of mutant 1263K was that, for all substrates, spin- 
Table 2 
Binding (dissociation) constants for wild-type and mutant P450s BM3 
state perturbation on substrate binding was much less than 
for wild-type P450 BM3. This prevented accurate determina-
tion of Kd values for substrates other than laurate and ara-
chidonate. Mutants 1263K and L75K showed encouraging 
changes in substrate chain length specificity. However three 
other mutants (R47AIY5IF, LI8IK and L75T/LI8IK) 
showed more dramatic alterations in activity and selectivity, 
and are discussed in more detail below. 
3.1. R47A/Y5IF 
In P450 BM3, both the arginine 47-to-carboxylate salt 
bridge and the tyrosine Si-to-carboxylate hydrogen bond 
are important for efficient catalysis [7]. The contribution of 
R47 is more important to fatty acid binding [9]. By creating 
the double mutant enzyme R47A/Y5 IF we sought to inves-
tigate two distinct problems: (I) whether total removal of this 
motif has severe effects on binding of long chain substrates, 
and (2) whether binding and catalysis of shorter chain sub-
strates is favoured due to their ability to diffuse further into 
the active site, following removal of a motif that would oth-
erwise 'trap' them distant from the heme iron. Significant 
decreases in kcat and increases in KM for both laurate and 
arachidonate were measured for R47A/Y5IF (Table 1). These 
resulted in 4.3- and 37.1-fold decreases in efficiency (kcat /KM) 
for laurate and arachidonate, respectively, compared to wild-
type. The cumulative effect of the two mutations is greater 
than the effect of either in isolation [9]. Thus, both residues 
are needed for efficient function of P450 BM3, supporting 
recent predictions [14]. 
Characterisation of the properties of the R47A/Y5 1 F en-
zyme with fatty acids shorter than C12 chain length showed 
that there was no improvement in binding (Table 2) and that 
Enzyme Substrate and Kd (mM) 
C4 C6 C8 C10 C12 C20 
Wild-type 261 ±27 131 ± 10 12±2 2.6±0.4 (241 ±7)X 10 (3.6±0.3)x 10 
R47AIY5IF ND ND 50±14 ND ND (5.3±0.2)x10 3 
L181K 91±18 246±32 4±1 (312±26)x10 3 (255±33)x10 3 (2±0.2)x10 3 
LI8IK/L75T 9.3± 1.9 18.5±5.4 5.1 ±0.9 0.99±0.12 (297±30)x 10 (14± 1.5)x 10 
Kd values were determined by spectral titration as described in Section 2. ND = 'not determinable', and indicates that extent of spectral shift in-
duced by the substrate was not great enough to enable the accurate determination of a Kd value. 
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Fig. 2. Model for substrate interaction in P450 BM3. A hydropho-
bic patch adjacent to the active site entrance makes initial interac-
tions with the alkyl chain of fatty acids. (A) Electrostatic forces ori-
entate the. substrate carboxylate group towards R47, and a 
hydrogen bond between the carboxylate and the hydroxyl group of 
Y51 further stabilises the binding. (B) The alkyl chain of the sub-
strate is drawn into the active site channel, where favourable hydro-
phobic interactions ensure strong association. (C) The final catalyti-
cally competent orientation is achieved, in readiness for haem 
reduction and the initiation of the catalytic cycle. 
catalytic efficiency was reduced > 2-fold for C6 to C 1 0 sub-
strates. For butyrate, there was no significant difference in 
catalytic efficiency between R47AJY5 I F and wild-type (Table 
I). Clearly, removal of the motif does not improve the short 
chain selectivity by preventing molecules from binding at the 
mouth of the active site. In fact, it appears to be important for 
the binding of substrates of all chain length, probably by the 
recognition of substrates from the bulk solution (Fig. 2). 
A hydrophobic patch at the surface of the haem domain, 
adjacent to the active site, is postulated to act as an initial 
surface for substrate interaction [7]. The palmitic acid binding 
properties of a P25Q mutant in this region (Kd increased 
100-fold) are consistent with this postulate [15]. However, 
substrate cannot enter directly into the long hydrophobic ac-
tive site channel, since mutual hydrophobic effects cannot be 
transmitted long-range in solution. Instead, we consider that  
the fatty acid carboxylate is attracted by electrostatic (solu-
tion-transmissible) forces to the guanidinium group of R47 at 
the mouth of the active site. Once this occurs, a hydrogen 
bond to the hydroxyl group of Y51 can also form. At this 
point, there is a strong driving force for the movement of the 
long hydrophobic tail of the fatty acid from the polar solvent 
phase into the substrate binding channel. Once inside, inter-
actions with several hydrophobic side-chains occur. Thus, the 
R471Y51 motif is critical for guidance of fatty acids into the 
active site. 
3.2. LI8JK 
This was the most successful single mutant studied. Ll8lK 
has decreased catalytic efficiency with long chain substrates, 
but markedly improved efficiency with shorter chain fatty 
acids, particularly butyrate (13-fold over wild-type) and octa-
noate (5-fold) (Table I). Catalytic efficiency is not significantly 
different from wild-type for hexanoate, and is decreased 7-fold 
for decanoate. However, in both cases it is kcat that is unfav-
ourably affected. The KM for hexanoate and decanoate is 
actually decreased compared to wild-type (Table 1). The 
LI81K Kd is also decreased for butyrate, octanoate and dcc-
anoate. Mutant LI81K shows large conversion in substrate 
selectivity, with the ratio of catalytic efficiency (k cat /KM) for 
short chain fatty acids to that for arachidonate increased 99-
fold for butyrate and 40-fold for octanoate over wild-type. 
Interestingly, LI8IR does not show similar characteristics 
and is severely affected in catalysis. The kca t values for this 
mutant are <40 min 	for all substrates :5 C 1 0, and only 
584± 14 min 	for arachidonate. Substrates of chain length 
<C 12 do not induce a significant spin-state shift in the LI8IR 
heme, preventing determination of Kd. Clearly, length and/or 
mobility of the lysine sidechain are critical factor(s) in pro-
moting the observed substrate selectivity changes in LI8IK. 
Also notable is that triple mutant R47A/Y5IF/LI81K is se-
verely impaired in binding and catalysis with all substrates. 
There is no measurable activity with substrates of chain 
length <C10, and activity is only 1213±38 min with ara-
chidonate. Clearly the LI81K mutation cannot compensate 
for the absence of the R47/Y51 substrate binding motif. 
3.3. L75T/LI81K 
In this double mutant, we combined the best single muta-
tion (LI8IK) with a second mutation in which L75 was mu-
tated to an amino acid (threonine) with a hydroxyl containing 
side-chain. Here, we attempted to recreate, close to the heme, 
a motif (lysine/threonine) with similar chemical character and 
bonding capability to the R47/Y5 I motif at the active site 
mouth. The L75T/1_I81K double mutant also showed marked 
alterations in substrate selectivity (Tables I and 2). The most 
striking improvements in catalytic properties of L75T/LI81K 
are the large increases in kcat with hexanoate and octanoate. 
KM values for these substrates are also lower than for wild-
type, leading to 15.5-fold (hexanoate) and 4.7-fold (octanoate) 
increases in catalytic efficiency. Kd measurements also indicate 
considerable improvements in binding of butyrate and hexa-
noate, with the Kd for octanoate essentially unaltered from 
that for LI8IK. Catalytic efficiency with butyrate is also un-
altered compared to L18IK. The L75T/LI8IK double mutant 
has a binding and catalytic profile distinct from the LI8IK 
single mutant, with improved catalytic parameters for hexa-
noate. 
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Few amino acids are well conserved throughout the P450s, 
ceptions being those in the heme binding motif around the 
bsolutely conserved cysteine that provides the sulfhydryl Ii-
And to the heme iron (C400 in P450 BM3) [16]. However, the 
ucine corresponding to 1_181 in P450 BM3 is conserved in 
veral P450s, particularly in members of the CYP 4 family - 
ttty acid hydroxylases. In many P450s, a hydrophobic resi- - 
ue is conserved at this position, usually a phenylalanine in 
450s exhibiting specificity for aromatic substrates [17]. One 
f the most interesting of all P450 protein engineering results 
'as obtained by mutation at the position corresponding to 
181 in mouse P450s 2A4 and 2A5. These two enzymes differ 
y only 11 amino acids, but have marked differences in sub-
rate specificity. P450 2A4 catalyses 15(x-hydroxylation of 
stosterone and has a leucine at position 209 (corresponding 
L181 in P450 BM3). P450 2A5 catalyses coumarin 7-hy-
roxylation and possesses a phenylalanine here. Swapping 
ese residues reverses substrate specificity, such that P450 
A4 L209F catalyses coumarin hydroxylation and vice versa 
r testosterone [18]. Thus it is possible that L181 of P450 
M3 is located at a position of importance in dictating 
450 substrate selectivity. Leucine 181 is located in the centre 
f the F-helix, a motif postulated to be involved in substrate 
iteractions as part of SRS2 (substrate recognition sequence 
in Gotoh's model [19]. The leucine is also conserved as the 
nal residue of the steroid recognition 'GERL' motif in P450s 
f subfamilies 1 IA and 1 I  [201. 
Conclusions 
In this study, we have demonstrated for the first time that 
P450 BM3 has measurable affinity for alkanoic acids shorter 
than C12, and also that preference for fatty acids of this chain 
length can be selectively enhanced by rational mutagenesis. 
The single mutation L18IK reduced the Kd for decanoate to 
micromolar levels (312 ± 26 tiM), and induced large increases 
in catalytic efficiency and affinity (Kd) for butyrate and octa-
noate. By introducing a second mutation (1-75T), some fur -
ther improvements were obtained. In particular, mutant 
L75T/L181K showed a huge kinetic improvement with hexa-
noate. Mutants L181K and L75T/L181K are considerably im-
proved enzymes for the binding and catalysis of short-chain 
fatty acids, providing evidence for a key role for 1_181 in 
controlling P450 BM3 substrate selectivity. 
Removal of the carboxylate binding R47/Y51 motif dimin-
ishes catalytic capacity with all substrate chain lengths, indi-
cating its importance in preliminary substrate binding inter-
actions (Fig. 2). Clearly, this motif should not be altered in 
future attempts to re-engineer P450 BM3 fatty acid chain 
length selectivity. 
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I. Introduction 
Protein engineering is generally understood to 
mean the use of site-directed or random mutagenesis 
to alter the properties of a protein or enzyme. This 
often involves the modulation of substrate specificity 
or selectivity of an enzyme. In this review we have 
extended the definition to encompass other impor-
tant aspects of structure/function investigations, par-
ticularly the construction of chimeras and genetic 
fusions to investigate substrate specificity and elec-
tron transfer, and the modification of the N-terminal 
• Corresponding author. Fan: +44 (531) 6554760/4743; 
E.mnil: s.k.chapman@ed.ac.uk  
membrane anchor of eukaryotic P-450s to facilitate 
overexpression and for the investigation of protein 
targeting. In the course of the review we will use 
specific examples to address these topics and high-
light the most significant breakthroughs made in re-
cent years. The variation of protein engineering ex-
periments applied to the cytochromes P.450 is a 
reflection of the medical and technological impor-
tance of these enzymes. It is useful, therefore, to 
briefly consider the properties of the cytochromea 
p-450 and some of the major advances in our under-
standing of their biological roles and catalytic mech-
anisms. 
The cytochromes P.450 are a family of b-type 
heme containing proteins found in virtually every 








Pig. I Schematic representation of the different classes of cyto-
chrome P.450 systems. Claus I systems are composed of an 
FAD containing flavodosin reductuse, an iron-sulfur cluster 
containing flavodoxin and the P.450. The P.450 in a class II 
system is partnered by a diflavin reductase, and in a class Ill 
system, the diflavin reductase is fused to the P.450 in a aingte 
polypeptide. 
of a diverse array of aromatic and aliphatic com-
pounds in numerous biosynthetic and metabolic 
pathways. In mammals, they are central to the pro-
cesses of drug metabolism and steroid hormone syn-
thesis. In plants they play important roles in herbi-
cide resistance and biosynthetic pathways (e.g. 
morphine biosynthesis), they are involved in antibi-
otic synthesis in fungi, plant toxin defence in insects, 
and in the metabolic and synthetic pathways of bac-
teria. The most common reaction catalyzed is by-
droxylation (see below) but forms that catalyze ep-
oxidation, dealkylation and sulfoxidation are known. 
RH +02+ 2H + 2e —s ROH + H20 
The P450 reaction requires two electrons (provided 
by redox partner proteins), dioxygen and two pro- 
tons. It proceeds via an activated oxygen species that 
effects controlled insertion of an oxygen atom into 
the substrate. Most bacterial and all of the eukary-
otic mitochondrial P450 systems are three compo-
nent protein systems (class I): the redox partners 
consist of an NADH-dependent FAD containing fer-
redoxin reductaae and a ferredoxin. Eukaryotic mi. 
crosomal P450 systems (those associated with the 
endoplasmic reticulum) are two component systems 
(class II): the redox partner is an NADPH-depen-
dent difiavin (FAD and FMN containing) reductase. 
A third class (class Ill), of which the representative 
system is the bacterial P.450 BM3, is a one compo-
nent system similar to class II but where the two 
components are fused in a single polypeptide. A 
schematic depiction of these system types 121 is illus-
trated in Fig. I. In the P450 itself, in all of these 
system classes, the heme iron is proximally ligated by 
a cynteine-thiolate, and in the resting state, the ferric 
iron is distally ligated by water, The reaction cycle is 
81 
Fig. 2. The catalytic cycle of cysochrome P.450. The cycle is in. 
itiated by substrate (RH) binding to the ferric P.450 (I), per-
mitting the first electron transfer (2) with consequent iron re-
duclion and binding of oxygen (3). Second electron transfer (4) 
results in formation of the iron-peroxo species (4) and subse-
quently the oxyferryl intermediate (5). This resets with bound 
substrate (6) and (7) to yield bydroxylated product that diffuses 
from the active site to complete the cycle (8). 
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represented in Fig. 2. Mechanistic information on 
this cycle has come largely from studies on the 
P450cam system, and is generally assumed to hold 
for all P.450s [3]. The cycle is initiated by substrate 
binding close to the heme, which usually induces a 
change in the spin state of the iron from low to high 
spin. The iron is reduced to the ferrous form by the 
transfer of one electron from a redox partner and 
oxygen binds rapidly. The second electron transfer 
to the heme results in the cleavage of dioxygen and 
the formation of a transient oxy-ferryl intermediate 
(similar to compound I seen in peroxidases) and the 
release of water. Ultimately, the reactive oxyferryl 
species attacks the substrate, resulting in the mono-
oxygenation of the compound. 
The number of P.450 genes now recognized is 
enormous and genome sequencing projects continue 
to add to this on a day-to-day basis. The sequences 
have been organized into what is now termed the 
P450 gene 'superfamily' [4] (see K.irill Degtysrenko's 
Directory of P.450 systems at http:I/www.icgeb. 
trseste.it/—p45osrv/and David Nelson's P.450 home 
page at http:/ldrnelson.utmem.edulCytochrOmeP450. 
html), allowing a greater understanding of the evo-
lution of the P-450s from primordial forms. The 
presence of a P.450 in the archaeon Sulfolobus sol-
fataricus indicates that they are ancient enzymes [5]. 
It is possible that they arose as a means for breaking 
down toxic oxygen when it first became abundant on 
earth, and an early physiological role may have been 
the modification of lipids for the cell membranes of 
microbes. 
The presence of P450s in organisms as diverse as 
bacteria and man is a reflection of the importance of 
the oxygen cleavage reaction that they catalyze. 
Through evolution, nature has adapted this reaction 
to suit the requirements of numerous different syn-
thetic and degradative pathways. P-450s are adapted 
to act on molecules as small as nitric oxide (P450nor 
from the fungus Fusarium oxysporum) [6] and as 
large as cholesterol and polycyclic aromatic hydro-
carbons (e.g. mammalian P-450s sec and IAI) [7,81. 
This substrate diversity demonstrates the potential 
for strategic engineering to provide a route for the 
generation of P450 enzymes tailored to a chosen 
molecule, enabling the regio. and stereoselective oxy-
genation of new substrates. The reactivity of oxygen 
makes selective oxygenation difficult to achieve by 
Fig. 3. Schematic representation of the hesne domain of Savocy-
tochoome P.450 DM3, showing the characteristic P.450 fold, 
produced using MOLSCRIPT 11531. The hem, cofactor is visi-
ble as a ball-and-stick elnacluee and helices A-L are labeled. 
conventional chemical means. This is one area 
great interest in the field of P450 engineering. 
1.1. The structural basis for cytochrome P.450 
engineering 
Rational re-design or re-engineering of an enzyme 
requires a firm structural basis. At present there are 
eight atomic structures for different cytochromes 
P450. Only five of these are freely available at 
present, although two others (mammalian P450 
2C5 [9) and S. solfataricus CYPII9 [101) will be re-
leased in 2001. Four of those currently accessible are 
for soluble bacterial enzymes. These are cytochrosne 
P-450cam (CYPIOI; camphor hydroxylase from 
Pseudomonas putida) [11]; the heme domain from 
cytochrome P.450 BM3 (CYPI02; a fatty acid hy. 
droxylase from Bacillus megaterium) [12]; cyto. 
chrome P.450terp (CYP108; a-terpineol hydroxylase 
from a Pseudomonas species) [13]; and the substrate-
bound form of P450eryF (CYPI07AI; 6-deoxy-
erythronolide B hydroxylase, involved in the synthe-
sis of erythromycin biosynthesis in Saccharopoly-
spora erylhraea) [14]. In addition, there are crystal 
structures of substrate-bound P450cam and P450 
BM3 heme domain [15,16], as well as other ligand-
bound structures for these enzymes. The fifth struc- 
lure currently accessible is also a soluble enzyme, 
cytochrome P450nor (CYP55AI), a nitric oxide re-
ductase from F. oxysporum [6]. The remaining P450 
is P.450 sca2 from Streptomyces carbophilus, an in-
dustrially important enzyme which catalyzes the final 
hydroxylation step in the synthesis of the cholesterol 
lowering drug pravastatin [17]. All these enzymes dis-
play close structural similarity, at least in terms of 
overall topology, in spite of very low sequence iden-
tity. Generally, sequence identities are no more than 
20%. The P.450 tertiary structure has an approxi-
mate trigonal prism arrangement containing both 
cs-helical and 3-sheet regions (Fig. 3). Helices domi-
nate the structure, and many of these lie approxi-
mately parallel to the plane of the hcme. The heme 
is bracketed by two helices: the I helix lies distal to 
the heme and spans the diameter of the protein struc-
ture, the shorter L helix lies proximal to the heme, 
and its N-terminus provides the cysteine-thiolate that 
proximally ligates the heme iron. The heme itself lies 
well buried within the structure, and the substrate 
binding site lies on its distal face. The substrate bind-
ing sites of the known P.450 structures are consid-
erably different in size and shape, reflecting the na-
ture of their substrates (Fig. 4). These differences are 
due to both topological variation in the polypeptide 
backbone and the nature of the side chains lining the 
active sites. In P450 BM3, the long chain fatty acid 
substrate lies in an elongated hydrophobic channel 
that extends from the surface of the protein to the 
distal face of the heme [16]. By contrast, the sub-
strate binding site of P450cam is much deeper 
seated, and the substrate access channel is much less 
apparent. Comparison of substrate-bound P450cam 
and P450 BM3 structures with the respective sub-
strate-free forms reveals conformational differences, 
demonstrating the importance of protein motion in 
allowing substrate access. The changes are particu-
larly large for P.450 BM3. Furthermore, a crystal 
structure of P-450cans complexed with an imidazole 
ligating inhibitor considerably larger than camphor 
reveals the range of protein conformational lability 
and highlights the access route to the binding site 
[18]. The substrate binding site of P450terp more 
closely resembles that of P.450cam, not unexpectedly 
given the similarity in substrate size, whilst that of 
P450eryF is considerably larger. A further feature of 
P450eryF is that in the substrate-bound form there 
is a network of hydrogen-bonded water molecules in 
the binding site. This is different from P450cam and 
P450 BM3 where water molecules are excluded. 
The crystal structures for seven of the eight P450s 
described above are of soluble enzymes that are read-
ily overexpressed, purified and crystallized. The eu-
karyotic P.4505 are membrane-bound and present 
major problems for X-ray structural determination. 
Until recently, no such crystal structure had been 
determined. Rational engineering of these enzymes 
has relied on sequence comparisons with bacterial 
enzymes whose structures had been determined and 
also on the generation of homology models. For the 
P450 family 2, Gotoh [19] used sequence homology 
studies to identify six regions termed substrate rec-
ognition sites (SRS). These were based on the posi-
tion of camphor in P450cam, the only P450 whose 
structure had been solved at the time. Subsequent 
(5) D5fl5th 	
OH 
0 	 (c) a-teepineol 
(b) 6.danxyetythemolide B' 
- 	 (d) palnsitoleic acid 
Fig. 4. Substrates for the cytochromes P.450 cam (a), eryF (b) seep (a) and DM3 (d). 
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protein engineering studies on P-450s 2A, 28 and 2C 
have validated this model for family 2 by showing 
that most residues identified as important for sub-
strate specificity lie either within or near to these 
regions (e.g. [20-22]). The early homology models, 
based on the structure of P450cam, include those 
generated for P4505 IAI [23], 2B1 [24] and sec 
(I lAl) [25]. They suggested residues that could inter-
act with the heme and substrate, or be involved in 
membrane attachment. A comparative study of the 
crystal structures of P-450cam, terp and BM3 and 
multiple sequence alignments, including P.4505 
from all the major families [26] suggested that all 
P450s possess the same tertiary structure. Examples 
of recent molecular models generated include those 
for P450 2A6 [27] and various members of the 4A 
subfamily [28] (based on the BM3 structure) and 
further models for P-450s 19Al [29], 2B1 [30,311 
(based on the structures of P4505 cam, BM3 and 
terp) and 3A4 [321 (based on the same three struc-
tures as well as that of eryF). Overall, the use of 
homology models of eukaryotic P-450s has facili-
tated both the elucidation of suitable candidates for 
mutagenesis and the interpretation of results of mu-
tagenic studies. Conversely, results from site-directed 
mutagenesis studies have aided in the refinement and 
development of the models [33]. 
The recent determination of the structure of the 
first mammalian microsomal P450 is a major break-
through [9]. Membrane bound P450s can be solubi-
lized through modification of the protein by removal 
of the hydrophobic N-terminal anchor sequence, 
which is the major determinant of membrane binding 
(see examples in Section 3). The elegant studies of 
Johnson and co-workers have not only proven this 
for members of the mammalian 2C family, but have 
also shown that exchange of key residues from rabbit 
P.450 20 into P450 2C5 generates highly soluble 
and monomeric P450 progesterone hydroxylase [341. 
This modified P450 2C5 was crystallized and the 
structure solved to 3.0 A [9]. There is remarkable 
similarity in the topology of this structure and those 
of the microbial P450s, particularly with the P.450 
BM3 structure (despite low amino acid sequence 
identity and different substrate selectivity). Key find-
ings include identification of a broad hydrophobic 
surface likely to facilitate membrane interactions, 
and a putative substrate entry site located in this  
membrane attachment surface providing a direct sub-
strate access/product exit route from the lipid bilayer. 
2 Substrate specificity 
The factors controlling the diversity in the sub-
strate specificity of P.450s are still not fully under-
stood. However, the availability of high resolution 
crystal structures for five of the microbial cyto-
chromes P.450 [6,11-16] (see Section 1.1) has al-
lowed the key active site residues that appear to be 
involved in substrate recognition to be identified. In 
the cases of cytochromes P.450 cam and BM3, the 
analysis of the crystal structures has been comple-
mented by site-directed mutagenesis studies. This 
has enabled the precise roles of some of these resi-
dues to be elucidated, and provides the basis fox 
active site re-design. Some of this work is outlined 
below. In addition, we also describe mutagenesis 
studies on P-450s 4Al and 3A4 for which there are 
no crystal structures. 
2.1. Changing the substrate specificity of cytochrome 
P-4iOcam 
P-450cam specifically catalyzes the 5-exo-hydroxy-
Istion of camphor. The crystal structure of camphor-
bound P.450mm [15] reveals a compact substrate 
binding region, surrounded by hydrophobic residues, 
lying distal to the heme (Fig. 5). The residues impor- 
T153,_ 
V4T'K$t' 
Fig. S. The active site of P.450cam. Camphor and the heme on, 
factor are shown as thick lines, amino acid residues are shown 
as narrow lines with a dot surface. 
tant for substrate binding and regio- and stereoselec-
tivity lie within three tiers, approximately parallel to 
the hemc plane. These include L244, V295 and T101 
(Tier I, closest to the heme) and Y96 and F87 (Tier 
2), with Y96 being the only residue to make contact 
(H-bond) with the substrate [35]. A series of studies 
have been performed that employ protein engineer-
ing to probe factors pertaining to substrate specificity 
and the control of monooxygenation not only to-
wards camphor, but also to substrates such as short 
chain alkanes and polycydic aromatic hydrocarbons 
[36-38]. 
Work by Fowler et al. [38] and Stevenson et al. [36] 
involving mutagenesis of residue Y96 in P-450cam 
demonstrated how just one mutation can achieve a 
significant specificity change. Study of the Y96A mu-
tant enzyme [38] showed that it favors the oxidation 
of diphenylmethanc, a reaction not observed for the 
wild-type enzyme. A further change of this residue 
(Y96F) abolishes the strict regio- and stereospecific-
ity observed for camphor hydroxylation. Further-
more, the Y96F mutation alters the specificity of 
P-450eani for polycycic aromatic hydrocarbons 
such as naphthalene and pymene [37]. With naphtha-
lene, a high degree of regiospecificity was achieved, 
with 1- and 2-naphthol being predominant products 
(ratio 93:3, respectively). This shift in specificity was 
rationalized in terms of the increased active site vol-
ume caused by this mutation. 
Stevenson et al. [361 examined the hydroxylation 
of alkanes such as pcntane, hexane and 3-methyl 
pentane. Wild-type P450cam hydroxylates these 
substrates at poor rates (kmt values 0.9, 0.4 and 28 
min', respectively, cf. approx. 300 min' for cam-
phor hydroxylation), and with a 80 1/6 uncoupling 
(cf., <5% uncoupling for wild-type-catalyzed cam-
phor hydroxylation). However, by increasing the hy-
drophobicity of the active Site, turnover rates, as well 
as the degree of coupling, are markedly improved. 
The mutant enzyme Y96A hydroxylates pentane, 
hexane and 3-methyl pentane with turnover rates 
>60 min- I: Y96F is better still, with rates in excess 
of 100 mint and improved coupling. It was postu-
lated that the increased hydrophobicity of the active 
sites in the mutants prevented protonation of the 
heme-bound oxygen in the ferric peroxide intermedi-
ate. The product profiles for both the wild-type- and 
the Y96 mutant-catalyzed oxidations are the same, 
Fig. 6. The active site of P.450 aM3. Psimitoleate and the 
heme cofactor are shown as thick line., amino acid residues are 
shown as narrow line, with a dot surface. 
with tertiary hydroxylation predominating over sec-
ondary and primary. This is consistent with the gen-
eral reactivity of CH bonds and implies that the sub-
strate is mobile within the active site pocket. This 
would mean that the protein superstructure has little 
or no control over the orientation of these alkanes. 
In more recent studies, the same group demon-
strated that mutation of the surface residue F193 
to slanine and isoleucine in a Y96F mutant back-
ground resulted in large decreases in catalytic rate 
with camphor, naphthalene and styrene [39]. F193 
has been proposed to undergo dynamic fluctuations 
to permit substrate entry, and these data are consis-
tent with structural changes that diminish catalytic 
potency of the enzyme. 
2.2. The roles of key active site residues in 
P450 BM3 
- 
Flavocytochrome P450 8M3 hydroxylates a wide 
range of saturated and unsaturated fatty acids of 
chain length C12-C25 at the co-I to co-3 positions. In 
contrast to the compact active site of P450cam, that 
of BM3 [16] consists of a long, hydrophobic channel, 
extending from the distal face of the heme to the 
protein surface (Fig. 6). In addition to the hydro-
phobic residues lining the site, comparisons of the 
substrate-free and palmitoleate-bound crystal struc-
tures have indicated that other residues are impor-
tant in protein-substrate interactions. At the mouth 
of the active site lies R47 (which provides an electro-
static interaction with the carboxylate end of the 
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fatty acid) and Y51 (which can provide a hydrogen 
bond to the carboxylate). One further notable resi-
due at the mouth of the active site, F42, appears to 
cover the opening to the active site channel, provid-
ing what might be termed a hydrophobic 'lid'. At the 
opposite end of the active Site channel, close to the 
heme, lies the side chain of F87. The importance of 
this residue was highlighted by the large conforma-
tional difference adopted by the phenyl ring in the 
substrate-free and palmitoleate-bound crystal struc-
tures [12,16]. In the substrate-free form the side chain 
lies perpendicular to the heme plane but in the pal-
mitoleate-bound form it has twisted to he almost 
parallel to it. In this section we describe the site-di-
rected mutagenesis studies that have defined roles for 
these residues in substrate binding and in the control 
of regiospecificity and altered substrate specificity. 
The important contribution of the guanidinium 
group of R47 has been confirmed by mutagenesia 
experiments. In a study by Oliver et al. [40] the sub-
strate binding characteristics of wild-type P450 BM3 
and the mutant R47E and their abilities to catalyze 
substrate oxidation were compared. The mutant en-
zyme retained activity towards C 12-C16 fatty acids 
(but with k,,,,,IK,,, values 14-21-fold lower than 
wild-type), as well as the regioselectivity of oxidation 
(co-I to co-3). However, unlike the wild-type enzyme, 
the R41E mutant was able to efficiently hydroxylate 
C12-C16 alkylammonium compounds (also at the co-I 
to w-3 positions), with kue values of up to 19 -1 
Optical spectroscopy showed that fatty acid binding 
to the mutant is much weaker than to the wild-type 
enzyme, and paramagnetic relaxation experiments 
showed that the fatty acid adopted a different orien-
tation in the active Site channel. In a further study, 
Noble et al. [41J demonstrated the dominance of the 
side chain of R47 over that of Y51 in providing the 
major interaction with the fatty acid carboxylate. 
The same study highlighted the importance of the 
phenyl side chain of F42 in providing a hydrophobic 
'Ed' to the active site (K,,, values were increased xi-
most 10-fold for laurate and arachidonate turnover). 
This latter phenomenon was interpreted as the con-
sequence of ingress of water molecules to the active 
site and the disruption of the strong ion pair inter-
action between the R47-guanidino group and the 
fatty acid carboxylate. 
Phenylalanine 87 is located at the base of the ac- 
tive Site of P450 BM3 and, from inspection of the 
palmitoleate-bound P450 DM3 crystal structure, ap-
pears to protect the terminus of the fatty acid from 
co-hydroxylation. Consistent with this, substitution of 
F87 by alanine converts P450 DM3 from a fatty 
acid hydroxylase that oxidizes at the co-I to w-3 
positions to one that oxidizes at the co position [42] 
(a reaction not observed for wild-type P450 BM3 
but common to many mammalian P450s such as 
those belonging to the 4Al family). In the F87A mu-
tant enzyme a decrease in K.3 for laurate of up to 
6-fold was observed, showing that the removal of 
the bulky phenyl side chain facilitates tighter binding 
of medium chain (e.g. C12) fatty acids. However, the 
Km  for laurate oxidation catalyzed by the F87A mu-
tant was found to be identical to that seen for the 
wild-type enzyme. This was suggested to be due to a 
difference in the substrate binding to the ferrous and 
ferric forms. The implication is that the F87A muta-
tion causes a change in the substrate binding, not in 
the initial Michaelis complex, but in a subsequent 
step in the catalytic cycle. Proton NMR experiments 
have shown that laurate and 12-bromolaurate bound 
in the active sites of wild-type and F87A P450 DM3 
move some 6 A closer to the heme upon iron reduc-
tion [43]. Molecular modeling studies indicate that 
the absence of the phenyl ring enables the (&-ter-
minus of laurate to approach closer to the heme 
in the F87A mutant than in the wild-type enzyme, 
and these data were supported by NMR studies 
(w-CH3----Fe'°5.I A in wild-type and 3.1 A in the 
F87A mutant enzyme). This explains the mixed 
product distribution observed in wild-type for laurate 
hydroxylation and the almost exclusive (>90%) 
co-terminal hydroxylation demonstrated by the F87A 
mutant. 
2.3. Modification of the regiospecficiiy of cytochrome 
P450 4A1 
P450s of the 4A family, found in the liver and 
kidneys of mammals, are long chain fatty acid mono-
oxygenaaes that predominantly hydroxylate at the 
to position. Of these, P450 4A1 is the most exten-
sively studied [44]. A possible explanation for the 
strict co-terminal specificity is that the active site of 
P450 4Al is highly constrained, so that substrate 
binding orientation is precisely defined. The specific- 
ity of this enzyme for a range of fatty acid chain 
lengths, such as laurate (C2), palmitate (C16) and 
arachidonate (C25), suggests a possible structural 
similarity with P450 DM3. Hence, by sequence 
alignment of P450s 4Al and BM3 (considered as 
the closest structurally defined model of the 4A fam-
ily), two residues of 4A1, £320 and D323, were iden-
tified as structural equivalents of A264 and £267 in 
P450 DM3. In the crystal structure of palmitoleate-
bound P450 DM3, these two residues lie close to the 
co-terminus of the fatty acid tail. To establish the 
importance of these residues in P450 4A I, the recip-
rocal mutants E320A. D323E and the double mutant 
E320A/D323E were constructed. For all three mu-
tant P4509, there was a relaxation of the regiospe-
cific hydroxylation of laurate: in wild-type P450 
4A1 the w:co-1 product ratio is 20:1. However, in 
the E320A/D323E double mutant enzyme this ratio 
drops to only 2:1. The NADPH consumption rate in 
the reconstituted P450 mutant system did not vary 
from that observed for the wild-type (approx. 300 
min'), but significantly lower laurate oxidation 
rates for the mutant-catalyzed reactions (<40 
min for all three mutants, compared to 150 
min for wild-type) were found, which indicates sig-
nificant uncoupling. The conclusion is that the two 
residues, E320 and D323, are located in the active 
site and are involved in substrate binding. At present 
there is no experimental evidence for key roles for 
either A264 or £267 in P450 DM3 substrate binding 
or catalysis. It would be interesting to see whether 
the reciprocal mutations in P450 BM3 (A264E and 
E267D) would confer co-hydroxylation activity. 
2.4. Identification of key residues in P450 3A4 
involved in substrate and effector binding 
Family 3 of the cytochromes P450 consists of just 
one subfamily, P450 3A [451, which plays a major 
role in hepatic biotransformation pathways. Human 
3A4 is the most abundant P450 in the liver (up to 
approx. 60°h of total P450 content in some cases) 
and metabolizes a wide range of clinically important 
drugs [46] in addition to steroids [47] and carcino-
gens [48]. Its importance is underlined by the fact 
that it is reported to be involved in the metabolism 
of around 501/. of currently used drugs [46,491. P450 
3A4 exhibits cooperativity towards some substrates;  
for example, homotropic cooperativity with proges-
terone [50] and testosterone [511. Activity can also be 
influenced heterotropically, as in the stimulation of 
progesterone and testosterone oxidation by the effec-
tor a-naphthoflavone (ANF) [50]. 
Rational protein engineering studies on P450 
3A4, to study, for example, the activation by ANF 
(several proposed mechanisms are outlined in [52]) or 
substrate specificity, are potentially obstructed by the 
absence of its crystal structure and the fact that there 
is little pronounced variation in substrate specificity 
for the 3A enzymes (in contrast to family 2, for ex-
ample) [52]. However, the construction of homology 
models of 3A4 has greatly aided determination of 
candidates for mutagenesis. One structural model 
was based on amino acid sequence alignments with 
P450 BM3 and a number of substrate and inhibitor 
interactions were investigated [53]. Another model 
was built using consensus modeling methods to 
base the structure on those of P450s cam, DM3, 
terp and eryF [32]. Although this model bore most 
resemblance to BM3, the use of the eryF structure 
was reported to be important in defining the size of 
the active site through localization of the B' helix. 
Progesterone or erythromycin were docked at the 
active site and the potential contact residues noted. 
The first site-directed mutagcnesis study was car-
ried out on P450 3A4 using alanine scanning muta-
genesis to probe the roles of residues 210-216 [52]. (It 
also indicated that Gotoh's substrate recognition site 
model was applicable to the P450s 3A.) Mutant 
enzymes L2I0A and L21 LA led to a decrease in stim-
ulation of testosterone and progesterone hydroxyla-
tion effected by ANF and changes in the regioselec-
tivity of testosterone hydroxylation were also 
observed with L2I0A. This indicated that substrate 
and effector binding sites could be partially overlap- - 
ping. To test this a double mutant was constructed in 
which L211 and D214 (the latter chosen after study 
of the Szldarz model [321) were changed to phenyl-
alanine and glutamic acid, respectively [54]. The idea 
was to mimic effector binding by narrowing the size-
able binding pocket, considered large enough to be 
able to accommodate both a steroid and ANF at the 
same time (e.g. [321), through the introduction of 
bulkier residues. As a consequence, homotropic co-
operativity for steroid hydroxylation was eliminated 
and a reduced response to stimulation by ANF was 
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observed. Further analysis of the model for residues 
that could affect cooperativity suggested that F304 
(positioned on the highly conserved I helix and sug-
gested experimentally [55) and from the model to 
play a role in substrate binding) was a likely candi-
date [561. As with the L2IIF(D214E double mutant, 
the F304W enzyme was unable to fully mimic effec-
tor binding. However, the triple mutant L2IIF/ 
D214E1F304W was much more effective. 
Other residues whose mutation influenced stimula-
tion of activity by ANF are 1369, L373 (SRS 5) [571 
and A305 (SRS 4) [551. 
Related studies of P.450 3A4 probed aspects of 
substrate binding and specificity. It was shown 
through mutagenesit of S 11 from SRS I, a residue 
predicted from modeling to be involved in progester-
one binding [32], that P.450 3A4 could be converted 
from a steroid 6-hydroxylaae to a 2-hydroxylase 
[581. This residue may occupy a similar position to 
F87 in P.450 BM3 [32,58), shown to be important in 
controlling regioselectivity of substrate oxidation (see 
Section 2.2). Cassette and site-directed mutagenesis 
were carried out on amino acids 364-377 in SRS S 
[57]. Two of these residues, 370 and 373, were pre-
dicted from the model to interact with progesterone 
when the substrate was docked in the 6-orientation 
[32]. Mutant enzymes 1369V, A370V and L373H all 
exhibited altered progesterone metabolic profiles. 
1369V and A370V showed decreased and increased 
l6ct-hydroxylation activities, respectively, compared 
to the wild-type enzyme. However, mutant L373H, 
whilst retaining progesterone 6§ and 16ix activities, 
produced a new, unidentified, metabolite. Analysis of 
progesterone docked in the 16a binding orientation 
in the model suggested that the effects observed with 
the 1369V and A370V enzymes (involving substitu-
tion with a smaller and a larger residue, respectively) 
were due to changes in substrate mobility within the 
active site. 
In addition to the above studies to probe substrate 
and effector binding, the structure-function relation-
ship between P4505 3A4 and 3A5 was investigated 
using differences in the regiospecificities of the two 
enzymes (which share >85% amino acid sequence 
identity) towards the biotransformation of the carci-
nogen afiatoxin B1 [59]. The six, putative substrate 
recognition sites of the two enzymes were compared 
and non-conserved residues between the two enzymes  
were replaced in P450 3A4 with those of P.450 3A5. 
Two, individual, mutations in SRS 2 (N206S and 
L2I0F) had the greatest effect, conferring the pheno-
type of the 3A5 enzyme onto P450 3A4. 
Thus far, analysis of P450 3A4 through the use of 
homology models and mutageneais in the absence of 
a crystal structure has provided significant advances 
in the understanding of substrate and effector bind-
ing in this enzyme. Eventually it is hoped that these 
and further studies will allow prediction of drug/drug 
interactions with P450 3A4 [56]. 
2.5. Chi,neragenesls as a probe of substrate specificity 
The absence (until recently) of crystal structures 
for mammalian P4508 limits solid understanding of 
the factors that confer substrate specificity. However, 
one approach to this problem that has proved suc-
cessful is the use of chimeric constructs in combina-
tion with site-directed mutagenesis to identify struc-
tural determinants of substrate specificity within a 
P450 subfamily. In most cases, two P450s with 
high sequence identity but different substrate specif-
icities have been investigated by substituting a region 
of one with the corresponding region from the other 
and analyzing for any change in substrate specificity. 
Once regions of interest have been elucidated, site-
directed mutagenesis can be used to pinpoint key 
individual residues that are responsible for the par-
ticular substrate specificity. A number of such studies 
using P450 chimeras have been published over the 
last 5 years, the majority concerning P450 family 2. 
These include: 2Cl and 2C2 [60]; 2Bl and 232 [61]; 
284 and 285 [62]; 2C9 and 2C19 [63-65]. For this 
reason, we have chosen to highlight this family in this 
section of the review, focusing on human P450s 2C9 
and 2C19. Other examples discussed are canine 
P4508 3Al2 and 3A26 [661 and P450a Cm2 and 
AIk3A from the yeast Candida ma/tosa [67]. These 
studies demonstrate the power of the chimeragenesis 
approach in elucidating the controlling factors of 
substrate specificity. 
2.5.1. Probing substrate specificity of cytochromes 
P.450 2C9 and 209 
The P450s of the 2C family comprise approx. 161/6 
of the total hepatic P450 content [68]. They are 
weakly inducible by phenobarbital, and are fre- 
Fig. 7. Substrates for P-450s 2C9 and/or 2C19. 
quently involved in hydroxylations of aromatic ring 
systems. Endogenous substrates for the 2C subfamily 
are usually steroids, although rabbit P450 2C2 is 
known to hydroxylate laurate at the 0)-I position. 
Human P450s 2C9 and 2C19 are closely related, 
with 92% sequence identity [69]. 2C9 is a testosterone 
16]3.hydroxylase, but the physiological substrate for 
2C19 is not clear. Both metabolize a number of clin-
ically important drugs, an example common to both 
being the anti-coagulant warfarin (Fig. 7, I) [65). 
However, the regio- and stereospecificities of 2C9 
and 2C19 towards this substrate differ. The non-ster-
oidal, anti-inflammatory drugs ibuprofen (11) and di-
clofenac (III) are principally metabolized by 2C9 
[70]. 2C19 does not metabolize either of these com-
pounds [71,72], but shows selectivity for 4'-hydroxy-
lation of the anti-convulsant S-mephenytoin (IV) [73] 
and 5'-hydroxylation of omeprazole (V) [71  (an anti-
ulcer drug). In general, 209 appears to have less 
stringent steric requirements than does 2C9 [65]. A 
further difference between the two is that 2C9 is in-
hibited by sulfaphenazole (VI) (K.j <1 tiM) whereas 
2C19 is not inhibited by this compound at concen-
trations even up to 100 tIM [75,76]. A detailed 
knowledge of the determinants of substrate specific-
ity in these two P450s could provide the basis for 
the design of drugs less dependent on metabolism by 
a specific isoform [65]. In other words, their metab-
olism would be less affected by genetic variation, an 
important factor considering, for example, that 15-
20% of Orientals and 2-5% of Caucasians do not 
express 2C19 [77]. 
Using the substrate recognitions sites identified by 
Gotoh [19], Ibeanu et al. [64] constructed 2C912C19 
chimeras and site-directed mutant forms of 2C9 to 
elucidate the key determinants of omeprazole by-
droxylation by 2C19. A 2C9 chimera containing res-
idues 160-227 from 2C19 in combination with the 
point mutation 199H gives an engineered P450 
2C9 which displays greater omeprazole 5.hydroxy. 
lase activity than does 2Cl9. Further site-directed 
mutagenesis showed that three residues from 209 
were found to confer omeprazole activity into 2C9. 
The 199H, S220T and P22 IT triple mutant of 2C9 
hydroxylated omeprazole as efficiently as 2C19. Res-
idue 99 is located within a predicted substrate recog-
nition site (SRS I) whereas 220 and 221 are not. 
According to the results of sequence analysis with 
P450carn they are located on the turn between the 
F and 0 helices [19]. This region varies considerably 
in length between P.450s and may form a flexible cap 
over the active site, thereby forming part of the sub- - 
strate ass channel [26,64,78]. 
More recent studies [63] have determined the crit-
ical areas of P450 2C9 which define the specificity 
for diclofenac and ibuprofen. Chimeras of both 2C9 
and 2C19 were constructed with the emphasis on 
SRS 3 and 4. Replacing residues 228-340, containing 
SRS 3 and 4, of 2C 19 with those of 2C9, generated a 
chimera that could hydroxylate both drugs. Interest-
ingly, the regiospecificity for ibuprofen hydroxylation 
differs from that of wild-type 2C9, probably indicat-
ing that the orientations of the bound substrate are 
slightly different. The converse construct had little or 
no activity towards diclofenac or ibuprofen. Individ-
ual substitution of SRS 3 and 4 revealed that the 
latter was the most important region for conferring 
specificity. As the two isoforms differ in only five 
residues within SRS 4 (283-340), site-directed mute-
genesis was carried out on a 2C19 chimera contain- 
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ing residues 228-282 of 2C9 (including SRS 3) to 
pinpoint the key residue(s). These studies showed 
that the 1289N mutation confers specificity for diem-
fenac hydroxylation. The activity increased when a 
second mutation, N286S, was introduced. In addi-
tion it was shown that S286 in combination with 
N289 confers specificity for ibuprofen, the former 
residue appearing to be the major contributor. 
Both these residues are found in a highly conserved 
region corresponding to the I helix of structurally 
characterized cysochromes P450. 
The importance of residues N289 and S286 in 
P.450 2C9 was again underlined by Jung et al. 
1651 who investigated the amino acid residues that 
confer a high affinity for sulfaphenazole binding 
and a high catalytic efficiency for warfarin metabo-
lism. Two substitutions of 2C9 residues into 209, 
N286S and 1289N, were found to be sufficient to 
confer high affinity binding of the inhibitor sulfaphe-
nazole (K4 = 4 sM). Interpretation of results was fa-
cilitated by the generation of a homology model of 
2C9 with docked sulfaphenazole which indicated that 
it was unlikely that S286 and N289 contacted the 
inhibitor. However, it was considered that these res-
idues could influence substrate access or active site 
packing. In combination with E241K (mutation of a 
residue located in the region corresponding to helix 
G), the 209 double mutant was able to hydroxylate 
both R and S enantiomers of warfarin with a higher 
catalytic efficiency than observed for wild-type 2C19 
[65). 
2.5.2. Substrate specificity in cy:ochromes 
P450 3Al2 and 3A26 
Chimeragenesis has been used to determine resi-
dues responsible for differences in steroid hydroxyla-
tion catalyzed by two canine P-450s, 3Al2 and 3A26 
[661. Although these enzymes have 96 1/6 amino acid 
sequence identity (differing by only 22 of 503 resi-
dues [451) the former exhibits higher rates of steroid 
hydroxylation. The approach used was to monitor 
the loss of progesterone 6-hydroxylation activity 
in P.450 3Al2 caused by the introduction of sequen-
ces from 3A26. Once regions responsible for the loss 
of activity had been identified, site-directed mutagen-
esis of non-identical residues within such regions was 
employed to restore activity of the chimera back to 
that of P450 3Al2. Three residues, at positions 187,  
368 and 369 were identified as those mainly respon-
sible for the differences in steroid 6]3-hydroxylation 
between the two proteins. When these three were 
mutated in P.450 3A26 to those of 3Al2 (11871, 
S368P and V369I), a 10-20-fold increase in the abil-
ity of 3A26 to hydroxytate steroids was observed. All 
the testosterone and androstenedione 6-hydroxylase 
activity of 3Al2 was conferred to 3A26. These canine 
cytochromes P450 are considered as models for hu-
man drug metabolism since residues identified in this 
study are also important for the function of human 
P450 3A4 [57,661. 
2.5.3. The substrate specificities , of cytochromes 
P450 cm2 and AIk3A 
Cytochromes P450 Cm2 and AIk3A are 
CYP52A4 variants naturally occurring in the yeast 
C. maltosa [791. The family 52 P-450s are alkane and 
fatty acid hydroxylases related to the mammalian 
P450 4A and the bacterial P450 BM3 (around 
25% amino acid identity) [80]. Zimmer et at. [80] 
used chitneragenesis to transpose the substrate spe-
cificities of cytochromes P450 Cm2 and AIk3A. 
Although both these enzymes show affinities for lau-
rate and palnuitate, P450 Crn2 displays greater effi-
ciency for the w-hydroxylation of laurate. Five pairs 
of chimeric constructs were devised in order to inves-
tigate each of the seven amino acid differences be-
tween the two enzymes. The key residue was found 
to be at position 527 (a valine in P450 Cm2 and a 
leucine in AIM). Analysis of an engineered enzyme 
pair in which V527 of Cm2 and L537 of AIk3A were 
exchanged showed a transposition of specificity, pro-
viding compelling evidence that position 527 was the 
key residue modulating fatty acid turnover. To show 
that this residue was acting independently it was 
changed to methionine in both P450s to give en-
zymes with almost identical activities (more similar 
to that of Cm2). The fact that such subtle differences 
in side chain lengths between valine and leucine 
could have such effects suggested that residue 527 
must be at the active site, and may even play a 
role in holding the terminal methyl group of the 
substrate at the correct position for monooxygena-
tion. 
In addition to this 'directed' chimeragenesis, an 
alternative random chimeragcnesis approach [81,82] 
has been used in an attempt to map the active sites of  
the distantly related P450s sec and c27 [831. It was 
concluded from this work that an amino acid iden-
tity of 25% or greater between P450s is necessary for 
the successful application of this technique [83J. A 
more recent study used random chimeragenesis to 
probe species-specific biochemical differences be-
tween rat and human P45067, two proteins with 
68% amino acid sequence identity [84]. However, 
the five chimeras generated did not exhibit activity 
patterns that equated to those of the parents, limiting 
the amount of useful structure/function information 
that could be obtained. 
2.5.4. Bacterial/mammalian chimeric cytochronses 
P450 
To examine whether mammalian and bacterial en-
zymes are structurally related and if the bacterial 
structures provide a valid basis for building homol-
ogy models of mammalian enzymes, Shimoji et al. 
[85] constructed a novel chimera from the cytosolic 
bacterial cytochrome P-450cam and the membrane-
bound mammalian cytochrorne P450 2C9. These 
two cytochromes have less than 15% amino acid se-
quence identity. To ensure solubility the chimera was 
designed with the N-terminal 216 amino acids of 
P450cam fused to a fragment of P450 2C9 from 
residue 257 to the C-terminus. This accommodated 
the putative substrate recognition sites 1-3 of 
P450cam and 4-6 of P450 2C9. No mammalian 
amino acids prior to the random coil between the 
0- and H-helices were included to avoid any poten-
tial membrane interactions. The resultant chimera 
was soluble and correctly folded. Assays of catalytic 
activity (the oxidation of 4-chlorotoluene to 4-chlo-
robenzyl alcohol) demonstrated that the chimera was 
functionally active. The fact that the chimera folded 
correctly was considered indicative of conservation 
between the three-dimensional structures of these 
bacterial and mammalian P450s. A further applica-
tion suggested for such chimeragenesis was the con-
struction of soluble P-450s with active site charac-
teristics of mammalian forms, which could prove 
of use in crystallization studies and bioremediation 
[85]. Also of interest would be to further character-
ize such chimeras with different reductase compo-
nents to delineate regions important in the two en-
zymes for protein/protein interactions and electron 
transfer.  
3. Protein engineering to alter membrane binding 
- 
With the exception of P450nor, all eukaryotic 
P450s identified are membrane-bound. For the mi-
crosomal P450s, which are bound to the endoplas-
mic reticulum (ER), the major determinant of mem-
brane binding seems to be a hydrophobic stretch of 
amino acids at the N-terminus. The remaining poly-
peptide folds into a globular form that resides above 
the membrane. In most mierosomal P450s the 
N-terminal region contains a sequence of 16-20 
non-polar side chains that are believed to provide 
the major hydrophobic interaction with the ER 
membrane. When the first 29 N-terminal residues 
of cytochrome P450 2C1 were fused to a globular 
secretory protein (B-galactosidsse),  or to a soluble 
cytosolic protein (alkaline phosphatase) the resulting 
polypeptide was translocated to the ER [86]. Experi-
ments on cytochrome P450 21B have shown that 
removal of more than one third of the hydrophobic 
residues in the N-terminus result in the production of 
a cytosolic P450 form [87]. Such studies demon-
strate that N-terminal deletion or modification could 
facilitate heterologous expression of the P450s, for 
the overproduction of soluble forms of microsomal 
P4505 for various applications. However, the over-
expression of N-terminally truncated forms of several 
P450s in &cherichla coli has shown that both the 
yield of soluble protein and the catalytic activity are 
highly variable and dependent on the P450 in ques-
tion [88]. For example, full-length P450s 2E1 and 
284 are both targeted to the bacterial inner mem-
brane, but whereas deletion of residues 3-29 from 
281 still locates the protein predominantly in the 
membrane fraction (65 1/6), deletion of residues 2-20 
from 284 locates 681/6 of the protein to the cytosol. 
Fusion of the N-termini from 281 and 284 to the 
heme domain of the soluble bacterial P450 BM3 
had the effect, in both cases, of locating only 20 
and 27%, respectively, to the bacterial membrane 
fraction [89), This indicates that there are different 
determinants of membrane binding between 2El and 
284 on the globular domain distinct from the N-ter-
minal anchor. Thus, the N-terminal portion of the 
eukaryotic P4509 is not the sole determinant of 
membrane binding. Further, isoform-specific, struc-
tural motifs on the surface of the globular P450 
domain must interact with the membrane. It has 
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been demonstrated by chemical labeling [90] and mu-
tagenesis [91] experiments that sites even close to the 
C-terminus may be involved in membrane interac-
tions. 
Although recombinant eukaryotie P450s often 
need to be purified in the presence of detergents 
(even after N-terminal modification) this is not al-
ways the case. For example, Sueyoshi ci al. [92] 
were able to purify a modified form of P450 2A4 
from E. coil without the use of detergents. The hy-
drophobic N-terminal residues 2-19 were substituted 
for a sequence that forms an amphipathic helix, and 
although the modified form of the protein was ini-
tially localized to the membrane fraction, it could be 
readily freed by treatment with sodium carbonate. In 
another example a soluble form of cytochrome P450 
51 (P.450 sterol 14a-demethylaae) from Candida a!-
bicans has been engineered with a modified N-termi-
nus containing a protease cleavage site [93]. Initial 
solubilization using detergent can be followed, after 
the cleavage reaction, by further purification without 
the use of detergent. 
The recent breakthroughs in the expression of 
soluble domains of eukaryotic P-450s and P450 re-
ductases without their N-terminal membrane span-
ning domains have provided great hope that more 
crystal structures can be solved for mammalian 
P450 systems. In addition, it has been shown that 
soluble P450 domains heterologously expressed in 
E. coil can retain activity, and that this activity can 
be supported by the host enzymes fiavodox.in and 
NADP-fiavodoxin oxidoreductase [94]. This has 
raised expectations that E. coil expressing different 
human P450 isoforms and utilizing either the host 
redox system or co-expressed human P450 reduc-
tase, can be used as a model to predict the metabolic 
fate of drugs and identify the P450s responsible [95]. 
Yeast (Saccharomyces cerevlsiae) is another attractive 
system for simultaneous expression of multiple hu-
man P450s [96]. Systems of this type have great 
potential in mutagenicity testing and predictive me-
tabolism [97]. 
Protein engineering studies to promote solubility 
of a P450 and to prevent its oligomerization have 
seen their greatest success only this year. After inten-
sive studies of rabbit progesterone hydroxylase 
P450s 20 and 2C5, Eric Johnson and co-workers 
were able to generate a modified P450 2C5 that  
could be expressed in a soluble, monomeric form in 
E. coil. In initial studies, these workers showed that 
by deletion of the regions encoding the N-terminal 
membrane spanning sections and by incorporation of 
a 4-histidine tag at the proteins' C-terminus, the 
P-450s could be overexpressed in E. coil and solubi-
lined from the membrane by high salt [34]. The 
P450s could then be purified without use of deter-
gents. However, the 20 and 2C5 enzymes formed 
dimers and tetramers, respectively, and these forms 
could not be crystallized. Subsequent studies of 
P.450 2C3/2C5 chimeras showed that replacement 
of selected amino acids in P450 2C5 with those 
from 20 resulted in production of P450 2C5 hy-
brids that retained catalytic activity and remained 
monomeric after solubiizing with salt [98]. The 
monomeric P450 2C5 enzyme containing five sub-
stitutions from 20 (N202H, R206E, 1270L, S209G 
and S2I0T) was crystallized successfully, leading to 
the determination of the first atomic structure of a 
mammalian P450 [9]. 
4. Electron transfer 
4.1. A thermodynamic switch 
For the well-characterized bacterial P450s cam 
and BM3, the binding of substrate (camphor and 
fatty acid, respectively) displaces the sixth heme Ii-
gand (water) and shifts the ferric heme iron from low 
to high spin. This results in a positive shift in heme 
reduction potential of some 130 mV. The magnitude 
of this change makes electron transfer from a redox 
partner thermodynamically favored [99,100]. The 
biological benefit of this thermodynamic 'switch' in 
electron transfer is an avoidance of the futile produc. 
000 of oxygen radicals and/or hydrogen peroxide in 
the absence of substrate. However, such control does 
not appear to be operative for all P450s. 
4.2. Probing the route of electron transfer 
The analysis of the route of electron transfer in 
the P450s has been intensively studied since the 
determination of the first P450 crystal structure, 
P450cam [Ill. In this class I system (Fig. I), 
NADH reduces the FAD containing putidaredoxin  
reductase (PdR), which shuttles electrons one at a 
time through the iron-sulfur containing putidaredox-
in (Pd) to the P450 [2]. The system is analogous to 
the eukaryotic mitochondrial class I P-450s, such as 
that for P450scc (partnered by adrenodoxin and 
adrenodoxin reductase) [101]. In this system, the in-
teractions between the various redox components are 
thought to be mainly electrostatic [102,103]. Electro-
statics are also thought to dominate redox partner 
binding in P450cam and other class I systems. Stay-
ton and co-workers defined the Pd docking site on 
P450cam [104]. At least four basic residues on the 
proximal side of the P450cam heme iron (R72, 
K344, RII2, Q343 and, perhaps, R364) are involved 
in the interaction with residues of opposite charge on 
Pd (D58, E65, E67 and E72). It has been postulated 
that the three components of these class 1 P450 sys-
tems can come together as a ternary complex for 
catalysis [105]. However, a more realistic model for 
the class 1 systems may be that the exposed iron-
sulfur centers of the redoxin proteins shuttle elec-
trons singly between the reductase and the P450. 
The reaction between putidaredoxin and the P450 
is among the best studied of all biological electron 
transfer reactions. The first and second electron 
transfers from putidaredoxin to the heme iron are 
the two slowest steps in catalysis. At physiological 
concentrations of Pd, the second electron transfer is 
the overall rate limiting step [1061. The decrease in 
apparent affinity (elevated Km value) for these redox 
partners observed with increasing ionic strength is 
consistent with an electrostatic interaction. However, 
what appears to be a straightforward set of electro-
static interactions between redox partners is in fact 
much more complex. This is demonstrated by the 
fact that P450eam has completely different affinities 
for oxidized and reduced putidaredoxin [99,107]. The 
C-terminal tryptophan of putidaredoxin has been 
found to be a major determinant for the higher 
affinity for reduced Pd [108]. Much recent attention 
has focused on the role of arginine 112 in P450cam 
- a surface residue which is hydrogen bonded to a 
heme propionate. Substitution to various neutral res-
idues resulted in decreased electron transfer rates to 
the heme iron, and resulted in more negative heme 
reduction potentials. Mutation RII2K had a less se-
vere effect, but did show similar trends in reduction 
rate and heme potential [109]. These data are consis- 
tent with the studies of Nakamura and co-workers, 
who also showed that heme content and P450 stabil-
ity were affected by mutation at this residue (RII2Q 
and RII2E mutant enzymes) [1071. Other recent 
studies on the P450cam system have implicated Pd 
residue E72 in the stabilization of the Pd/PdR com-
plex, and Pd residue V98 in hydrophobic interactions 
with P-450cani [110,111]. Through the application of 
electrostatic and electron transfer theories, and tak-
ing into account prior mutagenesis results, Roitberg 
and co-workers proposed an electron transfer path-
way from the iron sulfur center of Pd to the heme of 
P450cam involving R38 and C39 on Pd, and RI 12 
on the P450 as a conduit to the heme propionate 
group [112]. 
It appears that redox partner docking is similar in 
the prokaryotic and mammalian systems, in the sense 
that all interact with either ferredoxin or P450 re-
ductase partners and since the Site of docking is at 
the proximal face of the heme. However, strong evi-
dence for direct mediation of electron transfer by 
amino acid side chains has not been found. The in-
volvement of a tryptophan at the C-terminus of pu-
tidaredoxin (W106) in electron transfer was consid-
ered likely, based on the fact that its removal led to a 
large decrease in the rate of electron transfer [1131. 
Furthermore, a highly conserved tryptophan residue 
throughout the P450 enzyme superfamily, the equiv-
alent to W96 in P.450 8M3, for example, is notably 
absent from P-450cam. It was therefore postulated 
that this aromatic residue is an obligatory electron 
transfer mediator in the P450s, and that the 
P450cam system is an unusual example in which 
the tryptophan is a component of the redox partner 
instead [1141. The role of W96 in P450 BM3 was 
investigated, and it was found that mutant enzymes 
W96A, W96Y and W96F bound sub-stoichiometric 
amounts of heme, but were otherwise catalytically 
competent [115]. The subsequent solution of the crys-
tal Structure of the P450 BM3 heme domain indi-
cated that W96 is in hydrogen bonding distance to a 
heme propionate group [12], helping to explain the 
effects on heme content. In other studies on the 
P450cam system, it was found that the removal of 
W106 from putidaredoxin resulted in a large increase 
in the K,3 of the reduced form for P450cam [108]. 
Thus the tryptophan residues in the P450cam and 
P450 BM3 systems are required for efficient redox 
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partner interaction and heme binding, respectively. 
A direct role in electron transfer has yet to be 
proven. 
4.3. The role of cytochrome bi 
Cytochrome b5 is involved in many mammalian 
P450 reactions, particularly those catalyzing steps 
in steroid metabolism. It may donate the second 
electron to the oxyferrous P450 during catalysis, 
but is known to act as a structural effector of 
P.450 function - as evidenced by the ability of apo 
(heinz-free) b5 to stimulate activity of cytochrome 
P.450 3A4 [1161. Also, both holo- and apo-cyto-
chrome b3 augment the reaction profile of the human 
cytochrome P45007 system in favor of the 17,20-
lyase reaction (cleavage of the C17-C  bond), while 
the b5-free enzyme system favors 17a-hydroxylation 
[117]. These data indicate that b5 has allotteric roles, 
but redox functions may also be operative and the 
precise role is probably dependent on the P.450 sys-
tem involved. Cytochrome b5 binding frequently per-
turbs the P.450 heme iron spin state equilibrium in 
favor of the high spin form, in similar fashion to the 
binding of substrates. However, its binding site is on 
the distal, not the proximal, face of the heme. Micro-
somal cytochrome b5 has a highly charged surface 
and is also thought to bind electrostatically to 
P-450s, with carboxylate groups important to the 
interaction. In elegant experiments, Stayton and co-
workers modified bovine cytochrome bs by replace-
ment of surface threonines with cysteines. This en-
abled the attachment (via the suifbydryl groups) of 
the fluorophore acrylodan and the use of fluores-
cence as a tool to measure the binding of b5 to 
P-450cam. A K,5 value of 1.1 ILM was thus deter-
mined, and Pd was shown to competitively inhibit 
the binding of b5 [104,1181. These results indicate 
that both proteins bind at overlapping sites on the 
distal face of P-450cazn [119]. The fact that cyto-
chrome b5 binds tightly to P.450cam is indicative 
that the bacterial cytochromes P.450 retain strong 
structural Similarity to their mammalian counter-
parts. The incisive P.450 2134 mutagenesis studies 
of Waskell and co-workers have helped to define 
the binding site for cytochrome b3, demonstrating 
the importance of the P450 C- and C'-helices 
in the bs interaction site [1201. There is extensive,  
but not complete, overlap of the P450 reductase 
and b5 binding sites on the proximal surface of the 
P450. 
Until recently, the interaction between cytochrome 
bs and bacterial P-450s (P450 8M3 also binds b5) 
was considered to reflect merely an evolutionary link 
between redox partner binding sites in prokaryotic 
and eukaryotic P-450s, since b5 was thought to be 
exclusively a eukaryotic redox protein. However, re-
cent studies indicate that bacteria may also encode 
cytochromes b5, indeed the first three-dimensional 
structure of a bacterial cytochromt b5 has been re-
ported [121]. It may be the case, then, that certain 
bacterial P.450s are also able to use b5 as a redox 
partner. 
4.4. Fiavocytochrome P450 BM3 
The soluble flavocytochrome P450 BM3 system is 
considered the best model for deconvoluting electron 
transfer in class II P.450 systems [122]. Genetic dis-
section of the enzyme has allowed the expression of 
its component domains. Initially, the P450 domain 
(residues 1472) and the diflavin reductase domain 
(residues 472-1048) were expressed independently in 
E. coil [123]. More recently, the subdomains of the 
diflavin domain have been overproduced in E. coil. 
These subdomsins are ferredoxin reductase-like (res-
idues 654-1048) and flavodoxin.Iike (residues 471-
664), each binding a single flavin cofactor [124]. 
The ability to produce proteins with single redox 
cofactors has enabled the deconvolution of their 0th. 
erwise overlapping spectral properties, and the deter-
mination of the reduction potentials for all the co-
factors [124]. This study revealed that fatty acid 
substrate binding to the P450 resulted in an approx. 
130 mV increase in the reduction potential of the 
heme iron (from —368 to —239 mV on arachidonate 
binding), triggering electron transfer from the FMN 
(see Section 4.1). 
The electron transfer pathway in P450 BM3 has 
not been as intensively studied as that in P450cam, 
although W96 in the heme domain has been ruled 
out as an electron transfer mediator [115]. In studies 
of the reductase domain of the enzyme, Klein and 
Falco demonstrated that W574 affected electron 
transport in the enzyme [125]. However, these defects 
may be explained by low incorporation of FMN, and  
possibly by perturbation of the reduction potentials 
of the FMN. Recently, the crystal structure of the 
combined FMN and heme domains has been re,--
ported [126]. Unfortunately, the FMN domain of 
the protein was found to be proteolytically separated 
from the heme domain, and the stoichiometry of the 
domains was 1:2, not 1:1. An electron transfer path-
way through the polypeptide chain was proposed, 
but is perhaps unlikely given the excessive length of 
the route. Indeed, the search for proteinaceous elec-
tron transfer pathways through P.450 systems may 
be a pointless one. A short, through-space route is 
much more likely in the class II system, with the 
possible involvement of a small number of amino 
acids that themselves are hydrogen-bonded or inti-
mately associated with the FMN or heme cofactors, 
as postulated for the P450cam system [112]. The 
recently solved crystal structure of rat cytochrome 
P.450 reductase indicates that FAD-to.FMN elec-
tron transfer occurs between edges of the flavin 
ring systems and does not involve a protein pathway 
(127]. Rotation of the reduced FMN domain of the 
reductase away from its FAD/NADPH domain is 
probably necessary in order to expose the FMN for 
interaction at the heme proximal face and subsequent 
delivery of electrons to the heme. 
In the P450 BM3 heme domain, the cysteine-thi-
olate ligand to the heme iron (C400) is exposed to 
solvent at the distal face of the heme iron in the 
center of a region likely to represent a redox partner 
docking area. As such, it is accessible for direct elec-
tron transfer from FMN through to the heme iron 
[12,16]. 
4.5. Alternative reducing sources 
All P450 systems rely on NAD(P)H as the ulti-
mate electron donor. However, this is not a cost-
effective way to drive P.450 reactions, because 
NADPH is very expensive to produce commercially. 
There is much interest in developing alternative, 
cheaper means of driving P.450 reactions. These in-
clude the use of the 'peroxide shunt' mechanism to 
deliver oxygen and reducing equivalents simultane-
ously via an organic peroxide (e.g. cumene hydroper-
oxide) or hydrogen peroxide. However, such reac-
tions are generally inefficient and result in gradual 
oxidative destruction of the heme macrocycle by  
the peroxide. The future of such technology may 
rest with the design of mutant P.450s selected for 
optimal reactivity with peroxides. The ground break-
ing study of Joo et al. [128] demonstrated that 
'directed evolution' (i.e., successive rounds of ran-
dom mutagenesis coupled to a selection screen for 
mutants with desired activity enhancement) could 
be used to select for mutants of P-450cam able to 
hydroxylate naphthalene. In this study, mutants with 
hydrogen peroxide-driven activity greater than 20-
fold that of wild-type were isolated. This was 
achieved by co-expression of a peroxidase enzyme 
that converted the hydroxylated product into easily 
detectable fluorescent derivatives. This technique is 
in its infancy, but there are clearly great possibilities 
for the generation of mutant P.450s able to perform 
industrially or medically important processes that are 
driven by inexpensive chemicals. 
Perhaps an even more exciting prospect is the use 
of an electrode to drive P.450 catalysis. This tech-
nique has been pioneered by Faulkner and co-work-
ers in their study of the fatty acid hydroxylase P.450 
4A1 from rat [129]. The co-hydroxylation of laurate 
in a system containing distinct or fused P.450 and 
P.450 reductase and the redox mediator cobalt(III) 
sepulchrate could be driven from an electrode poised 
at low potential (approx. —650 mV). The system 
could be run for up to 2 h without significant de-
struction of P450 activity (130). The presence of a 
flavoprotein is essential for transfer of electrons from 
cobalt sepulchrate, the reduced form of which is re-
generated from the electrode. In studies with the pro-
gesterone hydroxylase P45007, Estabrook and co-
workers demonstrated that E. coil flavodoxin could 
substitute for P.450 reductase in the system, albeit 
with lower efficiency [131]. These studies demonstrate 
the potential for the bulk production of chemicals, 
and again have been greatly simplified by the break-
throughs in heterologous expression that have per-
mitted the high level expression of eukaryotic P.450s 
in E. coil (reviewed by Barnes [132]). 
4.6. Genetic fusions 
- 
- 
P450 BM3 represents a natural fusion between a 
reductase and a P450 and is the most catalytically 
efficient P.450 characterized to date. Another area of 
interest is the construction of 'artificial' fusions be- 
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Fig. 5. Schematic representation of the different P.450 fusion constructs described showing the variation in linkers used and the order-
ing of the component proteins. The stop eodons between protein pairs are deleted, fusing all components in a single, open reading 
frame. The amino acids in the linker regions are denoted by their single letter codes. (a) Fusion between human P.450 I Al and (al-
56)-rat NADP5I-P-450 reductose [140[; (b) putidaredoxin reductauc (PdR)/pusidaredoxin (Pd)/P-450esm triple fusion 11461; (c) human 
P-450c27/maturs adrenodosin reduetase (AdR)/mature adrenodoxin (Ad) triple fusion 11471; (d) triple fusion between rut microsomul 
P.450 ]Al, mature maize fereedosin t (Fd) and mature pea feeredouin NADP° redsctaue (FoR) 11501; (e) mitochoadrial P-450c27 
N.tersninaDy modified by deleting the mitochondriul targeting sequence (residues 1-32) and replacing it with the microsomal targeting 
sequence of P-45007 (residues I-IS) (mic-P-455c27) fused to (Al-4l)-yeast NADPH.P-450 reductase [151). 
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tween P.450 moieties and their electron transport 
accessory protein(s). The ultimate goal of such stud-
ies would be to reproduce the catalytic efficiency dis-
played by P.450 BM3. Failing that, self-sufficient 
enzymatic fusions could still be of great biotechno-
logical potential, obviating the need to express and 
purify independently the component proteins of 
P450 systems. 
4.6.1. Fusions with NADPH-P.450 reductase 
The first artificial P.450 fusion protein was re-
ported by Murakatni et al. in 1987 [133]. This group 
fused rat P.450 lAl with rat NADPH-P-450 reduc-
tase to give a functionally active enzyme expressed in 
yeast. Following on from this success, fusions using 
the bovine P.450s 17A [134) and 21A [135] and yeast 
NADPH-P450 reductase were generated by the 
same group. The development of heterologous ex-
pression systems for eukaryotic cytochromes P450 
in E. coIl [136] allowed the overexpression of P450 
fusion proteins in this bacterium. Fisher et al. [137] 
reported the fusion of two mammalian P.450s, bo-
vine 17A and rat 4Al, with rat liver NADPH-P450 
reductase and Shet et al. [138] generated a fusion 
between the human P.450 3A4 and the same reduc-
tase. The molecular biology involved in the construc-
tion of such fusions has been reviewed elsewhere 
[139]. The basic premise is that both cDNA5 are 
modified and joined in a single reading frame. The 
stop codors of the P.450 is removed and replaced 
with a short polypeptide linker encoding a restriction 
endonuclease site (e.g. Serllhr dipeptide linker con-
taining a Sail site (135]). This facilitates the fusing of 
the P450 with the reductase The latter is modified 
at its N-terminus to remove the major membrane 
binding region (e.g. first 56 residues of rat liver re-
ductase deleted [133)). 
In a more recent report, Chun et al. reported the 
construction of a human P.450 IAI/rat reductase 
fusion expressed in E. coil [140]. The study of human 
P450 IA  is of interest due to its potential role in 
activation of carcinogens and its inducibility by some 
environmental toxins [141,142]. The fused system 
was constructed essentially as described above, using 
a Ser/Thr linker (Fig. 8a). P450 reductase from rat 
was used, since attempts to utilize the human reduc-
tase in fusions with human P.450s 3A4 and 3A5 had 
resulted in constructs in which the reductase portion  
was not fully functional [46,143]. The fusion enzyme 
was expressed at high levels in E. call and found to 
be catalytically active either in purified form or with-
in the bacterial cells. Substrate turnover rates were 
comparable to those for the reconstituted system. 
An example of a reported application of a fused 
rat P450 IAI/yesst reductase protein was described 
by Shiota et al. [144]. The fusion was expressed in 
tobacco plants and although its expression level and 
activity were less than those observed in yeast, it 
conferred resistance to the herbicide chlortoluron to 
the plants. 
A further demonstration of the usefulness of 
P450/NADPH-P450 reductase chimeras is seen 
from studies of a fusion between canine liver P.450 
21111 and rat liver NADPH-cytochrome P450 re-
ductase. This was constructed to expedite the analy-
sis of mutated 2B11 enzymes [1451. The 2B11 fusion 
protein efficiently metabolized androstenedione when 
assayed as crude sonicated whole cell extracts. Activ-
ity and metabolic profiles were comparable with 
those of purified and reconstituted preparations. In 
this study, nine mutant forms of 2B1 1 were gener-
ated in the fusion protein and rapidly characterized 
using sonicated E. coil extracts. 
4.62 Fusions with electron donors other than 
P450 reductase 
Sibbesen et al. [146] described the first heterolo-
gous, self-sufficient catalytic system for oxidation of 
P450cam substrates. Fusions of the CDNAs of 
P.450cam and its electron donors PdR and Pd (both 
soluble) were generated and expressed in £ coil. The 
ordering of the components as well as the regions 
linking them were varied. Activities of the fusion 
proteins were compared by measuring oxygen con-
sumption in the presence and absence of camphor. 
The most active of the constructs was that with 
P450cam at the C-terminus: PdR-Pd-P-450cam (in 
contrast to the P450 reductase fusions) (Fig. 8b), the 
order of the proteins in the fusion having more of an 
effect than the nature of the linkers between them. 
The limiting feature of catalytic turnover was found 
to be the interaction between P450cam and Pd, 
most likely due to structural constraints. Evidence 
for this included the increase in catalytic activity of 
the fusion upon addition of both exogenous Pd and 
P450cani and the high activity observed when 
P.450cam was incubated with fused PdRIPd. Be-
cause the activity of the triple fusion increases line-
arly with its concentration the electron transfer from 
NADPH is considered to occur via an intramolecular 
pathway. Although this fusion protein is less efficient 
than the reconstituted wild-type system, the turnover 
is comparable to that of other reconstituted P450 
systems. 
Similar fusions, expressed in mammalian COS-I 
cells, have also been reported for the class I mito-
chondrial P450s c27, sec and 1 1]) with their redox 
partners sdrenodoxin and adrenodoxin reductase 
[147-149]. In the case of P450c27, the fusion (Fig. 
8c) was more efficient than the native reconstituted 
system in transfected mammalian cells. 
4.6.3. Fusions with non-physiological electron 
donors 
Whereas the above fusions describe P450s in com-
bination with their physiological' electron donors, 
Lacour and Ohkawa [150] have reported a fusion 
(expressed in yeast) in which rat P.450 IA!, a class 
II P450 normally supplied with reducing equivalents  
- 
from NADPH-P.450 reductase, has been fused to 
ferredoxin (Fd) and ferredoxin NADP reductase 
(FnR) from plant chloroplasts to recreate an electron 
transfer chain resembling a class I system. The order 
of the proteins in the most efficient triple fusion gen-
erated was P450-Fd-FnR (Fig. 8d) for all activities 
assayed. Not surprisingly, activities were lower when 
compared with P.450 IAI fused to its physiological 
electron donor NADPH-P.450 reductase (e.g. the 
lAlfreductase fusion was 5-fold more active with 
7-ethoxycoumarin as the substrate than the triple 
fusion). It was concluded that electron transfer 
from FnR to Fd was not optimal in the triple fusion 
due to unfavorable redox potentials. The ultimate 
aim of generating such a system is to produce mam-
malian P.450s in plant chloroplasts to improve her-
bicide detoxification (to date, no P.450 monooxyge-
nase system has been identified in plant chloroplasts) 
[150]. 
Sakski et al. [151] describe the fusion of a modified 
class I P450 with the class II microsomal yeast re- - 
ductase (Fig. 8e). In modified P450c27 (mic-F-
450c27), the mitochondrial targeting signal was re- - 
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placed by the microsomal targeting sequence of bo-
vine P-45007. This localized the protein to yeast 
microsomes where it appeared able to function as a 
microsomal P.450 by accepting electrons from 
NADPH-P-450 reductase. To study further electron 
transfer from NADPH-P.450 reductase to mic-P-
450c27, a fusion between the two proteins was 
constructed. It was shown that the reductase in 
the fusion efficiently transferred electrons to the 
P.450, the rate of heme reduction being much 
faster than observed for the separate enzymes 
(similar results were obtained from studies with a 
fusion between rat P.450 tAl and NADPH-P450 
reductase [152]). The rate of substrate hydroxyla-
tion was also 5-fold greater than that obtained 
when the two separate proteins were expressed simul-
taneously. 
S. ConclusIons 
The cytochromes P450 catalyze the monooxyge-
nation of a vast array of substrate types. Some of 
these reactions have great medical or industrial im-
portance with a huge potential for the application of 
protein engineering. This review demonstrates the 
attractive and realistic proposition that protein engi-
neering approaches can be used to modulate cyto-
chromes P.450 to catalyze the oxygenation of a mol-
ecule of choice. Protein engineering has also been 
shown to be a key tool for probing the role of active 
site residues and for dissecting the route of electron 
transfer through the protein. In addition, the manip-
ulation of properties such as membrane binding and 
even the possibility of employing alternative reducing 
sources have been shown to be amenable to protein 
engineering methods. 
Acknowledgements 
We thank the Biotechnology and Biochemical Sci-
ences Research Council (BBSRC) UK for support 
for CSM and MAN and for a studentship to 
TWBO. We are also grateful to the Leverhulme trust 
for financial support for this work. AWM wishes to 
thank the Royal Society of Edinburgh and Caledo-
nian Research Foundation for the award of a re- 
search fellowship. We also thank Dr. Simon Daff 
for helpful discussions. 
References 
Ill D.R. Nelson. T. Kamalaki, D.J. Waxman, F.P. Ouengrrich, 
R.W. Eutabrook, R. Feyereiscn, F.J. Gonzalez, M.J. Coon, 
I.C. Gunaalus, 0. Ootoh, K. Okuda, D.W. Nebert, The 
P450 superfamily: update on new sequences, gene-mopping, 
accession numbers, early trivial names of enzymes, and no-
menclature, DNA Cell Bid. 12(1993)1-51. 
12) A.W. Munro, J.G. Lindsay. Bacterial cytochromes P450, 
Mol. Microbial. 20 (1996) 1115-1125. 
13 1 E.J. Mueller, P.J. Loida, S.G. Sligar, Twenty-five years of 
P450mm research, in: Ortiz de Mootellano (Ed.), Cyto-
chrome P450: Structure, Mechanism and Biochemistry, 
New York: Plenum Press; 5995, Ch. 3, pp. 473-535. 
[4] DR. Nelson, L. Koymans, T. Kamataki, 12. Stegetnan, R.  
Peyercisen, D.J. Waxman, MR. Waterman, 0. Ootob, M.J. 
Coon, R.W. Eslabrook, I.C. Gunsalus, D.W. Nehert, P450 
superfamily: update on new sequences, gene mapping, scam. 
sian numbers and nomenclature, Pharnsacogenetics 6 (1996) 
1-42. 
[5) R.L. Wright, K. Harris, B. Solow, R.H. White, P.J. Ken-
sicily, Cloning of a potential cytodirome P450 from the at-
chores Salfolabses .enlfa:arlcus, FEllS Lett. 384 (1996) 235-
239. 
(6] S.M. Past, H. Shimizu, S. Adachi, A. Nakagawa, I. Tanaka, 
K. Nakahara, H. Shaun, E. Obayaahi, H. Nakamura, T. 
lizuka, Y. Shim, Crystal structure of nitric oxide reductaae 
from denitrifying fungus iissarlum oxysporwn, Nat. Slruct. 
Biol. 4 (1997) 827-832, 
171 IA. Pikuleva, R.L. Mackmnn, R.L. Kugawa, MR. Water-
man, P.R. Ortiz do Montcllano, Active site topology of ho. 
vine cholesterol side-chain cleavage cytocbrome P450 sac and 
evidence for interaction of tyrosine 94 with cholesterol, 
Arch. Biochem. Biophys. 322 (1995) 189-197. 
A.P. Koley, J.T.M. Butars, R.C. Robinson. A. Markowitz, 
F.K. Friedman, Interaction of polycycic aromatic hydrocar. 
bons with human cytocbrome P450 lAl: a CO flush photol-
ysis study, Arch. Biochem. Biophys. 336 (1996) 261-267. 
P.A. Williams, J. Cosine, V. Sridhar, E.F. Johnson, 040. 
McRee, Mammalian esicrosomal cysochrome P450 mono-
oxygenase: structural adaptations for membrane binding 
and functional diversity, Mol. Cell 5 (2000)121-131. 
(10] S.Y. Park, K. Yasnane, S. Adachi, Y. Shiro, K.E. Weiss, 
S.G. Sligar, Crystallization and preliminary X-ray diffraction 
analysis of a cytochrome P450 (CYPI 19) from Salfolobscr 
solfa:arlcur, Ada Crystallogr. D Biol. Crystallogr. 56 
(2000) 1173-1175. 
[II] T.L. Poulos, B.C. Fiord, Al. Howard, Crystal structure of 
ssbstrntc-frec Pzeudomoeaz psitlda cytochrome P450, Big-
chemistry 25 (1986) 5314-53224 
[12] K.G. Ravialtandrun, S.S. Boddupalli, C.A. Hascmana, JA. 
Peterson, J. Deisenhofer, Crystal structure of hcmoprotein 
domain of P450 BM3, a prototype for microsomal P450s, 
Science 261 (1993) 731-736. 
(13] C.A. Hasesnann, K.G. R.avichandrun, JA. Peterson, J. Dei-
senhofer, Crystal structure and reflnemcnt of cytocbrume 
P450trop at 23A resolution. J. Mol. Biol. 236(1994)1169.-
1185. 
[14) 1.8.. Cspp-Vickery, T.L. Poulos, Structure of cyeochrome 
P450 eryF involved in erythromycin biosynthesis, Nat. 
Struct. Biol. 2 (1995) 144-153. 
[IS] T.L. Poulos, B.C. Finzel, Al. Howard, High resolution crys-
tal structure of cytochrome P450cam, I. Mol. Biol. 195 
(1987) 687-700. 
H.Y. Li, T.L. Psalm, The structure of the cytochrome P450 
DM3 heme domain complexed with the fatty acid substrate, 
palmitoleic acid, Nat. Stract. Biol. 4 (1997) 140-146. 
S. Ito, T. Matauoks, I. Watanabe, T. Kagasaki, T. Scriwuza, 
T. Hula, Crystallisation and preliminary X-ray diffraction 
analysis of P450 sca2 from Ssrcptomyces carhophllus in-
volved in production of pravastatin sodium, a tissue-selective 
inhibitor of HMO-CoA raductase, Acta Cryslallagr. D Biol. 
Crystuilogr. 55(1999)1209-1211. 
R. Rang, H.Y. Li. B.C. Jones, T.L. Poulos, Inhibitor-in-
duced conformational change in P450mm. Biochemistry 32 
(1993) 4571-4578. 
1191 0. Goloh. Substrate recognition tiles in cytochrome P450 
fussily 2 (CYP2) proteins inferred from comparative analyses 
of amino acid and coding nucleotide sequences, I. Dint. 
Chess. 267 (1992) 83-90. 
1201 M. Iwasaki, T.A. Darden, L.G. Pedersen, D.G. Davis, R.O. 
Juvonen, T. Sucyoshi, M. Negishi, Engineering mouse 
P43Ocoh to a novel corticosterone 15-a-hydroxylase and 
modelling steroid binding orientation in the substrate pock-
et, I. Biol. Chem. 268 (1993) 759-762. 
(21) J. Liu, V.A. He, 3.8.. Halpert, Role of residue 480 in sub-
strate specificity of cytocbrome P450 285 and 2811, Arch. 
Bischem. Biophys. 327 (1996) 167-173. 
[22) M.-H. Mao. K.J. Griflln, Y. Wang, B. Kemper, E.F. John. 
son. A single amino acid substitution confers progesterone 
6B-bydrosylase activity to rabbit cytochrome P450 2C3, 
J. Biol. Chem. 268 (1993) 6939-6944. 
M.JJ.M. Zvelebil, C.R. Wolf, M.J.E. Sternberg, A predicted 
3.13 structure of human cytochrome P450-implications for 
substrate specificity, Protein flag. 4 (1991) 271-282. 
G.D. Szklarz, R.L. Ornstein, 3.8.. Halpert, Application of 3. 
Dimensional homology modelling of cytochrome P450 2111 
for interpretation of site-directed mulagenesia results, I. Bio. 
mol. Steuct. Dyn. 52 (1994) 61-78. 
S. Vijayukamar, J.C. Salerno, Molecular modelling of the 3- 
D structure of cytochrome P450scc, Biochim. Biophys. Ada 
1160 (1992) 281-286. 
[26) C.A. Hasemann, R.G. Kurumbail, S.S. Boddupahli, JA. Pe-
terson, J. Deisenhofer, Structure and function of cyto-
chromes P450: a comparative analysis of three crystal struc-
tures, Structure 2 (1995) 41-62. 
[27] D.F.V. Lewis. M. Dickens, B.G. Lake, P.J. Eddershaw, 
M.H. Tarbit, P.S. Goldfarb, Molecular modelling of site hu- 
man cytocbmome P450 isoform CYP2A6 and investigations 
of CYP2A substrate selectivity, Toxicology 533 (1999) 1-33. 
D.F.V. Lewis, B.G. Lake, Molecular modelling of CYP4A 
subfamily members based an sequence homology with 
CYPI02, Xenobiotica 29 (1999) 763-781. 
S. Oraham.Lorence, B. Amarneh. R.E. White, IA. Peter-
son, E.R. Simpson, A three-dimensional model of oromasuse 
cytochrome P450, Protein Sot. 4 (1995)1005-1080. 
G.D. Szklnrz, Y.A. He, JR. Halpeet, Site-directed mutagen-
mis as n tool for molecular modeling of cytuchrome P450 
2111. Biochemistry 34 (1995)14312-14322. 
[SI) R.K. Din, MR. Pincus, F.K. Friedman, Molecular modeling 
of cylochrome P450 281: mode of membrane insertion and 
substrate specificity, J. Protein Chem. 17 (5990) 121-129. 
G.D. Szklasz 5.8.. Halpert, Molecular modeling of cyto-
chrome P450 3A4, I. Comp.-Aided Mot Des. II (1997) 
265-272. 
R.L. Haining, J.P. Jones, K.R. Henne, M.B. Fisher, DR. 
Koop, W.F. Trager, A.E. Rellie. Enzymatic determinants of 
the substrate specificity of CYP2C9: role of the B'-C loop 
residues in providing the s-stacking anchor site for warfarin 
binding. Biochemistry 38 (1999) 3285-3292. 
J. Cosme, E.F. Johnson. Engineering micrasomal P-450 2C5 
to be a soluble, monomeric enzyme: mutations that alter 
aggregation, phospholipid dependence of catalysis, and 
membrane binding. I. 8601, Chem. 275 (2000) 2545-2553. 
P.S. Loida, S.G. Sligsr, Molecular recognition in cytochiome 
P450: mechanism for the control of uncoupling reactions, 
Biochemistry 32 (1993) 11535-.11538. 
[36) JA. Stevenson, A.C.G. Westlake, C. Whitlock, L.-L. Wong, 
The catalytic oxidation of linear and branched alkanes by 
cytochrome P450mm, J. Am. Chem. Soc. 118 (1996) 12846-
12847. 
[37] P.A. England, C.P. Hanford-Cross. 1.-A. Stevenson, D.A. 
Rauch, L.-L. Wong. The oxidation of naphthalene and pyr-
ene by cytochrome P450cam, FOBS Lett. 424 (1998) 275-
274. 
[30] S.M. Fowler, P.A. England, A.C.G. Westlake, DR. Rough, 
D.P. Nickerson, C. Blunt, D. lirsybrook. S. West, L.L. 
Wong, S.L. Flitsch, Cytochrome P450mm mosooxygenase 
can be redesigned to catalyze the regiosclecxive aromatic by-
droxylation of diphenylnsethanc, J. Chem. Soe. Chess. Corn-
man. 24 (5994) 2761-2762. 
[39] JA. Stevenson, J.P. loses, L.L. Wong, Mutations of pltenyl-
alanine 193 in the putative substrate access channel alter the 
substrate specificity of cytochrome P450 cam. 1st. J. chess. 
40 (2000) 5542. 
(40) C.F. Oliver, S. Moth, W.U. Primrose, L.Y. Usa, O.C.K. 
Roberts, Engineering the specificity of Baclibcs megarerlam 
P450 DM3: hydroxylation of alkyl triammoalum com-
pounds, Biochent. J. 327 (1997) 537-544. 
(41] M.A. Noble, C.S. Miles, S.K. Chapman, D.A. Lysek, A.C. 
Mackay, G.A. Reid, R.P. Hanciik, A.W. Munro, Roles of 
key active-site residua in flavocytochrome P450 DM3, Bin-
them. J. 339 (1999) 371-379. 
CS. Mile, et at /Biorlrfrnlra or Blophysica Arta 1543 (2000) 383-407 	 403 
	
404 	 CS. MOre or at /Eiodmlonica em Bloohysira Aria 1543 (2000) 383-407 
[42) C.F. Oliver, S. Modi, M.J. Sutcliffe, W.V. Primrose, L.Y. 
Lion, G.C.K. Roberts, A single mutation in cytochrome 
P450 BM3 changes substrate orientation in a catalytic inter-
mediate and the regiospecificity of hydroxylation, Biochem-
istry 36 (1997) 1567-1572. 
(43) S. Moth, Mi. Sutcliffe, W.U. Primrose, L.-Y. Liars, O.C.R. 
Roberts, The catalytic mechanism of cytachrome P450 BM3 
involves a 6 angstrom movement of the bound substrate 
upon redaction, Nat. Struct. Biol. 3 (1996) 414-417. 
[44) E.A. Dierks, S.C. Davis, P.R. Ortiz de Moutellano, GJa.320 
and Asp-323 are determinants of the CYP4AI hydroxylation 
regiospecificity and resistance to inactivation by 1-aminoben-
zotriazole, Biochemistry 37 (1998) 18394847. 
D.F. Fraser, R. Feyereisen, OR. Harlow, J.R. Halpert, Iso-
lation, heterologons expression and functional characteeisa' 
tins of a novel cytochrome P450 3A enzyme from a canine 
cDNA library, J. Pharmacol. lisp. Ther. 283 (1997) 1425-
1432. 
F.P. Gaengericb. Roman cytechronse P450 enzymes, in: Or-
tiz de Montellano (Ed.), Cytochrome P450: Structure, 
Mechanism and Biochemistry, New York: Plenum Press; 
1995, Ch. 14. pp.  473-535. 
[47] Di. Waxman, C. Attisano, F.P. Guengerich. D.P. Lapen-
son, Human liver miceosomal steroid metabolism-identifica-
tion of the major microaomal steroid-hormone 6-beta-hy-
drouylase cytochromc P450 enzyme. Arch. Biachem. 
Biophys. 263 (1988) 424-436. 
T. Shimada. F.P. Guengerich, Evidence for cytochrome 
P450NF. the nifedipine onidase, being the principal enzyme 
involved in the bioactivalion of aflatoxins in human liver, 
Proc. Natl. Acad. Sal. USA 86 (1989) 462-465. 
L.Z. Benet, D.L Kroetz. L.B. Sheiner, in: J.G. Hardman, 
L.E. Umbird, P.B. MolinolL R.W. Ruddon, A.D. Oilman 
(Edo.), Goodman and Oilman's The Pharmacological Basis 
of Therapeutics. 91h edo., McGraw-Hill, New York, pp. 3-
27. 
G.E. Schwab, J.L. Remy, E.F. Johnson. Modulation of rab-
bit and human hepatic cytochrome P450 catalysed steroid 
hydroxylations by e-naphthoflavone, Mol Pharmacol. 33 
(1988) 493-499. 
[SI) Y.F. Ueng, T. Kuwabara, Y.J. Chars, F.P. Gurngerich, Co-
operativity in oxidations cataiysed by cytochrome P450 3A4, 
Biochemistry 36 (1997) 370-581. 
G.R. Harlow, J.R. Halpert, Alanine-scanning mutagenesis of 
a putative substrate recognition site in human cytochrome 
P450 3A4, J. Biol. Chem. 272 (1997) 5396-5402. 
D.F.V. Lewis, P.J. Eddemshaw, P.S. Goldfarb, M.H. Tarhit, 
Molecular modelling of CYP3A4 from an alignment with 
CYPI02: identification of key interactions between putative 
active site residues and CYP3A4peciflc chemicals, Xenobio-
tim 26 (1996) 1067-1086. 
G.R. Harlow, J.R. Halpert, Analysis of human cytochrome 
P450 3A4 cooperativity: construction and characterisation 
of a site-directed mutant that displays hyperbolic steroid 
hydroxylation kinetics, Proc. Ned. Aced. Sci. USA 95 
(1998) 6636-6641. 
[55] T.L. Domanski, J. Lin, G.R. Harlow, J.R. Halpert, Analysis 
of four residues within substrate recognition site 4 of cyto- 
chrome P450 3A4: role of steroid hydrosylasr activity and 
tx.naphthoflavone stimulation, Arch. Biochem. Biophys. 350 
(1998) 223-232. 
(56) T.L. Domanski, Y.-A. He, G.R. Harbor, J.R. Halpert, Dual 
role of human cytoclsrome P450 3A4 residue Phe-304 in 
substrate specificity and coopemutivity, J. Pharmucol. Exp. 
Thor. 293 (2000) 585-591. 
[57] Y.A. He, Y.Q. He, G.D. Szklarz, J.R. Halpert, Identification 
of three key residues in substrate recognition site 5 of humors 
cytochrome P450 3A4 by cassette and site-directed mutagen-
esia, Biochemistry 36 (1997) 0831-8839. 
[58) F. Roussel, K.K. Khan, J.R. Halpert, The importance of 
SRS-1 residues in catalytic specificity of cytocbrome P450 
3A4, Arch. Biocbrns. Biophyu. 374 (2000) 269-278. 
H. Wang, R. Dick, H. Yin, E. Licad.Coleu, D.L. Kroeta, 0. 
Szklarz, G. Harlow, J.R. Halpert, M.A. Correia, Structure-
function relationships of human liver cytochromcs P450 3A: 
afintoxin BI metabolism as a probe, Biochemistry 37 (1998) 
12536-12545. 
M.K. Rarnnrao, P. Straub, B. Kemper, Identification by in 
vitro mutagenmis of the interaction of two segments of 
C2MsICI, a chimera of cytochromes P450 2C2 and P450 
2Cl, J. Biol. Christ. 270 (1995)1875-1880. 
J.H. Hunnu, E.S. Roberts, P.F. Holleuberg, Molecular basis 
for the differences is lidocaine binding and regioselectivity of 
oxidation by cytochrome P450 2B1 and 202, Biochemistry 
37(1998)311-318. 
G.D. Szklarz, Y.Q. He, K.M. Kedrie, J.R. Halpert, V.L. 
Burnett, Elucidation of amino acid residues critical for 
unique activities of rabbit cytocltrnme P450 2115 using hy-
brid enzyntes and reciprocal site-directed matagenesis with 
rabbit cytochrome P450 200, Arch. Biochem. Biopbyt. 327 
(1996) 300-318. 
T.S. Kiore, G.C. Ibeana, B.1, Ghnnayem, L.G. Pedersen, L. 
Li, S.D. Hall, J.A. Goldstein, Identification of residues 206 
and 289 as critical for conferring substrate specificity of ha-
roan CYP2C9 for diclofeuac and ibuprofen, Arch. Biochem. 
Biophys. 357 (1998) 240-248. 
G.C. Ibeanu, B.I. Ghanayem, P. Unko, L Li, L.O. Peder-
sen, J.A. Goldstein. Identification of residues 99, 220 and 
221 of human cytcchrome P450 2C19 as key determinants 
of oeteprazole hydroxylase activity, J. Biel. Chem. 271 
(1996) 12496-12501. 
P. Jung, K.J. Griffin, W. Song, T.H. Richardson, M. Yang, 
E.F. Johnson, Identification of amino acid substitutions that 
confer a high affinity for salfaphenazole binding and a high 
catalytic efficiency for warfarin metabolism to P450 2Cl9, 
Biochemistry 37 (1998)16270-16279, 
D.J. Fraser, Y.Q. He, G.R. Harlow, J.R. Halpert, Use of 
chimeric enzymes and rite-directed matageuesis for identifi-
cation of three key residues responsible for differences in 
steroid hydroxylation between canine cytocltromes P450 
3AI2 and 3A26, Mol. Pharrnacol. 55 (1999) 241-247. 
T. Zimmer, U. Scbelter, M. Takagi, W.-H. Schack, Mutual  
conversion of fatty-acid substrate specificity by a tingle ami-
no acid exchange at position 527 in P45OCns2 and 
P450AIk3A, Ear. J. Biochem. 256 (1998) 398-403. 
[68) T. Shimada, H. Yamazaki, M. Mimura, Y. Inai, F.P. Guru. 
gerich, Inter-individual variations in human liver cytochromr 
P450 enzymes involved in the oxidation of drug, carcinogens 
and toxic chemicals, J. Pharmacol. Exp. Thee. 270 (1994) 
414-423. 
M. Rorukes, M.B. Fabebto, J.A. Blaisdell, J.L. Raney, J.A. 
Goldstein, Cloning and expression of complementary DNAs 
for multiple members of the human cytochrome P450Iic cub. 
family, Biochemistry 30(1991)3247-3255. 
J.A. Goldstein, S.M.F. de Moraio, Biochemistry and molec-
ular biology of the human CYP2C subfamily, Phurmacoge. 
netics 4 (1994) 205-299. 
M.A. Hamman, G.A. Thompson, S.D. Hall, Rrgioaelective 
and stereoselective metabolism of ibuprofen by human cyto-
chrome P4502C. Pharmacology 54 (1997) 33-41. 
[72) T.S. Klose, B.I. Ohauayem, J.A. Goldstein, G.C. lbeauua, 
Abstracts of 17th International Congress of Biochemistry 
and Molecular Biology, San Francisco, CA, 1997, p. A794. 
(73) J.A. Goldstein, M.B. Falello, M. Romkea-Sparks, I. Sulli-
van, S. Kitareewan, J.L. Raucy, I.M. Lanker, B.I. Oha-
nayem, Evidence that CYP209 is the major (S)-mepheny-
loin 4'-hydroxybose in humans, Biochemistry 33 (1994) 
1743-1752. 
B.I. Ghaaayem, W.G. Karam, J.A. Goldstein, Sixth North 
American International Society for the Study of Xenobiotics 
Meeting, 23-27 October 1994, Raleigh, NC, p.  50 (abatr.). 
M.E. Veronese, P.I. Mackenzie, C.J. Doeske, M.E. McMa-
nus, 1.0. Miners, D.J. Birkelt, Tolhatamide and phenytoin 
hydrosylatious by cDNA-expressed human liver cytochrome 
P4502C9, Biochem. Biophys. Res. Common. 175 (1991) 
1112-1118. 
[76) A. Mancy, S. Dijols. S. Poli. F.P. Oaengerich, D. Mausay, 
Interaction of uulfapheaazole derivatives with human liver 
cytochromes P450 2C: molecular origin of the specificity 
inhibitory effects of salfapbeaazale on CYP2C9 and conse-
quences for the substrate binding site topology of CYP2C9, 
Biochemistry 35 (1996) 16205-16212. 
(77) J.A. Goldstein, T. Ishicaki, K. Chiba, S.M. do Morals, D. 
Bell, P.M. Krahn, D.A. Evans, Frequencies of the defective 
CYP2CI9 alleles responsible for the mcpheuytoin poor me-
tabolizer phenotype in various Oriental. Caucasian, Saudi 
Arabian and American block populations, Pharmuacogenetics 
7 (1997) 59-64. 
(78] D.F.V. Lewis, H. Macsods, The sequence homologies of 
cytochromes P450 and active-site geometries, I. Comp.. 
Aided Mob. Des. 6 (1992) 235-252. 
[79) W.-H. Schanck, F. Vogel, B. Gross, E. Kfirgel, S. Mauers-
berger, K. Kflpke, C. Geugnagel, H.-G. MliOer, Comparison 
of two cytochrommses P450 from Ca,rdida nrairosa: primary 
structure, substrate specificities and effects of their expres-
sion in Saccharomyces rerevisiae on the proliferation of the 
endoplaunsic reticsrlum, Ear. J. Cell Biol. 55 (1991) 336-
345. 
[80) T. Zimmer, U. Scheoer, M. Takagi, W.-H. Schnuck, Mutual 
conversion of fully acid substrate specificity by a single ami-
no acid exchange at position 527 in P450Cta2 and 
P450AIk3A, Ear. J. Biochem. 256 (1998) 398-403. 
(813 J.-Y. Kim, P.N. Devreotes. Random chitneragenetis of G- 
protein-coupled receptors-mapping the affinity of the cAMP 
chemoatlractaat receptors in Dictyoatelium. J. Biol. Chests. 
269 (1994) 28724-28731. 
[82] L.R. Lavin, R.R. Reed, Identification of functional domains 
of adenylyl-cyclase using in-viva chimeras, J. Biol. Chem. 
270 (1995) 7573-7579. 
[83) I.A. Pikuleva, t. Bjorkhem, M.R. Waterman, Studies of dis-
tant members of the P450 superfamily (P450sca and 
P450c27) by random chinteragesresis, Arch. Biochem. Bio-
phys. 334 (1996)183-192. 
[84] B.J. Brock, M.R. Waterman, The use of random chimera-  
genesis to study structure/function properties of rat and hu-
man P450cI7, Arch. Biochem. Biophys. 373 (2000) 401-408. 
(85] M. Shimoji, H. Yin, L.A. Higgins, J.P. Jones, Design of a 
novel P450: a functional bacterial-human cytochrome P450 
chimera. Biochemistry 37 (1998) 88484852. 
]86) K. Alm, E. Szczesaa-Skorupa, B. Kemper, The amino-ter-
minal 29 amino acids of cytachrome P450 2Cl are sufficient 
for retention in the endoplarmic reticulum, J. Biol. Chem. 
268 (1993) 18726-18733. 
(07] L.-C. Hsu, M.-C. Ha, H.-C. Cheng, J.-C. La, B. Chung, The 
N-terminal hydrophobic domain of P450c21 is required for 
membrane insertion and enzyme stability, J. Biol. Chem. 268 
(1993)14602-14686. 
(80) S.J. Pernecky, M.J. Coon. N-terminal modifications that al-
tee P450 membrane targeting and function. Methods Euzy-
mob. 272 (1996) 25-34. 
[89) S.J. Pesnecky, J.R. Larson, M.J. Coon, Cytosolic localisa-
tion of N113-terminal-modified microsomal P450 in E rail, 
PASEB J. 7(1994) A1200. 
[90] V.Y. Uonrov, Al. Satxichexko, E.L. Vodovozova, J.G. Mo' 
lotkovxky, E.F. Kobesanovs, Y.A. Lyulkia. A. Stier, V. 
Krueger, Al. Archakov, Determination of mcmbeane-bound 
fragments of cytochrome P450 200, Our. J. Biochem. 222 
(1994) 483-489. 
B. Doray, C.D. Corn, B. Kemper. Substitutions in the C. 
terminal portion of the catalytic domain partially reverse 
assembly defects introduced by mutations in the N.icrminal 
linker sequence of cytoclrrome P450 2C2, Biochemistry 38 
(1999) 12100-12186. 
T. Sueyoahi, L.J. Park, R. Moore, R.O. Juvonea, M. Ne' 
gislti, Molecular engineering of microuosnnl P450 2A4 to a 
stable, water-soluble enzyme, Arch. Biochem. Biophys. 322 
(1995) 265-271. 
(93] D.C. Lamb, D. E. Kelly, K. Venkateswaela, N.J. Manning, 
H.P.J. Bliglt, W.-H. Schnak, S.L. Kelly, Generation of a 
complete, soluble, and catalytically active sterol 14tt-deme-
thylase'reductaae complex, Biochemistry 38 (1999) 8733-
8738. 
[94) C.M. Jenkins, M . R. Waterman, NADPII.flavodosia reduc. 
tare and fiavodoxin from Escherlrhla roil: characteristics as 
CS. Mile, et of lBludslmlco et Biop6ysica Aria 1543 (2000) 383-407 	 405 
	
406 	 C.S. Miles et of IBiodslnslca ci Biophysico Acts 1543 (2000) 383-407 
a soluble microsomal P450 reductose. Biochemistry 37 
(1998) 6106-4113. 
(95] M. Kranendoak, F. Carreira. P. Theisen, A. Laires, C.W. 
Fisher, J. RacE, R.W. Eatabrook, N.P.E. Venneulen, Sc-
rhorlrhla coil MTC, a human NADPH P450 reductase com-
petent mutageaicity, tester strain for the expression of hu-
man cytochrome P450 isoforms lAl, lA2, 2A6, 3A4 or 
3A5: catalytic activities and mutagenicity studies, Mutut. 
Res. Genoa. Touicol. Enviroa. Mutagea. 441 (1999) 73-83. 
(961 S. LuCoace, 3.-C. Gautier, C. Belloc, A. Gaulire. P.H. 
Beaune, Use of beterologous expression systems to study 
aatoimmnoe drug-induced hepatitis. Methods Euzysnol. 
272 (1996) 76-05. 
R.W. Estabrook, J.M. Train, P.A. Mathew, IL Mason, 
M.R. Waterman, Designee membranes-construction of a 
cell containing multiple membrane-bound cytocheomes 
P450, Cur, Top. Cell Regul. 33 (1992) 419-431. 
C. von Wacltenfrldt, TM, Richardson, J. Cosme, E.F. 
Johnson, Microsomal P450 20 is expressed as a soluble 
dimer in E.sche,'lchla cull following modifications of its 
N-terminus, Arch. Biochem. Biophys. 339 (1997) 107-
114. 
S.D. Sugar, IC. Gunsalus, A thcrmodyaamic model of reg-
ulation: modulation of radon equilibria in camphor mono-
oxygenate, Proc. Nan. Aced. Sol. USA 73 (1976) 1078-
1082. 
(108] S.N. Doff, S.K. Chapman. K.L. Turner, R.A. Holt, S. Go-
visadaraj, T.L. Poulos, A.W. Munro, Reclos control of the 
catalytic cycle of fiavocytochrome P450 BM3, Biochemistry 
36(1997)13816-13823. 
(lOt] J.D. Lambeth, S.E. Kitchen, A.A. Faeooqui, K. Tuckey, H. 
Kasnin, Cytochronse P450scc-suhstrute interactions: studies 
of binding and catalytic activity using hydroxycholesterols, 
J. Biol. Chess. 257 (1982) 1876-1884. 
J.D. Lambeth, H. Kamin, Adrenodoxin reductase-adreno-
donin complex: Bavin to iron-sulfur electron transfer as the 
rate-limiting step in the NADPH.cytochrome c reductase 
reaction, J. Biol. Chem. 254 (1979) 2766-2774. 
J.D. Lambeth, S. Kriensiri, Cytochrome P-450scc-adreno-
doxin interactions: ionic effects on binding, and regulation 
of cy*ochrome redaction by hound steroid substrates, 
J. Biol. Cbost. 260 (1905) 8810-8816. 
P.S. Stayton, T.L. Poulos, S.D. Sligar, Putidaredoxin com-
petitively inhibits cytocheome b5-cytochrome P450 cam 
electron transfer complex. Biochemistry 28 (1989) 7381-
7386. 
11051 T. Kido, T. Kimura, The formation of binary and ternary 
complexes of cytochrome P450 soc with adrenodoxin and 
adrenodoxin ceductase-adrenodonin complex, J. Biol. 
Chests. 254 (1979) 1180641815. 
[106] C.B. Brewer, J.A. Paterson, Single turnover kinetics of the 
reaction between oxycytachrome P450 cam and reduced 
putidaredoxin, J. Biol. Chem. 263 (1986) 791-798. 
(107] K. Nakamura, T. Hotiaciti, T. Yasukochi, K. Sekimizu, T. 
Hues, V. Sngara, Significant contribution of atginine 112 
and its positive charge of Paeado,ssonao paalds P450 cam in 
the electron transport from putidaredoxin, Biochim. Bio' 
phya. Acts 1207 (1994) 40-48. 
(108) M.D. Davies, S.G. Sligar, Genetic variants in the putida-
redosin-cytochrome P450 cam electron transfer complex: 
identification of the residue responsible for redox.state-de-
pendent conformers, Biochemistry 31(1992)11383-11389. 
(109] M. Unno, H. Shimada, V. Toba, R. Makino, V. Ishimura, 
Role of Arg 112 of cytochrome P450 cam in the electron 
transfer from reduced putidaredoxin-analyses with site-di-
rected mutants, J. Biol. Chem. 271 (1996) 17869-17874. 
[1 101 M. Aoki, K. Ishimori, 1. Morishima, Roles of negatively 
charged surface residues of putiduredoxin in interactions 
with redox partners in P450cam monoosygenase system, 
Biochim. Biophys. Acts 1386 (1998) 157-167. 
(Ill] M. Aoki, K. Ishimori, I. Morishma, V. Wada, Roles of 
valine 98 and glutasnic acid 72 of putiduredosiss in the 
electron transfer complexes with NADH-putidatedouin re-
ductase and P450 corn, borg. Chim. Acta 272 (1998) 80-. 
88. 
(112] A.E. Roitberg, M.J. Holden, M.P. Mayhew, IV. Kurnikov, 
D.N. Beratan, V.L. Vilker, Binding and electron transfer 
between putidaredoxiu and cytochrome P450 cam. Theory 
and experiments, J. Am. Chem. Soc. 120(1990)8927-8932. 
[113] S.G. Sligar, P.G. Debrunnee, S.D. Lipscomb, M.J. Namt-
vedt, I.C. Gunsalas, A role for putidaredoxin COOH-ter-
minus in P450 cant (cylachrome m) hydroxylalions, Proc. 
Null. Acad. Sol. USA 71(1974)10. 
J.E. Baldwin, G.M. Morris, W.G. Richards. Electron trans-
port in cytochromes P450 by covalent switching, Proc. K. 
Sec. London See. B 245 (1991) 43-51. 
A.W. Munro, K. Malarkey, J. McKnight, Al. Thomson, 
S.M. Kelly, N.C. Price, J.G. Lindsay, J.R. Coggins, J.S. 
Miles, The role of tryptophan 97 of cytochrome P450 
BM3 from Burl/las megaterinm in catalytic function. Evi-
dence against the 'covalent switching' hypothesis of P450 
electron transfer, Biochem. J. 303 (1994) 423-428. 
H. Yamazaki, W.W. Johnson, Y.F. Ueng, T. Shimada, F.P. 
Guengerich, Lack of electron transfer from cytocbrome b, 
in stimulation of catalytic activities of cytochrome P450 
3A4-characterization of a reconstituted cytochrome P450 
3A4 NADPH-cytochrome P450 redsictase system and stud-
ies with apo-cytochrome b3, J. Biol. Chem. 271 (1996) 
27438-27444. 
R.J. Achus, T.C. Lee, W.L. Miller, Cytochrome b5 aug-
ments the 17. 20-1yase activity of human P450 c17 without 
direct electron transfer. J. Biol. Chests. 273 (1998)3158-
3165. 
[118] P.S. Slayton, M.T. Fisher, S.G. Sligar, Determination of 
cytochrome b, association reactions: Characterization of 
metmyoglobin and cytodtrome P450 cam binding to genet-
ically engineered cytochrome b5, J. Biol. Chem. 263 (1908) 
13544-13548. 
11191 P.S. Stayton, S.G. Sligar, The cytochtome P450 cam bind. 
ing surface as defined by sile-directed mutageaesis and elec- 
trostatic modelling. Biochemistry 29 (1990) 7381-7384. 
[120] A. Bridges, L Gruenkr, Y.-T. Chang, I.A. Vasher, G. 
Loew, L. Waskell, Identification of the binding site on cy-
tocbrome P450 286 for cytochrome b5 and cytochrome 
P450 redactase, J. Biol. Chem. 273 (1990) 17036-17049. 
V. Kostanjevecki, D. Lays, G. Van Driessche, T.E. Meyer, 
M.A. Cusanovich, U. Fischer, Y. Guise,, J. Van Becomes, 
Structure and characterization of Ertoilsiurhodosplro vacsso. 
Iota cytoohronse bsss, a prokasyotic homologue of cyto-
chrome b5, J. Biol. Chem. 274 (1999) 35614-35620. 
L.O. Narhi, AJ. Fulco, Identification and characterisation 
of two functional domains in cytochrome P450 BM3, a 
catalytically self-sufficient monooxygenase induced by bar-
biturates in Bacillus ntegaterlam, J. Biol. Chem. 262 (1987) 
6683-6690. 
J.S. Miles, A.W. Munro, B.N. Rospendowtki, W.E. Smith, 
J. McKnight, A.I. Thomson, Domains of the catalytically 
self-sufficient cytochrome P450 BM3'genetic construction, 
overexpression, purification and spectroscopic characterisa-
tion, Biochem. J. 288 (1992) 503-509. 
S. Govindarig, T.L. Poulos, The domain architecture of 
cytocltrome P450 BM3, J. Biol. Chem. 272 (1997) 7915-
7921. 
M.L. Klein, Al. Fulco. Critical residues involved in FMN 
binding and catalytic activity in cytochronse P450 DM3, 
J. Biol. Chess. 268(1993)7553-7561. 
[126) I.F. Sevrioukova, H . -Y. Li, H. Zhang, J.A. Peterson, T.L. 
Poulos, Structure of a cytochromo P450-redox partner eec-
troa.transfer complex, Proc. Null. Acad. Sci. USA 96 
(1999) 1863-1868. 
M. Wang, D.L. Roberts, K. Pascltke, T.M. Shea, B.S.S. 
Masters, J.J.P. Kim, Three-dimensional structure of 
NADPH-cytochrome P450 sedacsase: prototype for 
FMN- and FAD-containing enzymes, Proc Nut]. Acad. 
Ba. USA 94 (1997) 8411-8416. 
H. Joo, Z.L. List, F.H. Arnold, Laboratory evolution of 
peroxide-mediated cytochrome P450 bydronylution, Nature 
399 (1999) 670-673. 
]129( K.M. Faulkner, K.M. Shet, C.W. Fisher, R.W. Estabrook, 
Electroentalytically driven omega-hydroxylation of fatty 
acids using cytechrome P450 4A1, Proc. Nall. Acad. Sci. 
USA 92 (1995) 7705-7709. 
R.W. Estabrook, K.M. Faulkner, M.S. Sher, C.W. Fisher, 
Application of electrochemistry for P450-catalyzed reac-
tions, Methods Enzymol. 272 (1996) 44-5I. 
R.W. Eutabrook, M.S. Shet, C.W. Fisher, C.M. Jenkins, 
M.R. Waterman, The interaction of NADPH-P450 reduc-
tase with P450: an electrochemical study of the role of the 
flavis mouonucleotide-binding domain, Arch. Biochem. 
Biophys. 333 (1996) 308-315. 
H.J. Barnes, Maximizing expression of eukaryotic cyto-
chrome P450s in Eudsrrtchla coil, Methods Enzymol. 272 
(1996) 3-14. 
(133) H. Murakansi, V. Yabuaaki, T. Sakaki, M. Shibata, H. 
Ohkawa. A genetically engineered P450 monooxygenase: 
construction of the functional fused enzyme between rat 
cytochromc P450c and NADPH-cysochrome P450 redac-
taue. DNA 6(1987) 189-197. 
(134] M. Shibata, T. Sakaki, V. Yabosaki, H. Murakami, H. 
Ohkawa, Genetically engineered P450 monooxygenases: 
construction of bovine P450671yeast reduclase fused en-
zymes, DNA Cell Biol. 9(1990)27-36. 
[135] T. Sakahi, M. Shibata, Y. Yabusaki, H. Marakami, H. 
Ohkuwa, Expression of bovine cytochrome P450c2l and 
its fused enzymes with yeast NADPH-cytochrome P450 
reductase in Saocharomyces cerevisine, DNA Cell Biol. 9 
(1990) 603-614. 
H.J. Barnes, M.P. Arlotto, M.R. Waterman, Expression 
and enzymatic activity of recombinant cytochrome P450 
17a.hydroxylsse in £ roll. Proc. Nat!. Acad. Sci. USA 88 
(1991) 5597-5601. 
C.W. Fisher, M.S. Shot, D.L. Caudle, C.A. Martin-Win-
trom, R.W. Eatabrook, High-level expression in £tchertchis 
call of enzymatically active fusion proteins containing the 
domains of mammalian cytochromes P450 and NADPH. 
P450 redactase fiavoproteiu, Proc. NatI, Acad. Sri. USA 89 
(1992) 10817-10821. 
[138] M.S.Shet, C.W. Fisher, P.L. Holmans, R.W. Estahrook. 
Human cyuochrome P450 3A4: enzymatic properties of a 
purified recombinant fusion protein containing NADPH-
P450 reductase, Proc. Nall. Acad. Sd. USA 90 (1993) 
11748-11752. 
C.W. Fisher, M.S. Shet, R.W. Estabrook, Construction of 
plasmids and expression in S coil of enzymatically active 
fusion proteins containing the heme domain of a P450 
linked to NADPH-P450 redactase, Methods Enzymol. 
272 (1996)13-25. 
Y.-J. Chun, T. Shimoda, F.P. Gaengerich, Construction of 
a human cytochrome P450IAI :raINADPH'cytochrome 
P450 reductaae fusion eDNA and expression in &c/serlchho 
roll, purification and catalytic properties of the enzyme in 
bacterial cells and after purification, Arch. Biochern. Bio-
phys. 330 (1996) 48-58. 
[141] D.W. Nebert, The AH locus-genetic differences in toxicity, 
cancer, mutation, and birth-defects, Crit. Rev. Tosicol. 20 
(1989) 153-174. 
(142] P.J. Wedlund, S. Kimura, F.J. Gonzalez, D.W. Nerbert, 
1462V mutation in the human CVPIAI genetack of corre-
lation with either the Msp 11.9 kB (m2) allele or CYPIAI 
inducibility in a 3-generation family of east Mediterranean 
descent, Pharmucogenetics 4 (1994) 21-26. 
F.P. Guengerich, Cytochoome-P450 enzymes, Am. Sd. 81 
(1993) 440-447. 
N. Shiota, A. Nagasawa, T. Sakaki, V. Yabusaki, H. Oh-
kawa, Herbicide-resistant tobacco plants expressing the 
fused enzyme between rat cytochrome P450IAI 
(CYPIAI) and yeast NADPH-cytochrome P450 osidore-
ductaae, Plant Plsysiot. 106 (1994)17-23. 
G.R. Harlow, J .R. Halpert, Matagenesis study of Asp-290 
in cytochrome P450 2Bt I using a fusion protein with rat 
NADPH'cytochroase P450 redsctase, Arch. Biochem. Bio-
phyt. 326 (1996) 85-92. 
(146] 0. Sibbesen, JJ. do Vms, P.R.O. de Montellano, Putida-
redosin reductase-putidaredotin-cytochrome P450cam tn- 
CS. Mile, et oil lBlochtmjru et Biophyslcu Actu 1543 (2(0)0) 383-407 	 407 
pie fusion protein, J. Biol. Cheat. 271 (1996) 22462-
22469. 
11471 F.J. Dilworth, S.M. Black, Y.-D. (3no, W.L. Miller, G. 
Jones, Construction of a P450c27 Onion enzyme: a useful 
tool for analysis of vitamin D3 25 hydroxylase activity, 
Biochem. J. 320 (1996) 267-271. 
[148[ J.A. Ha,ikrishna, S.M. Black, G.D. Bobbin, W.L. Miller, 
Construction and function of fusion enzymes of the human 
cytochrome-P450sx system, DNA Colt Biol. 12 (1993) 371-
379. 
11491 P. Can, H. Balow, B. Damon, R. Bernhardt, Construction 
and characterisation of a catalytic fusion protein system: 
P450 I t-adreoodoxin reductane-adrenodoxin, Biochim. 
Biophys. Acta 1476 (2000) 253-264. 
[150] T. I,acour, H. Ohknwa. Engineering and biochemical char- 
acterisation of the rut microsomul cytochrome P450IAI 
fused to ferredoxin and feoredoxin-NADP reductase 
from plant chtoroptants, Biochim. Biophys. Acts 1433 
(1999) 87-102. 
[1511 T. Sukuki, S. Kominami, K. Hayashi, M. Akiyoshi-Shibutu, 
Y. Ynbusuki, Molecular engineering study on electron 
transfer from NADPH.P450 reductase to rut mitochondriul 
P450c27 in yeast microsomes, J. Biol. Cheat. 271 (1996) 
26209-26213. 
(152( T. Snkuki, S. Kominami, S. Takemori, H. Okhuwu, M. 
Akiyoohi-Shihata, Y. Yubusaki, Kinetic studies on a genet-
ically engineered fused enzyme between rut cytochrome 
P450 IAI and yeast NADPH-P450 reductase, Biochemistry 
33 (1994) 4933-4939. 
(153] J. Krautis, J. AppI. Crystattogr. 24 (1991) 946-950. 
Phenylalanine 393 Exerts Thermodynamic 
Control over the Heme of 
Flavocytochrome P450 BM3 
Tobias W. B. Ost, Caroline S. Miles, Andrew W. Munro, 
Jane Murdoch, Graeme A. Reid, and Stephen K. Chapman 
Department of Chemistry, University of Edinburgh, West Mains 
Road, Edinburgh, EH9 3JJ, U.K., Institute of Cell and Molecular 
Biology, University of Edinburgh, Mayfield Road, Edinburgh, 
EH9 3JT, U.K., and Department of Biochemistry, The Adrian 
Building, University of Leicester, University Road, Leicester, 
LE1 7RH, U.K. 
Biochemistry® 
Reprinted from 
Volume 40, Number 45, Pages 13421-13429 
Biochemistry 2001, 40, 13421-13429 
Phenylalanine 393 Exerts Thermodynamic Control over the Heme of 
Flavocytochrome P450 BM3t 
Tobias W. B. Ost,* 4 Caroline S. Miles,1 Andrew W. Munro," Jane Murdoch, 1 Graeme A. Reid, 1 and 
Stephen K. Chapman 
Department of Chemistry, University of Edinburgh, West Mains Road, Edinburgh, EH9 3JJ, U.K., Institute of Cell and 
Molecular Biology, University of Edinburgh, Mayfield Road, Edinburgh, EH9 YT, U.K., and Department of Biochemistry, 
The Adrian Building, University of Leicester, University Road, Leicester, LEI 7RH, U.K 
Received April 9, 2001; Revised Manuscript Received September 4, 2001 
.nsiicr: Site-directed mutants of the phylogenetically conserved phenylalanine residue F393 were 
constructed in flavocytochrome P450 BM3 from Bacillus megaterium. The high degree of conservation 
of this residue in the P450 superfamily and its proximity to the heme (and its ligand Cys400) infers an 
essential role in P450 activity. Extensive kinetic and thermodynamic characterization of mutant enzymes 
F393A, F393H, and F393Y highlighted significant differences from wild-type P450 BM3. All enzymes 
expressed to high levels and contained their full complement of heme. While the reduction and subsequent 
treatment of the mutant P450s with carbon monoxide led to the formation of the characteristic P450 
spectra in all cases, the absolute position of the Soret absorption varied across the series WT/17393Y (449 
run), F393H (445 nm), and F393A (444 nm). Steady-state turnover rates with both laurate and arachidonate 
showed the trend WT > F393Y >> F393H> F393A. Conversely, the trend in the pre-steady-state flavin-
to-heme electron transfer was the reverse of the steady-state scenario, with rates varying F393A > F393H 
>> F393Y wild-type. These data are consistent with the more positive substrate-free [-312 mV (F393A), 
—332 mV (F393H)] and substrate-bound [-151 mV (F393A), —176 mV (F393H)] reduction potentials 
of F393A and F393H heme domains, favoring the stabilization of the ferrous-form in the mutant P450s 
relative to wild-type. Elevation of the heme iron reduction potential in the F393A and F393H mutants 
facilitates faster electron transfer to the heme. This results in a decrease in the driving force for oxygen 
reduction by the ferrous heme iron, so explaining lower overall turnover of the mutant P450s. We postulate 
that the nature of the residue at position 393 is important in controlling the delicate equilibrium observed 
in P450s, whereby a tradeoff is established between the rate of heme reduction and the rate at which the 
ferrous heme can bind and, subsequently, reduce molecular oxygen. 
The cytochromes P450' are a superfamily of heme 
b-containing monooxygenase enzymes (1). They are wide-
spread in all life forms (from bacteria through to man) and 
are notable for their diversity in substrate selectivity. The 
best understood P450 systems are the bacterial P450cam 
(camphor hydroxylase from Pseudomonas putida) and P450 
BM3 (fatty acid hydroxylase from Bacillus megaterium) (2, 
3). Study of the crystal structures (4, 5) of these soluble 
enzymes has enabled the design of site-directed mutants, 
allowing the roles of several key amino acids to be 
determined. Despite similar tertiary structure, these two 
enzymes belong to two different classes of P450. P450cam 
is a class I (or B-class) P450, receiving electrons from a 
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two component reductase system (ferredoxin and NADH-
ferredoxin reductase) (6). P450 BM3 is a class II (or E-class) 
P450, receiving electrons from a eukaryotic-like diflavin 
NADPH-cytochrome P450 reductase fused to the P450 in 
one continuous polypeptide (7). This fused arrangement of 
its redox partners correlates with the high catalytic activity 
of P450 BM3 and makes the system very convenient as a 
model for mechanistic studies of P450s and P450-related 
enzymes (such as the nitric oxide synthases) (8). 
Comparisons of the amino acid sequences of all P450s 
reveal only a few residues which are implicitly conserved 
throughout the superfamily. One of these is the cysteine that 
provides the thiolate ligand to the heme iron (Cys400 in P450 
BM3) (Figure 1). In addition there are several residues, 
located close to this ligand, which display high conservation 
within what is termed the "heme binding" motif (9). A 
phenylalanine residue (17393 in P450 BM3) is almost totally 
conserved within this region, with a small number of 
exceptions, including the dehydratase P450 74 (an allene 
oxide synthase from flax seed) and P450 10 from the pond 
snail Lymnaea stagnalis, with potential involvement in 
steroid synthesis (10, 11). The analogous residues are proline 
and tryptophan, respectively. This high level of conservation 
10.1021/biOl0716m CCC: $20.00 © 2001 American Chemical Society 
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Cyp101(cam) 345VSHTTGHGSHLCLGQH1, 362 
Cyp102(BM3) 388HAFKPGNGQRACIGQQF 405 
Cyp6Al (Housefly) 437LDWLGFGDGPRNCIGMRF 444 
Cyp2El (Rabbit) 425 D Y F K PS A G K R VCV G H G L 	442 
CypliAl (Human) 450 F R N L G FiG N G V R Q C L G R R I 467 
Cyp74 (flaxseed) 477 P E T E T P S V A N K Q:CA G K D F 	494 
CyplO (snail) 481 T S Q L V W G H G A R MC L G R R I 499 
icuitu 1: Sequence alignment within the heme-binding region of selected P450s (2, 26-29). The alignment shows the implicitly conserved 
ysteine residue which provides the sixth ligand to the heme iron of all P450s (dotted box). Seven residues downstream is located the 
•ghly conserved phenylalanine, corresponding to Phe 393 of P450 BM3 (grey box). Two of the known P450s lacking this phenylalanine 
e also shown, where the phenylalamne is replaced by a tryptophan (10) or a proline (11) (solid box). 
ghlights the importance of this residue, yet, to date, no 
satisfactory explanation as to its role has been made. 
Previously, the aromatic side chain of the corresponding 
phenylalanine in P450 cam (F350) was proposed to partici-
pate directly in electron transfer to the P450 heme in a 
cytochrome b5/P450 complex (12). Mutagenesis of this 
phenylalanine in rat liver P450 1A2 (F449) and rabbit P450 
2E1 (F429) and subsequent characterization of the mutant 
enzymes led the investigators to different conclusions (with 
respect to P450 cam) regarding its role. In P450 1A2, F449 
mutants showed diminished catalytic capacity and were 
affected in heme binding (13). In P450 2E1, only an effect 
on heme binding was observed in F429 mutants (14). 
However, neither study has conclusively resolved the ques-
tion as to the conserved phenylalanine's importance in the 
catalytic competence of P450s. To elucidate its role, we 
describe here a series of comprehensive studies, character -
izing both the kinetic and thermodynamic properties of site-
directed mutants at phenylalanine 393 in flavocytochrome 
P450. Our results indicate that F393 is not essential for heme 
incorporation, but does have a key role in controlling the 
electronic properties of the heme system. We postulate that 
the interaction between this residue and the heme iron—sulfur 
bonding system is central to the control of the reactivity of 
oxygen with the ferrous heme. 
EXPERIMENTAL PROCEDURES 
Escherichia coli Strains and Plasmid Vectors. Escherichia 
coli TGI [supE, hsdL5, thi, A(lac-proAB), F [traA36, 
proAB, /acJ,  /acZAMI511 was used for all cloning work 
and for overexpression of intact P450 BM3 and its compo-
nent cytochrome domain. The preparation of plasmids for 
the overexpression of intact P450 BM3 (pBM23) and heme 
domain (P450, residues 1-472; pBM20) has been described 
in previous publications (15, 16). Mutants F393A, F393H, 
and F393Y (intact) and F393A-HD, F393H-HD, and F393Y- 
HD (HD denotes heme domain) were constructed by oligo- 
nucleotide-directed mutagenesis of pBM23 and pBM20 
respectively, using the Kunkel method (17, 18). Single-
stranded DNA was prepared using the helper phage M13K07. 
Oligonucleotide primers used in the mutagenesis procedures 
were as follows (mismatches are indicated by the underlined 
bases and the names of the resulting expression plasmids 
are in parentheses): F393A and F393A-HD (pCM36, 
pCM80), 5'CTGACCG1TFCCAGCCGGTVfAACGC 3'; 
F393H and F393H-HD (pCM 37, pCM8I), 5' CTGAC- 
CGTITCCATGCGG1TFAAACGC 3'; F393Y,and F393Y-
HD (pCM 109, pCM 125), 5' CCGTVFCCATACGGTI'-
TAAAC 3'. 
To ensure that no secondary mutations had occurred, pCM 
36, pCM37, and pCM109 were sequenced by the dlideoxy 
chain termination method. These plasmids were digested with 
restriction enzymes SnaBI and SpeI, generating a 3 kbp 
fragment containing the required mutation. The SnaBIJSpeI 
fragment was then ligated with the 4 kbp band liberated from 
a similar digestion of pBM23 (containing the WT P450 BM3 
coding sequence under the control of the native CYP 102 
promoter) generating pJMi, pJM2, and pJM3, respectively. 
Mutants were overexpressed in E. co/i strain TG1 in an 
identical fashion to the wild-type clone. 
Enzyme Preparations. All flavocytochromes P450 (wild-
type and mutants) were purified from E. co/i TG1 transfor-
mants (which express the P450 to high levels in the stationary 
phase under the control of the authentic promoter from 
Bacillus) by growth of transfonnant cultures (2-5 L of Luria-
Bertani medium at 37 °C with shaking at 200 rpm) for '36 
It after entry into the stationary phase. For the heme domains 
of wild-type and mutants, cells were induced (1 mM IPTG) 
at an A 0 = 1, and growth was continued for 6-12 h prior 
to harvesting cells. Cells were disrupted by sonication. A 
similar purification protocol was employed for all enzymes 
using ion-exchange chromatography on DEAE-Sephacel and 
hydroxyapatite, as described previously (19). A final step 
(HiLoad 26/10 Q-Sepharose high performance column at-
tached to a Pharmacia FPLC system, with protein elution 
gradient 0 to 500 mM KC1 in 50 mM TrisHClJl mM EDTA, 
pH 7.4) was employed to maximize the final purity of all 
the proteins. PMSF (1 mM) was added to all buffers to 
minimize proteolysis. All pure proteins were concentrated 
to >500 uM by ultrafiltration and were stored at —20 °C 
after dialysis against two successive 500-fold volumes of 
buffer A (50 mM Tris HC1, pH 7.4) containing 50% (v/v) 
glycerol. Enzymes were used within 1 month of isolation. 
Spectrophorometric Analysis of Fatty Acid and Carbon 
Monoxide Binding to P450s. UV—vis absorption spectra 
were recorded over the 300-800 nm range using a Shimadzu 
2101 spectrophotometer and quartz cuvettes of 1 cm path 
length. Typically, the concentration of wild-type or mutant 
P450 BM3 used was 1-5 MM in 1 mL of assay buffer (20 
mM MOPS/100 mM KC1 pH 7.4) at 30 °C. 
Fatly Acid Binding Titrations. For enzyme titrations with 
arachidonic acid, aliquots (0.1-0.5 ML; not exceeding 3 ML 
total addition) of a 33 mM solution (in ethanol) were added 
to the enzyme solution (1-5 MM in assay buffer). For 
enzyme titrations with sodium launte, 10 uL aliquots of P450 
BM3 (1-5 MM in assay buffer) were withdrawn and replaced 
with aliquots of a solution of enzyme at identical concentra-
tion in the same buffer, but containing in addition 1 mM 
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sodium laurate. Spectra were recorded after each addition 
of substrate. Difference spectra were generated by subtraction 
of each spectrum recorded from the substrate-free spectrum. 
Dissociation constant (Kj) values were determined by plotting 
the maximal absorbance changes calculated from each 
difference spectrum against the concentration of substrate, 
and fitting the data to a rectangular hyperbola using Origin 
software (Microcal). 
Carbon Monoxide Binding. Fe—CO complexes of wild-
type and the mutant enzymes were prepared in the same 
fashion. Proteins were reduced by the addition of a few grains 
of sodium dithionite and were converted to the P450-complex 
by slow bubbling of the solutions with carbon monoxide gas 
for one minute. 
Steady-State Kinetics. All steady-state kinetic measure-
ments were performed at 30 °C in assay buffer using 1 cm 
path-length quartz cuvettes. Initial rates of fatty acid (arachi-
donate and laurate) oxidation were measured as described 
previously (20), by monitoring the oxidation of NADPH at 
340 nm (c340 6.21 niM' cm') with 10-100 nM enzyme 
and NADPH at saturating concentration (200 NM). The initial 
arachidonate concentration was varied by addition of small 
volumes (<2.0 4uL) from a 33 or 3.3 mM ethanolic stock 
using a 10 uL Hamilton gastight syringe (Hamilton, Reno, 
NV), and the initial laurate concentration was varied by 
dilution of a 1 mM aqueous stock. Rate measurements were 
converted into activity units, s' (mol of NADPH oxidized/ 
s per mol of P450) and plotted against fatty acid concentra-
tion. Data were fitted to the Michaelis—Menten equation 
using Origin software. 
Determination of Enzymatic Coupling Efficiency. The 
coupling efficiencies of wild-type and the F393A, F393H, 
and F393Y mutant holoenzymes were determined by nega-
tive-ion electrospray mass spectrometry. Turnover assays 
were performed on each P450 under limiting concentrations 
of NADPH and excess arachidonate and oxygen (980 uL of 
20 mM MOPS, pH 7.4, 4 1uL of 33 mM arachidonate, SaL 
of 19.7 mM NADPH, and 10 uL of 4 4uM P450). Reactions 
were initiated by addition of P450. The air-saturated con-
centration of oxygen in aqueous solution was '-'260 uM (21). 
Under these conditions, NADPH consumption can only be 
coupled to product formation or oxygen reduction (due to 
the absence of other electron acceptors in the assay and with 
both [substrate] and [oxygen] in excess of [NADPH]). 
Samples of each reaction mixture were injected into the mass 
spectrometer (Micromass Platform electrospray mass spec-
trometer) and analyzed under the following conditions: ESI-
ye, cone voltage = 35 V, acquired range 150-500 Da. The 
concentration of unreacted substrate (mlz 303) and hydrox-
ylated substrate (m!z 319) in each reaction mixture was 
evaluated from the total ion current for each peak (MassLynx 
software). The concentration of NADPH was calculated from 
its absorption spectrum (e 0 = 6.21 rnM cm'). All 
appropriate controls were run, and under these conditions, 
no interfering signals from NADPH, buffer, or enzyme were 
observed, with monohydroxylated arachidonate being the 
only observable product. The reactions were performed at 
30 °C and conditions were optimized so that each reaction 
proceeded to completeness (total consumption of NADPH) 
within 30 s of initiation by addition of the catalytic 
concentration of enzyme. The quoted percent coupling was 
calculated from the relative stoichiometries of NADPH 
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consumed to product formed, and is an average of fo 
separate experiments for each P450. 
Pre-Steady-State Kinetics of Herne Reduction. Meas 
ment of the rate of the first flavin-to-heme electron transf 
step was performed at 30 °C as described previously (1 
using CO-saturated buffers and monitoring the formation o 
the ferrous-CO adduct at 450 nm using an Applied Photo 
physics stopped-flow spectrophotometer (SX. 17MV). On 
syringe contained NADPH (200 suM) and the second syring 
contained intact wild-type or mutant P450 BM3 (1-5 ,UM) 
Both syringes contained assay buffer of identical substrat 
concentration (arachidonate or laurate), previously deoxy-
genated (by bubbling extensively with oxygen-free nitrogen 
and saturated with CO by bubbling for 5 mm. Rates for eac 
substrate concentration were obtained by fitting the progres 
curves obtained to a double exponential function using the 
Applied Photophysics. The kiim  values were calculated by 
plotting the observed rates (k) at a variety of substrate 
concentrations against fatty acid concentration, and fitting 
the data to the Michaelis—Menten equation using Origin 
software. 
Generation of the Oxy-Ferrous Complex. All experiments 
were conducted within a Belle Technology glovebox under 
a nitrogen atmosphere ([021 < 5 ppm). Samples of wild-
type HD, F393A-HD, F393H-HD, and F393Y-HD ('-'2 huM) 
were prereduced by addition of a few grains of sodium 
dithionite. Excess dithionite was removed by elution of the 
protein through an anaerobic Biorad Econo-pac 1ODG gel-
filtration column, pre-equilibrated with degassed 100 mM 
MOPS, pH 7.0, ensuring no direct reduction of oxygen by 
dithionite. Generation of the oxy-ferrous complex was 
attempted by addition of 2.6 duM 02 (addition of a 10 uL 
aliquot of air-saturated buffer) to 1 mL of reduced P450 (2 
suM). The reaction was monitored at 424 mn over a 300 s 
time period, using a Shiinadzu Multispec 1501 diode array 
UV—vis spectrophotometer. Experiments were conducted at 
15 °C. 
Potentiometric Titrations. All redox titrations were con-
ducted within a Belle Technology glovebox under a nitrogen 
atmosphere, with the oxygen concentration maintained at less 
than 5 ppm. Degassed, concentrated enzyme samples (WT-
HD, F393A-HD, F393H-HD, and F393Y-HD) were eluted 
through an anaerobic Bio-Rad Econo-pac IODG gel filtration 
column, preequilibrated with 100 mL of degassed buffer (100 
mM potassium phosphate, pH 7.0) immediately upon admis-
sion of the sample to the glovebox. This ensured removal 
of all traces of oxygen. Enzyme solutions (—'20 pM in 10 
mL total volume) were titrated electrochemically according 
to the method of Dutton (22) using sodium dithionite (from 
a 34 mM stock) as reductant and potassium ferricyanide 
(from a 18 mM stock) as oxidant. Mediators were added to 
facilitate electrical communication between enzyme and 
electrode, prior to titration. Typically, 7.0 pM 2-hydroxy-
1 ,4-naphthoquinone, 0.3 pM methyl viologen, and 1.0 1uM 
benzyl viologen were included in the 10 ml, sample volume 
(to mediate in the range —95 to —195 mV, —380 to —480 
mV, and —260 to —360 mV, respectively). After a sufficient 
equilibration period (typically 10-15 mm) following each 
reductive/oxidative addition, visible spectra were recorded 
over a 300-800 nm range using a Shimadzu 2101 UV—vis 
spectrophotometer contained within the anaerobic environ-
ment. The electrochemical potentials of the equilibrated 
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FIGURE 2: UV—vis spectra of the ferrous—CO complexes of wild-
type P450 BM3 and F393A, F393H, and F393Y mutant forms. The 
spectra highlight the deviation in the position of the Soret absorption 
maximum. The spectra have been offset along the absorbance axis 
in the order indicated, for clarity. The Soret peak positions were 
blue-shifted by 4 nm (F393H), 5 run (F393A), and 0 nm (F393Y) 
relative to that of wild-type (A m = 449 nra, vertical line). 
sample solutions were monitored using a CD740 meter 
(WPA) coupled to a Pt/calomel combination electrode 
(Russell pH Ltd.) at 25 ± 2 °C. The electrode was calibrated 
using the Fe31/Fe2I EDTA couple as a standard (+ 108 mV). 
A- factor of +242 mV was employed to correct relative to 
the standard hydrogen electrode. For substrate-bound redox 
titrations, arachidonate was added to the sample prior to the 
titration. Conversion to the high-spin form was observed 
spectrophotomettically as a shift from 418 to 390 nm. The 
KM values for arachidonate for all the enzymes studied were 
much lower than 10 suM. Therefore, 33 duM arachidonate was 
sufficient in all cases to saturate the P450 (no further spin-
state shift was observed upon further additions of substrate). 
RESULTS 
Overexpression and Purification of Mutant Enzymes. The 
successful overexpression and subsequent purification of the 
holoenzymes F393A, F393H, and F393Y, along with the 
heme domains (HD) F393A-HD and F393H-HD, immedi-
ately negated the previous assumption that phenylalanine 393 
(Phe393) was essential for heme incorporation and stability. 
All mutant enzymes expressed to high levels, similar to wild-
type, and remained stable when stored at —20 °C. All of the 
enzymes generated a native-like P450 absorbance spectrum, 
with no P420 contribution. An absorption peak at 420 tim 
would indicate the presence of enzyme with non-cysteine 
heme ligation. 
Spectrophotometric Analysis of Carbon Monoxide Binding. 
Typically, treatment of a sample of reduced P450 with carbon 
monoxide will generate the characteristic P450—CO Soret 
absorption at 450 nm. This was the case for both wild-type 
P450 BM3 (A max = 449 nm) and the most conservative 
mutant F393Y. However, a '5 nm blue-shift in the P450-
0 Soret absorption for mutants F393A (A mL , = 444 ran) 
and F393H (A max = 445 nm) was observed (Figure 2). This 
Lndlcates a change in the strength, and hence the vibrational 
snergy, of the CO bond, induced by changes in the degree 
Table 1: Substrate Dissociation Constants (Kd) for Wild-Type and 
F393 Mutants of P450 BM3' 
K(uM) 
wild-type 	F393A 	F393H 	F393Y 
arachidonate 	3.6 ± 0.3 	2.6 ± 0.3 	7.6 ± 0.5 	4.2 ± 0.3 
laurate 	241±9 230± 11 525± 10 520 ±9 
"Parameters were determined as described in the Experimental 
Procedures. 
of back-bonding from the ferrous heme iron to the CO 
antibonding orbitals. This is indicative of changes in the 
electron density at the iron. High electron density increases 
the degree of back-bonding to the CO antibonding orbitals, 
effectively weakening the CO bond, accompanied by a 
decrease in the Fe11—CO vibrational energy (absorption 
would be red-shifted). A blue shift in the Fe'—CO absorption 
is indicative of an increase in the strength of the CO bond 
(less back-bonding) as a direct result of a decrease in the 
electron density at the heme iron. Substitution of phenyl-
alanine by either histidine or alanine appears to decrease the 
electron density of the heme iron, providing evidence that 
stabilization of the ferrous forms of mutants F393A and 
F393H is favored more so than in wild-type. The nature of 
the residue at position 393 appears to have an influence over 
this fundamental property of the heme. The most conservative 
substitution of phenylalanine (by tyrosine) does not appear 
to affect significantly the heme environment as its spectral 
properties are identical to wild-type. 
Fatty Acid Binding. The values for the dissociation 
constants for arachidonate and laurate binding to wild-type 
P450 BM3 and the mutant enzymes F393A, F393H, and 
F393Y are shown in Table 1. The major observation is that 
changing the nature of the side chain of residue 393 does 
not significantly alter the fatty acid-binding properties of the 
enzyme. This is intuitive considering the fact that the 
mutation is on the opposite side of the heme to the substrate-
binding channel. Although mutations of Phe393 appeared 
to have little effect on substrate binding, differences in the 
degree of spin state shift (low- to high-spin) associated with 
the dehydration of the ferric iron center are apparent. For 
wild-type P450 BM3, there is a correlation between the 
degree of spin-state conversion and both the Kd and chain 
length of saturated fatty acid substrates. Fatty acids of chain 
length C 15 and C16 (pentadecanoic and palmitic acids) have 
the lowest Kd values, and induce the largest degree of spin-
state change. However, these substrates are highly insoluble 
in water. Lauric acid has better solubility in aqueous media 
(to approximately 1.2 mM) and has a Kd of —250 ,UM. A 
much better substrate for P450 BM3 than any of the saturated 
fatty acids is the C20, tetra-unsaturated arachidonic acid 
(Kd 4 ,uM), which also has acceptable water solubility. 
Arachidonate induces a much greater spin-state shift than 
laurate (>95 and <40%, respectively). Comparisons between 
the mutants and wild-type P450 BM3 show differences in 
the degree of spin-state conversion with lauric acid. The 
arachidonate-induced (33 4uM) spin-state shift for wild-type 
and all mutants was >95%, whereas the laurate-induced 
(1.0 mM) spin-state shift varies across the series F393A > 
F393Y> WT> F393H, with F393A giving - 12% higher 
proportion of the high-spin form than wild-type P450 BM3 
(Figure 3). 
Thermodynamic Control by Phe393 in P450 BM3 
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FIGultn 3: UV—vis spectra of the ferric (solid line), laurate (dotted line)-, and arachidonate-saturated (dashed line) forms of wild-type P450 
BM3 and the F393A, F393H, and F393Y mutants. Rel. Abs. = relative absorbance compared to ferric Soret absorption maximum in each 
case. Arachidonate (33 uM) induces near-complete shift in spin-state in all forms. Laurate induces a much lower degree of spin-state shift 
in all enzymes, with F393H showing the smallest proportion of high-spin ferric heme at saturation with laurate (1 mM). 
Table 2: Steady-State Kinetics of Fatty Acid (arachidonate and Iaurate)-Stimulated NADPH Oxidation by Wild-Type and F393 Mutant 
Flavocytochrome P450 BM3° 
wild-type 	 F393A 	 F393H 	 F393Y 
KM (uM) 	kcat (s') 	KM (uM) 	kcat (s) 	KM (uM) 	k (s) 	KM (uM) 	k, 1 (s) 
arachidonate 	4.7 ± 0.3 285 ± 3 2.7 ± 0.3 21 ± 1 3.8 ± 0.5 33 ± 1 9.5 ± 1.1 143 ± 8 
laurate 	288± 15 	86±2 	18.5±2.7 	29±1 	60±5 	37±1 	274±20 	65±2 
a Parameters were determined as described in the Experimental Procedures. 
Kinetics of Fatly Acid Oxidation. Although binding of the 
fatty acids was essentially unaffected by the nature of the 
residue at position 393, steady-state kinetic analysis shows 
significant differences in the rates of turnover of the mutant 
flavocytochromes compared to wild-type (Table 2). For both 
arachidonate and laurate oxidation, the observed trend in k at 
was WT> F393Y>> F393H> F393A. The differences in 
turnover are most obvious when arachidonate is the substrate, 
with 14-, 8-, and 2-fold decreases in k 1 for F393A, F393H, 
and F393Y, respectively, compared to wild-type P450 BM3. 
Although the magnitude of the difference between wild-type 
P450 BM3 and the mutants is smaller when laurate is the 
substrate, the trend is the same. Clearly some step in the 
catalytic cycle, other than substrate binding, has been 
perturbed and has become rate-limiting in the mutant 
enzymes. 
The coupling efficiencies for wild-type, F393Y, and 
F393H ("-90%) for arachidonate hydroxylation are all within 
experimental error of each other (Table 3) and suggest near 
exclusive coupling of NADPH oxidation to product forma-
tion. While the coupling of the F393A mutant is lower than 
the other P450s studied, this decrease cannot fully account 
Table 3: Coupling Efficiency of the Wild-Type and F393 Mutant 
Holoenzymes in the Presence of Arachidonate, as Determined by 
Electrospray Mass Spectrometry, 
[unreacted substrate] 	[product] 	% 
(MM) 	 (MM) coupling 
wild-type 	43 ± 3 89:L 7 	91 ± 11 
F393A 77±6 	55±5 56±8 
F393H 	 53±4 79±6 	81± 10 
F393Y 39 ± 3 	93 ± 7 95 ± 11 
° The concentrations of unreacted substrate and product were 
calculated from the total ion count for the negative ion of each relevent 
species in the mass spectrum, as outlined in the Experimental 
Procedures. In each case, the starting concentrations of arachidonate 
and NADPH were 132 and 99 juM, respectively. Percent coupling was 
determined from the relative stoichiometries of NADPH consumed to 
product generated. 
for the order of magnitude difference observed between the 
steady-state parameters for the F393A mutant with respect 
to wild-type. 
This indicates that all enzymes are catalytically functional, 
and that the lowered catalytic activity observed for all the 
F393 mutants is due to decreased rate(s) of steps in the 
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able 4: Pie-Steady-State Kinetics of Heme Reduction in Wild-Type and F393 Mutant Flavocytochromes P450 BM3° 
wild-type 	 F393A 	 F393H 	 F393Y 
Kd(uM) 	kjjm (s) 	Kd(uM) 	kiim(s) 	Kd(/LM) 	kij,,,(s') 	Kj (uM) 
arachidonate 	13.8 ± 2.0 348 ± 17 19.3 ± 3.5 1176 ± 78 13.3 ± 2.9 832 ± 53 6.4 ± 0.8 	366 ± 11 
laurate 	300±65 	172± 14 	124±13 	468±11 	291±37 	439±20 	400±42 215± 10 
a Rates were determined in the presence of both arachidonate and laurate substrates as described in the Experimental Procedures. 
ata1ytic cycle after substrate binding and not as a result of 
he uncoupled reduction of oxygen. 
Kinetics of Heme Reduction. To investigate whether the 
dnetics of flavin-to-heme electron transfer in the F393 
iiutants was affected, we undertook stopped-flow experi-
ments to determine the rate of this process. The rate of the 
first electron-transfer step from the reductase FMN to the 
substrate-bound P450 BM3 heme can be conveniently 
measured using CO-saturated buffer, monitoring the forma-
tion of the ferrous iron-CO adduct at 450 nm (16). For each 
of the mutant flavocytochmmes (F393A, F393H, and F393Y), 
the rate of flavin-to-heme electron transfer at 30 °C was 
measured by rapid mixing of CO-saturated solutions of (a) 
NADPH (200 1uM) and substrate (either arachidonate at 
concentrations between 0 and 80 1uM, or laurate at concen-
trations between 0 and 1000 AuM) and (b) wild-type or mutant 
flavocytochrome (1-5 1tM) and substrate (equal concentra-
tion to mixture a). The observed initial fast-phase rate 
constants (k) for heme reduction were plotted against 
substrate concentration and fitted to a rectangular hyperbola. 
From these data, maximal apparent rates of first electron 
transfer to the heme iron (k1 ) and apparent dissociation 
constants for the substrates (Kd) were obtained and are shown 
in Table 4. The trend in kijm  F393A > F393H >> 17393Y 
WT was the reverse of that observed for the steady-state 
turnover of both laurate and arachidonate. Thus, although 
steady-state experiments suggest an overall decrease in the 
turnover rates of these F393 mutant enzymes, the first flavin-
to-heme electron transfer reaction is actually faster in all the 
mutant enzymes than in wild-type. In the wild-type P450 
BM3, the apparent rate of flavin-to-heme electron transfer 
(as measured by the formation rate of the ferrous-CO adduct) 
is 348 s, where the overall turnover rate of the enzyme is 
285 s_I (in the presence of arachidonate). Clearly, this 
microscopic rate is the major determinant of catalytic 
turnover rate, as observed previously (19). However, with 
the F393A and F393H mutants, the situation is markedly 
different. For instance, in F393A, the flavin-to-heme rate is 
1176 but the steady-state rate is only 21 s W '. Evidently, 
a step after the first electron transfer to the heme iron has 
become rate limiting in these mutants. 
Generation of the Oxy-Ferrous Complex of F393A-HD. 
Binding of oxygen to the ferrous wild-type heme domain 
and F393Y-HD was too transient to be monitored on a 
macroscopic time scale. Addition of oxygenated buffer to 
the prereduced protein led to immediate oxidation to the 
ferric resting state, without noticeable formation of any oxy-
ferrous intermediate. This was unsurprising considering that 
the oxy-ferrous intermediate has only been transiently 
observed for wild-type P450 BM3 at cryogenic temperatures 
(23). However, the formation of the oxy-ferrous complex 
for the F393A-HD and F393H-HD was observed (Figure 4) 
and had a half-life of approximately 30 S. This result provides 
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FIGURE 4: UV—vis spectra showing formation of the stable oxy-
ferrous intermediate of P450 BM3 F393A mutant. The spectra were 
generated prior to (ferrous, dotted line), immediately after (oxy-
ferrous, heavy solid line), and 300 s after (low-spin ferric, light 
solid line) addition of 2.6 1uM oxygenated buffer to a sample of 
prereduced protein. 
iron is significantly faster in wild-type and F393Y than in 
either F393A or F393H. It also suggests an increase in the 
stability of the ferrous-form of the F393A and F393H 
mutants with respect to wild-type, allowing the stable binding 
of oxygen to the heme for a appreciable period prior to 
eventual reoxidation of the heme. This supports the idea that 
the substitution of phenylalamne 393 alters considerably the 
reactivity of the P450 heme with molecular oxygen. 
Heme Domain Potentiometric Titrations. The substrate-
free and arachidonate-saturated (33 M) reduction potentials 
of wild-type HD, F393A-HD, F393H-HD, and F393Y-HD 
were measured in an attempt to establish effects of the 
mutations on the thermodynamic properties of these variants. 
Figure 5 shows the spectral shifts observed during the course 
of these potentiometric titrations. At the high P450 concen-
tration ('--'20 4uM) required for efficient communication 
between the P450/mediators/electrode, the absorption at the 
Soret maximum is much too high for accurate spectropho-
tometric measurement. A convenient part of the spectrum 
that reflects accurately the change in reduction state of the 
heme iron at this P450 concentration is the region between 
460 and 470 nm. Therefore, data for the substrate-free 
titrations at 465 nm were plotted against measured potential 
(mV vs SHE). Due to the spectral differences generated upon 
addition of substrate to the enzymes, substrate-saturated 
titrations were evaluated differently, plotting the difference 
in absorbance A - A 730 against measured potential (Figure 
6). Data were fitted to a one-electron Nernst function, and 
values obtained are presented in Table 5. The first observa-
tion is that the reduction potential of the wild-type P450 BM3 
heme iron has been more accurately re-determined in light 
of improved experimental techniques. The more negative 
reduction potential determined fits better to the proposed 
redox organization within P450 BM3. At this potential, the 
substrate-induced redox switch (24) can still operate, since 
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FLGu1 5: UV-vis spectra showing spectral changes associated 
with reduction of substrate-free (low-spin) and substrate (arachi-
donate)-saturated P450 BM3 (high-spin) heme domain. For the 
wild-type ferric enzyme (solid line), the substrate-free Soret 
maximum is at 418 nm, and for the substrate-bound form (dotted 
line) it is located at 390 nm. In both cases, the fully reduced ferrous 
form (dashed line) has its Soret maximum at approximately 410 
rim. The millimolar extinction coefficients of the different species 
are indicated. The reduction of all heme domains was freely 
reversible (reduction by dithionite, oxidation by ferricyanide) with 
minimal hysteresis. Complete reoxidation of the ferrous-form results 
in the regeneration of the initial starting spectra (ferric low- or high-
spin). 
binding of substrate increases the reduction potential by 138 
mV (to -289 mV) allowing electron transfer from NADPH, 
through the reductase and ultimately to the heme. However, 
there is tighter control than previously imagined over 
uncoupling by virtue of the fact that the substrate-free heme 
potential is considerably more negative than that of the 
physiological electron donor NADPH (-320 mV) in the low -
spin ferric form of wild-type P450 BM3. The midpoint 
potentials of the two mutants F393A and F393H are 
considerably more positive than wild-type (-312 and -332 
mV, respectively) and both display similar magnitudes of 
reduction potential shift upon substrate binding to wild-type 
('-140-160 mV shift). The more positive heme reduction 
potentials of these two mutants are also consistent with the 
higher rates of flavin-to-heme electron transfer observed. A 
thermodynamic consequence of the more positive reduction 
potentials of the heme iron is an increase in the stabilization 
of the ferrous form. This is borne out by the ability to 
generate the ferrous form (A m = 410 nm) for the F393H 
and F393A mutant P450s aerobically, whereas this is 
achievable only under strictly anaerobic conditions for the 
wild-type P450 BM3. It is notable that the increase in 
reduction potential correlates to the relative size of the side 
chain at position 393. As the steric bulk is decreased (Phe/ 
Tyr - His - Ala), the reduction potential increases 
accordingly (-4271-418 - -332--- -312 mV). 
DISCUSSION 
Phenylalanine 393 of P450 BM3 is one of only a small 
number of residues highly conserved throughout the P450 
superfamily. While previous mutagenesis studies have been 
performed to characterize mutants at this position in other 
P450s (e.g., 2E1, 1A2) (13, 14) no satisfactory explanation 
has been offered as to why this residue should be a 
phenylalanine or how this residue may influence P450 
mechanism. What is clear (in the case of P450 BM3 as well 
as those P450s studied previously) is that changing the nature 
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FIGURE 6: Heme-domain reduction potentials of wild-type and 
mutant P450s BM3. Overlaid, normalized one-electron Nernst 
curves showing the changes in the proportion of reduced species 
with reduction potential (vs standard hydrogen electrode) are 
presented. The data for F393Y-HD is essentially identical to WT -
HD, and has been omitted for clarity. From these, the midpoint 
potentials of the substrate-free (A) and arachidonate-saturated (B) 
wild-type heme domain (circles), F393A-HD (squares), and F393H-
HD (triangles) were determined (Table 5). The measured heme 
reduction potentials of both the F393A-HD and F393H-l-ll) 
(substrate-free and substrate-saturated) mutants are considerably 
more positive than wild-type heme domain (between 95 and 138 
mV) suggesting stabilization of their ferrous forms. The substrate-
induced redox shift, observed for wild-type (24), still operates in 
the F393A, F393H mutants (whereby addition of substrate causes 
a 138-161 mV increase in the reduction potential), suggesting that 
substrate binding exerts the same type of control over the heme 
reduction potential as observed in wild-type. The nature of the 
residue at position 393 appears to control the thermodynamic 
properties of the heme. 
Table 5: Midpoint Heme Reduction Potentials for Substrate-Free 
and Arachidonate-Saturated Wild-Type and F393 Mutant P450s 
BM3 
midpoint potential (my) 
WT-HD° F393A-HD F393H-HD F393Y-HD 
substrate-free 	-427±4 -312±4 -332±6 -418±6 
arachidonate-sat" -289 ±5 -151±4 -176±4 -295 ±6 
"HD denotes heme domain. 
of this residue has severe implications on the catalytic 
competence of the resultant mutants compared with native 
forms. The purpose of our study was to attempt to resolve 
the role of this conserved phenylalamne using the flavocyto-
chrome P450 BM3 system. Certain parallels can be drawn 
between our data and those reported previously for mutants 
of P450 lA2 (e.g., similar blue-shifts in the ferrous-CO 
spectra) (13) and P450 2E1 (slower turnover kinetics) (14). 
However, in the light of our studies, it is clear that previous 
assumptions made as to the role of the phenylalanine 
(decreased enzyme stability and alteration of electron flow) 
are unlikely to fully account for the observed decreases in 








IGURE 7: Diagrammatic representation of relevant reduction 
potentials in the P450 BM3 system. The reduction potentials of 
NTADPH (-320 my), the arachidonate-saturated heme domains of 
wild-type (-289 mV), F393A (-151 mV), F393H (-176 mV), 
and the one electron reduction potential of oxygen to superoxide 
(-160 mV) are presented. A much greater driving force is 
associated with heme reduction for the mutants F393A/H (B, C) 
'compared to wild-type (A), while the gap in reduction potential 
associated with oxygen reduction is much smaller for the mutants 
F393A1H (D, E) compared to wild-type (F). 
catalytic activity. It is clear that F393 plays a much more 
important and fundamental role—by controlling the ability 
of P450 BM3 to bind and activate molecular oxygen. 
- The successful overexpression of F393A, F393H, and 
F393Y mutants demonstrates the lack of a requirement for 
a phenyl ring to stabilize heme binding. Also, the kinetic 
profiles of these mutant enzymes dismisses the argument that 
this residue is essential in facilitating electron transfer to the 
heme. We have shown that while the F393A and F393H 
enzymes are less catalytically competent (lower turnover 
rate), the study of individual steps in the catalytic cycle 
reveals that the rate of heme reduction is actually faster for 
these mutants than for wild-type. Thus, replacement of the 
phenylalanine can actually elevate the rate of heme reduction. 
Hence, contrary to previous suggestions, the residue is non-
essential for mediation of electron transfer, either directly 
or indirectly, to the heme. It is not required absolutely for 
electron transfer, but instead plays a vital role in the control 
of the process. The question is then one of how this control 
is achieved. The most convenient starting point for discussion 
is with the thermodynamic data obtained from the potentio-
metric titrations. All other results are consistent with, and 
can be explained in light of, data from these experiments. 
Substitution of phenylalanine 393 by either histidine or 
alamne results in an increase of the heme iron reduction 
potential with respect to wild-type P450 BM3, whereas the 
reduction potential is unchanged upon substitution by ty-
rosine. This explains the apparent contradiction in effects 
on steady state (decreased) and heme reduction (increased) 
kinetic rates observed for the mutants relative to wild-type 
P450 BM3. Creating a large positive gap in reduction 
potential between the electron donor [NADPH at —320 mV 
ultimately providing the electron(s) to the FMN semiquinone 
at —213 ± 5 mV] and the substrate-bound heme (e.g., —151 
± 4 mV for F393A) increases the driving force (AG) for 
heme reduction in this system (Figure 7). The observed 
increase in pre-steady-state flavin-to-heme electron-transfer 
kinetics (k1 ,, = 1180 s cf. 348 5 for wild-type P450 BM3) 
is totally consistent with the more positive reduction 
potentials of heme iron (suggesting stabilization of the ferrous 
form) in the F393A and F393H mutants. However, the fact 
Ost et al. 
that F393A and F393H mutants give much lower steady-
state rates of fatty acid-dependent NADPH oxidation is 
explained by the concomitant decrease in driving force for 
molecular oxygen to superoxide (-160 mV, Figure 7). Thus, 
whereas having alanine or histidine at position 393 facilitates 
faster electron transfer to the heme iron, the rate at which 
the ferrous iron can then reduce bound molecular oxygen is 
much lowered, with a net large decrease in enzyme turnover 
rate. 
Substrate affinity for these mutant enzymes is not signifi-
cantly perturbed compared to wild-type, and the rate of 
substrate-induced spin-state change is known to be rapid from 
previous studies (16). For wild-type P450 BM3, the rate of 
first electron transfer to the ferric heme (348 s with 
arachidonate) is similar to the steady-state k for turnover 
of this substrate (285 s'), indicating that the sequence of 
events leading to the first electron transfer to the heme plays 
a major role in turnover rate limitation. In contrast, in the 
F393A and F393H mutants, not only are the rates of heme 
reduction elevated (1176 and 832 respectively, with 
arachidonate), but the steady-state turnover rates are dimin-
ished (21 and 33 s', respectively). Obviously, there is a 
new major factor in overall rate limitation that occurs after 
the first heme reduction and, presumably, does not involve 
substrate binding. This factor almost certainly reflects the 
increased stability of the oxy-ferrous form in the mutants. 
The elevated reduction potential of their hemes results in 
decreased driving force for reduction of bound dioxygen, 
leading to the oxy-ferrous form being considerably more 
stable than the superoxy-ferric form. This is borne out by 
the observation that in the mutants with the most positive 
heme reduction potential (F393A and F393H), the substrate-
saturated, oxy-ferrous form is not only observable (A m = 
424 nn), but also has a long half-life (-j 30 s) at 15 °C. 
Under similar conditions, the decay of the oxy-ferrous form 
of wild-type P450 BM3 is virtually instantaneous, and even 
at cryogenic temperatures, the species can be observed only 
transiently (23). The consequence of the elevated heme 
reduction potential in F393A and F393H is that oxygen 
activation is disfavored and that the stabilized oxy-ferrous 
intermediate becomes a thermodynamic trap, which decreases 
the rate of overall catalysis. It appears likely that, in these 
mutants, oxygen reduction replaces heme reduction as the 
overall rate-limiting step. 
In conclusion, we have established for flavocytochrome 
P450 BM3 that the phylogenetically conserved phenylalanine 
residue F393 has an important role in control of the reduction 
potential of the P450 heme iron. As evidenced by a 
combination of steady-state and stopped-flow studies, we 
have shown that the ability to poise the heme potential 
appropriately is critical for efficient catalysis. The physical 
origin of these catalytic modifications is still unclear and 
are presently under investigation. In ongoing studies, we are 
characterizing site-directed mutant F393W. In the nitric oxide 
synthases (NOSs), a tryptophan residue is conserved in place 
of the phenylalamne (25). Analysis of this mutant may allow 
a clearer understanding of the differences in catalytic 
properties of NOS and the P450s. 
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ABsTRAcT: In the preceding paper in this issue [Ost, T. W. B., Miles, C. S., Munro, A. W., Murdoch, J., 
Reid, G. A., and Chapman, S. K. (2001) Biochemistry 40, 13421-13429], we have established that the 
primary role of the phylogenetically conserved phenylalanine in flavocytochrome P450 BM3 (F393) is to 
control the thermodynamic properties of the heme iron, so as to optimize electron-transfer both to the 
iron (from the flavin redox partner) and onto molecular oxygen. In this paper, we report a detailed study 
of the F393H mutant enzyme, designed to probe the structural, spectroscopic, and metabolic profile of 
the enzyme in an attempt to identify the factors responsible for causing the changes. The heme domain 
structure of the F393H mutant has been solved to 2.0 A resolution and demonstrates that the hislidine 
replaces the phenylalanine in almost exactly the same conformation. A solvent water molecule is hydrogen 
bonded to the histidine, but there appears to be little other gross alteration in the environment of the 
heme. The F393H mutant displays an identical ferric EPR spectrum to wild-type, implying that the degree 
of splitting of the iron d orbitals is unaffected by the substitution, however, the overall energy of the 
d-orbitals have changed relative to each other. Magnetic CD studies show that the near-JR transition, 
diagnostic of heme ligation state, is red-shifted by 40 nm in F393H relative to wild-type P450 BM3, 
probably reflecting alteration in the strength of the iron-cysteinate bond. Studies of the catalytic turnover 
of fatty acid (myristate) confirms NADPH oxidation is tightly coupled to fatty acid oxidation in F393H, 
with a product profile very similar to wild-type. The results indicate that gross conformational changes 
do not account for the perturbations in the electronic features of the P450 BM3 heme system and that the 
structural environment on the proximal side of the P450 heme must be conformationally conserved in 
order to optimize catalytic function. 
The cytochromes P450' are a family of monooxygenase 
enzymes implicated in a wide variety of biosynthetic and 
degradative pathways in organisms throughout nature 
(1-3). One essential feature shared by all P450s is a cysteine-
ligated b-type heme (J)rotoporphyrin IX) cofactor (4). Re-
placement of this cysteine residue results in a lack of heme 
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incorporation yielding catalytically inactive enzyme (5). 
Sequence comparisons of P450s clearly illustrate the implicit 
conservation of this cysteine throughout the P450 superfam-
ily. It has been proposed that the electron-donating character 
of this residue facilitates the stabilization of the putative 
Fe'O oxyfen-yl reactive species (6, 7) and, hence, is 
considered as an integral structural and mechanistic feature 
required by P450s. 
Although overall topology is common to all of the 
structurally characterized P450s, the degree of sequence 
identity is often quite low between members (<25% amino 
acid identity) (8). However, investigations into a number of 
highly conserved residues over a range of P450s (primarily 
those of P450 cam—the camphor hydroxylase from Pseudomo-
nas putida, and P450 BM3—the fatty acid hydroxylase from 
Bacillus megaterium) indicate their necessity for controlling 
aspects of the P450 catalytic cycle. For example, residues 
homologous to Thr252 of P450cam are implicated in 
providing a hydrogen bond to ferrous-bound molecular 
oxygen, participating in oxy-ferrous complex stabilisation 
(9). Also, a tryptophan residue (Trp96 in P450 BM3) 
10.1021/biOl0717e CCC: $20.00 © 2001 American Chemical Society 
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interacting with the heme-proprionates encourages heme 
binding and has been shown to have a controlling influence 
over the spin-state of the heme (10). The fact that the number 
of implicitly conserved residues common to all P450s con-
stitutes only a small proportion of a "typical" P450 polypep-
tide infers that they are essential for catalytic competence 
and, hence, an evolutionary prerequisite. 
Our previous study (11)/has shown that substitution of 
one of these highly conserved residues, phenylalanine 393 
(by alanine or histidine), in P450 BM3 results in a mutant 
form with appreciably different catalytic characteristics to 
wild-type. We have postulated this residue to be vital in 
ontroUing the reaction of the heme iron with molecular 
Dxygen. The few examples in which this phenylalanine is 
not conserved fall into a small group of P450s which do not 
have to activate molecular oxygen. Examples of these are 
allene oxide synthase (Cyp74) (12), divinyl ether synthase 
(Cyp74) (13), prostacycin synthase (Cyp8) (14), and throm-
boxane synthase (-Cyp3) (15). In all cases, the phenylala-
nine is substituted by either prohne or tiyptophan. Unlike 
typical P450s, these enzymes do not function as mnooxy-
genases and do not require molecular oxygen or NAD(P)H-
dependent P450 reductase for activity. These enzymes cata-
lyze rearrangement or isomerization reactions, for which the 
activation of molecular oxygen is non-essential. This provides 
additional, yet unsubstantiated, evidence that this phenyl-
alanine residue is intimately involved in steps in the P450 
catalytic cycle, concerned with the binding and activation 
of molecular oxygen. The focus of our previous study (11) 
identified and characterized the catalytic differences of a 
series of F393-mutant enzymes, relative to wild-type. In this 
paper, we have attempted to resolve the origin of these 
perturbations to the kinetic and thermodynamic profile of 
wild-type P450 BM3 by focusing on spectroscopic and 
structural inspection of the mutant enzyme P450 BM3 
F393H. 
EXPERIMENTAL PROCEDURES 
Escherichia coli Strains and Protein Preparation. Plasmids 
encoding the intact wild-type (pBM23), F393H (pCM37), 
and the heme domain of wild-type (pBM20) and F393H 
(pCM8 1) mutant enzymes were used to transform Escheri-
chia coli strain TG1 (11). Cell growth and the extraction 
and purification of protein followed the same protocol as 
described previously (16). 
Product Characterization. The products of the catalytic 
turnover of myristic acid (tetradecanoic acid) by wild-type 
P450 BM3 and F393H mutant were determined using gas 
chromatography/mass spectrometry according to the follow-
ing methodology. A Hewlett-Packard 5971A GC/MS utiliz-
ing electron impact ionization (70 ev) instrument was used 
to determine structural information on the monohydroxylated 
metabolites of myristic acid. Metabolites were generated by 
incubation of 120 4uM myristate in the presence of 5 mM 
NADPH and a catalytic amount of P450 (ca. 1 nM) in 2 ml, 
samples of 100 m K2HPO4/KH2PO4, pH 8. The metabolites 
were extracted into diethyl ether and converted to their 
methyl ester derivatives using diazomethane, before analysis 
by GC/MS. Chromatography of the samples was performed 
on a HP-35 capillary column (30 m x 0.25 mm id x 0.25 
cM film thickness) with a thermal gradient beginning at 100 
Table 1: Characteristic Retention Times and Fragmentation Patterns 
of Myristate Metabolites Used to Identify the Site of Substrate 
Hydroxylationb 
position of hydroxylation w-1 w-2 a-3 
retention time (mm) 24.66 24.54 24.23 
fragment mlz ?n/z mfz 
M - CH3(CH2),,_ 1 243 229 215 
M - CH3(CH2) 1 CH30H 211 197 183 
M 	CH3(CH2),,_1CHO 214 200 186 
°The conditions under which these data were generated is described 
in the Experimental Procedures. 
°C for 0.5 min and increasing to 200 °C at a rate of 5 
°C/min for 5 min and then to'a final temperature of 250°C 
at a rate of 10 °C/min. Injector temperature was set to 250 
°C and the GC/MS transfer line was set at 280 °C. Column 
flow rate was set at 0.76 mljmin. 
The mass spectra of the products from the control run 
(wild-t)pe P450 BM3) were used to identify each GC peak. 
Monohydroxylated products were identified by their char-
acteristic fragmentation pattern as shown in Table 1. The 
distribution of products was based on the relative peak area 
of the gas chromatogram, in which the total ion current was 
used to assess quantity. 
UV— Vis Spectroscopy of Exogenous Ligand-Binding. The 
binding characteristics of azide, cyanide, imidazole, and 
pyridine (all from Aldrich and to the highest purity possible) 
to P450 BM3 wild-type and the F393H mutant were 
investigated. Protein concentrations in all cases were <5 uM 
and were made up to 1 mL of total volume (100mM MOPS, 
pH 7.0) in a 1 mL quartz cuvette (10 mm path length). Final 
ligand concentrations were no greater than 1.0 mM. The 
visible spectra of the ligand-bound P450s were taken in both 
the ferric- and ferrous-forms. Reduction was achieved by 
the addition of a few grains of dithionite to the cuvette. All 
specirophotometric measurements were conducted using a 
Shiinadzu 2101 Spectrophotometer at 25 °C. 
MCD and EPR Spectroscopy. EPR spectra were recorded 
on an EPR spectrometer comprising an ER-200D electro-
magnet and microwave bridge interfaced to an EMX control 
system (Brüker Spectrospin) and fitted with a liquid helium 
flow cryostat (ESR-9, Oxford Instruments) and a dual-mode 
X-band cavity (Brüker, type ER4I1613M). MCD spectra 
were recorded using circular dichrographs, JASCO models 
J-500D and J-730 for the UV—vis and near-infrared regions, 
respectively. An Oxford Instruments superconducting sole-
noid with a 25 mm ambient temperature bore was used to 
generate a magnetic field of 6 T for the room temperature 
MCD measurements. Room temperature MCD intensities are 
linearly dependent on magnetic field and are plotted normal-
ized to magnetic field as AE/H (M' cm' T'). 
Crystallography and Determination of the Crystal Struc-
ture of the F393HHeme Domain. Crystallization of F393H-
lID (heme domain) was carried out by hanging drop vapor 
diffusion at 4 °C in Linbro plates. Crystals were obtained 
with a well solution comprising 100 mM sodium PIPES 
(piperazine-N,N'-bis[2-ethanesulfothc acid]), pH 6.5,40 mM 
MgSO4, 18-21% PEG 8000. Hanging drops of 4 pL were 
prepared by adding 2uL of 41.7 mg/ml, protein (in 50 m 
TrisHCl/l mM EDTA, pH 7.4) to 2 4uL of well solution. 
Plates of up to 1 x 0.3 x 0.3 mm were formed after about 
1 week. 
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Table 2: Relative Proportions of Different Hydroxylated 
Metabolites from the Reactions of Wild-Type and F33H Mutant 
Flavocytocbromes P450 BM3 with Myristic Acid' 
co-1 	cy-3 
OH 
Product distribution (%) 
ENZYME 	 w-1 	 co-2 	 co-3 	Unreacted 
P450 BM3 wr 53.6 24.5 20.0 1.9 
P450BM3F393H 	57.7 	22.5 	15.0 	4.8 
'Products were determined as described in the Experimental 
Procedures. 
Crystals were immersed in well solution containing 22% 
glycerol as a ciyoprotectant, before being mounted in nylon 
loops and flash-cooled in liquid nitrogen. A data set was 
collected to 2.0 A = 1.3 A) on station 9.5 at Daresbury 
synchrotron source using a MAR CCD detector. The crystals 
are isomorphous with those of the hemoprotein domain of 
wild-type flavocytochrome P450 BM3, with space group P2 1 
and cell dimensions a = 58.8 A, b = 153.0 A, c = 61.4 A, 
and fi = 94.7° and have two molecules in the asymmetric 
unit. This compares with unit cell dimensions of a = 59.4 
A, b = 154.0 A, c = 62.2 A, and fi = 94•70 obtained for 
crystals of wild-type heme domain (17). 
Data processing was carried out using the HKL package 
(18). The wild-type flavocytochrome P450 BM3 heme 
domain structure (2HPD), stripped of water, was used as the 
initial model. Electron density fitting was carried out using 
the program 0 (19). Restraints for the heme group were 
calculated from the CNS parameter file. Structure refinement 
was carried out using SHELX-97 (20). The atomic coordi-
nates have been deposited in the Protein Data Bank (1JME). 
RESULTS 
Product Characterization. It is well established that wild-
type P450 BM3 displays strict substrate-specificity for long-
chain fatty acids, performing hydroxylation in a highly regio-
specific manner. For wild-type enzyme, the sole hydroxylation 
products of palniitic acid are the co-i, w-2, and w-3 hydroxy 
derivatives (21, 22). The same trend has been demonstrated 
here for the hydroxylation of myristate (Table 2) by the 
F393H mutant. 
Previously reported substrate-binding characteristics of the 
F393H mutant enzyme indicated that its affinity for long-
chain fatty acids was insensitive to the nature of the residue 
at position 393 (11). This mutant shows comparable affinity 
toward laurate and arachidonate as wild-type (Kd = "-250 
and -"4 pM, respectively). Characterization of the F393H-
mediated turnover of myristate reveals an identical product 
profile to wild-type, indicating that both the substrate 
specificity and the regiospecificity of hydroxylation is 
unaffected by the F393H substitution. There is a virtually 
identical product profile to wild-type, although there appears 
to be a slightly higher proportion of the co-i metabolite with 
respect to the co-3 product for F393H compared to wild-
type. Notwithstanding this, the trend in regiospecificity 
between wild-type and the F393H mutant is the same 
((o-1:co-2:w-3:unreacted = 28:13:11:1 (12:5:3:1), respec-
tively). There is a slightly higher proportion of unreacted 
Ost et 
myristate in the case of F393H turnover, resulting from 
lower overall catalytic activity in this mutant, i.e., the F393 
mutant turns over less myristate in the same time period 
wild-type. 
The important result is that the substitution of pheny 
alanine 393 by histidine results in a mutant-form that retain  
the same selectivity for long-chain fatty acids and display 
the same regiospecificity of hydroxylation as wild-type P45 
BM3. 
Ligand Binding. Figure 1 shows the spectral characteristic 
of azide, cyanide, inudazole, and pyridine binding to wild 
type (Figure la) and the F393H mutant (Figure lb). The ke 
features of the ferric, ferric ligand-bound and ferrous ligand 
bound spectra are shown in Table 3. 
For the F393H mutant, the ferrous spectrum in th 
presence of azide is identical to the ferrous, ligand-free 
spectra, the generation of which (in aerobic conditions) is 
only feasible due to its increased reduction potential. A 
similar argument can be made when pyridine is ligated. The 
F393H mutant displays a 19 rim red-shift (423 - 442 nm) 
in the Soret absorption upon reduction of the ferric -pyridine
complex. The wild-type ferric-pyridine complex can also be 
generated, but addition of dithiomte fails to form the ferrous-
pyridine form. This reflects the very negative wild-type heme 
reduction potential (-427 mV) compared to the more 
positive value (-332 mV) for the F393H mutant. This is 
substantiated by the ferrous-cyanide complex, where a shift 
in the Soret absorption peak (440 -. 437 nm) is observed 
(100% conversion) for F393H, yet incomplete conversion 
is observed (-50%) for wild-type. The ferrous-cyanide 
complex of wild-type seems to be intermediate between the 
ferric and ferric-cyanide complex, probably as a conse-
quence of incomplete heme reduction. 
Magnetic Circular Dichroism (MCD) Spectroscopy. The 
room-temperature UV-vis electronic spectrum of the F393H 
mutant is shown in Figure 2a, with its visible MCD spectrum 
in Figure 2b. Features at wavelengths 300-600 rim are due 
to 3j_2T*  transitions of the porphyrin ring. Mixing of 
porphyrin-sr with iron-d levels occurs to the extent that 
the spectra become diagnostic of the spin- and oxidation-
state of the metal ion. This is especially so in the MCD where 
the spectroscopic changes are most pronounced (23, 24). At 
these wavelengths, the room-temperature MCD of F393H 
is almost identical in form to that of the WT P450 BM3 
heme-domain (25). 
The most informative low-spin ferric heme MCD feature 
is a positive-signed porphyrin (n)-to-ferric (d) charge transfer 
transition, the exact energy of which varies systematically 
with changes in axial ligation (26). In the room temperature 
near-infrared MCD of F393H (Figure 2c), this charge-transfer 
band is at "-1085 nm, a red-shift of -40 nm relative to the 
WT heme-domain. 
Electron Paramagnetic Resonance (EPR) Spectroscopy. 
Figure 3 shows the perpendicular-mode X-band EPR spec-
truni of F393H, recorded at 10 K using 2.01 mW microwave 
power. The g-values of features discussed are indicated on 
the figure. Minor signals at g 5.8 and 4.3 are due to trace 
amounts of high-spin femc.heme and adventitious Fem  ion, 
respectively. The three major features at g = 2.43, 2.25, and 
1.92 are characteristic of a low-spin ferric heme and are 
virtually identical to those reported for the wild-type protein. 
These g-values are typical of native low-spin ferric P450s 
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FIGURE 1: Visible spectra of azide (N 3 - ), cyanide (CN), imidazole (imid), and pyridine (py) binding to wild-type P450 BM3 (Figure Ia) 
and to the F393H mutant (Figure lb) in their oxidized (dotted line) and reduced (dashed line) ligand-bound forms. The spectra have been 
corrected to the same relative absorbance. The ligand-free, oxidized spectrum is also shown for each case (solid line) as a comparison. 
and nitric oxide synthases (NOS) in which the heme is bound 	1182 water molecules. For both molecules, the electron 
axially by cysteinate and water and also match those of density for the first two N-terminal residues and the loop 
adducts in which the water is displaced by a range of oxygen- 	region containing residues G1n189-G1u200 was uninter- 
donor ligands (27-31). 	 pretable, so these have been omitted from the model. The 
Determination of the F393H Crystal Structure. A data set 	rmsd fits fusing the Dali server (32)1 of all remaining Ca 
to a resolution of 2.0 A was used to refine the structure to atoms for the wild-type and F393H-HD enzymes have been 
a final R-factor of 17.9% (Table 4). The final model consists 	calculated using all possible combinations of molecules A 
of two protein molecules, A and B, each containing residues and B in either model. The smallest difference (0.3) is found 
Lys3-Leu 188 and Asn201-Leu455, 1 heme, and a total of 	by comparing F393H-HD chain A with wild-type chain A, 
Table 4: Crystallographic Data Statistics for the Crystal Structure 
of P450 BM3 Herne Domain Mutant F393H 
refinement (A) 40.0-2.0 
total no. of reflections 480 222 
unique reflections 73 016 
completeness (%) 96.9 
30 (1j/[a(I)] 19.4 
Rmerge (%)" 5.4 






rmsd from restraint values 
0 	. bond length (A) 0.006 
bond angle distance (A) 1.8 
-10 Ramachandran analysis 
most favored (%) 90.8 
-20 additionally allowed (%) 8.8 
" Rm,rge = 	I(J) - II/(I) over all reflections. b  R0 = Y—IF. - F011 
30 F0 ; Rfree calculated with 5.2% data withheld from refinement. 
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Table 3: Spectral Characteristics of Ligand Binding to Wild-Type 
and F393H Mutant Cytochromes P450 BM3" 
absorption maxima (nm) 
P450 BM3 wild-type 	P450 BM3 F393H 
Soret 	a 	9 Soret 	a 	/9 
F&" 	 419 569 	536 	419 	571 	538 
Fe"LN 3 419 	569 536 419 571 538 
Fe"-CN 	440 560* 	440 	560* 
Fe"-imidazole 	425 	573 	543 426 576 	543 
Fe"-pyridine 422 568 538 	423 	572 538 
Fe" 	 407 	550* 	413 
554* 
Fe"-N3 419 569 	536 	413 	
554* 
Fe"-CN 	434 	563 541 437 564 	540 
Fe"-imidazole 	425 573 	543 	426 	576 543 
Fe"-pyridine 422 	568 538 442 565 	538 
The table illustrates the positions of the major heme absorption 
bands [a, [3, and y (or Soret)] for ferric- and ferrous-forms of the 
enzymes in the absence and presence of exogenous ligands azide, 
cyanide, imidazole and pyridine. Asterisks denote fused absorbance 
bands whose components cannot be resolved into two separate 
contributions. Spectra were collected as described in the Experimental 
Procedures. 
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FIGURE 2: Spectral characeristics of P450 BM3 F393H heme 
domain, (a) electronic absorption spectrum, (b) UV — vis region 
MCD spectrum, (c) NIR-region MCD spectrum. MCD were 
recorded using a magnetic field of 6 T. MCD Sample concentration 
was 218 uM. 
and the largest (0.8) is found by comparison of F393H-HD 
chain A with wild-type chain B, indicating no significant 
structural differences. The regions surrounding residue 393 
in the two structures is shown in Figure 4. Superposition of 
the phenyl ring of Phe393 from wild-type P450 BM3 onto 
His393 of F393H-HD molecule A is shown in Figure 5, and 
the comparison shows that the substitution causes little 
difference in the conformation of the residue side chain. 
The only significant difference between the wild-type 
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FIGURE 3: EPR spectrum of ferric P450 BM3 F393H heme domain. 
The spectrum was recorded at 10 K, using a I mT modulation and 
2.01 mW microwave power. Sample concentration was 218 uM. 
The g-values of 2.43, 2.25, and 1.92 are typical of low spin, ferric 
heme. Signals at g 5.8 and 4.3 are due to small amounts of high 
spin ferric heme and adventitious iron. 
replacement of phenylalanine by histidine (Figure 5). The 
side chain of residue 393 is in a very similar position in 
both structures, sandwiched between the side chains of 
Pro392 and G1n403, with no major conformational changes 
of surrounding residues as a result of the mutation (Fig-
ure 6). 
In the structure of the substrate-free wild-type heme 
domain, the distance of closest contact between Phe393 and 
Cys400 (the thiolate ligand to the heme iron) is 3.67 A, while 
in the structure of F393H-HD, the closest contact is between 
C62 of the histidine side chain and C3 of Cys400, a distance 
of 3.50 A (resulting from a slight tilt in the imidazole ring 
of H393, toward the heme ligand). 
A possibility as to why the thermodynamic properties of 
the heme of the F393H mutant differ so much from wild-
type is the ability for this histidine to be protonated and to 
form a hydrogen bond with Cys400 (analogous to the 
Trp Cys hydrogen bond observed in NOS) (33). It can be 
seen from the structure of the mutant enzyme that there is a 
solvent water molecule (X526 in molecule A) positioned on 
the opposite side of His393 to the heme, which is hydrogen 
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FIlRr1 4: A stereoview of the heme binding region of the F393H mutant. Electron density is shown in cyan. while the heme niacrocycle 
and peptide are shown in atom-type colors (red = oxygen. blue = nitrogen, and green = sulfur), the heme iron is depicted in oranie. This 
figure clearly shows electron densit for water molecule X and the likelihood of an intermolecular hydrogen bond to histidine 393. The 
electron density map was calculated using Fourier coefficients (2F, - F, where F,, and F are the observed and calculatc(l structure 
factors, respectively. The contour level is 1.5,. where a is the rms electron density. This diagram was generated using TURI3( )—lROD() 
(46). 
q 
FIGURE 5: Superposition of phenylalanine 393 of wild-type P450 BM3 (magenta) onto histidine 393 of the F393H mutant. This clearly 
illustrates the minimal perturbation caused to the heme binding region by substitution of phenylalanine by histidine. 
effects on kinetic and thermodynamic properties have been 
experimentally substantiated, the physical process (i.e.. the 
I. 	 precise cause) by which these differences have occurred remained un resolved. 
The product profile characterization of the F393H mutant 
• 	 confirmed the kinetics of NADPH oxidation described in 
• • the previous paper. with NADPH consumption being almost 
exclusively coupled to substrate turnover (-904, coupling) 
UI) Pioduct analysis of the F93H mutant -catalyzed 
myri state- tumover was essentially identical to wild-type, with 
(1)-I hydroxylation predominating. No unusual oxidation 
products suggestie of a change in the specificity of the 
mutant. were observed. From this we can conclude that F393 
• 	. 	. 	. 	. 	- 	 does not influence sienificantly the redo- and substrate- FiGURE 6: Constrained conformation of Phe393 in P4() BM3. The 	 - 	 . 
dotted regions describe the van der Waals surfaces of residues and specificity of the enzyme. This is an important observation. 
the heme macrocycle surrounding histidine 393. The proximity of 	confirming that F393H is able to act as a P450, yet is 
Prn392 and G1n403 pre\ents rotation of the imidazole ring of H393. catalytically impaired relative to wild-type. 
precluding the possibility of the formation of an intramolecular 	The EPR spectrum of the F393H mutant is identical to 
14393 Cys40() hvdru"en bond. 	 . 
- 	 that of the wild-type enzyme. This infers that the iron in the 
" 	
ferric form is in a similar environment (no chance in g 
bonded to Nol of the histidine side chain (N 'O = 2.77 	 - 
values ) in both enzymes and that they share a common ferric A). The apparent prototittion state of this histidine and the 
restine stat e. The form of the EPR spectrum is determined presence of' 	 intermolecular olecular hydro°en bond to water 	. 	 . 	.. 	. 
• 	. - 	 . 	 mainly by the relative splitting of the ferric d-orbitals. and 
appears to Preclude the formation of an intramolecular . . 
• 	. 	 if all five are moved in energy tocether by a process that His393"'Cvs4O() h drocen bond. 	 • 	 - 
- 	 does not substantially alter the iron geometry. then the 
DISCUSSION 	 \pectnim would remain the same. It is surprising, therefore. 
that the elevation in the reduction potential of the heme does 
Anal sis of the F393H intitant of tiavocvtuchrome 1>45() 	not induce a significant change in the EPR spectrum. This 
13M3 highlights the sensitivity of this enzyme to the nature is our observation, which implies that the positive shift in 
of the residue at this position. Induced changes in the 	the reduction potential of the F393H mutant relative to wild- 
catalytic properties of the enzyme by substitutions at F393 type [reported previously (II)] is due to a difference in the 
suggest an important role for this residue, and have been 	energy of their feiTous-forms. relative to this common ferric 





EI1 	AEwT 	• 
A 	U 
ç 	1 b, 
1 a t 	 AE F.119311 
44b 2 
2g u'wi--------- 	1 	e 
llGt.kE 7: Diagrammatic representation of the proposed perturba-
tion in the itOfl d-orbital energies between the ferric-resting state 
(A). the substrate-bound state (B), and the one-electron reduced 
forms of wild-type (C). and F393H mutant (D). caused by the 
substitution of phenylalanine 393 by histidine. The energy difference 
(AE) between the ferric- and ferrous-d-orbitals (related to the Fe"! 
Fe" reduction potential by the Nernst equation. AG = —nFAE) is 
smaller for the F393H mutant (AEF393H) than wild-type AE,-). 
This is consistent with the elevated reduction potential of the F393H 
mutant compared to the wild-type enzyme. The similarity of the 
ferric-EPR spectra for the F393H and wild-type enzymes suggest 
that the magnitude of the crystal field splitting parameter (A,) is 
unchanged by the mutation. 
to the iron frontier orbitals of the F393H mutant as a 
consequence of the difference in the energy (AE) between 
the ferric- and ferrous-forms being smaller than for wild-
type. This is reflected in the Fell'/Fe ll couple for the F3931-1 
mutant being more positive than wild-type (reduction requires 
less energy). While this is an unusual observation, it is not 
unique. It has been demonstrated that loading the core of 
the bacterioferritin from Azotobacrer uinelandii drops the 
reduction potential of its heme group by 250 mV, without 
changes being observed in the EPR and MCD spectra of the 
loaded and unloaded forms (34). However, the most infor-
mative difference between wild-type and the F393H mutant 
is seen as a '-40 nm shift in the NIR charge transition in the 
MCD spectrum. This absorption has been assigned to a 
porphyrin (.r) —. ferric (d) ligand to metal charge transition. 
The position of this band has been shown to vary greatly 
with axial ligation, for example a shift of -350 nm is 
observed between a bis-his li gated (e.g.. cytochrome C3. 
Desulfin'ib,-io i'ulgaris) and met-his ligated (e.g., cytochrotne 
hs2. E. co/i) heme (26). Although we are concerned with a 
six coordinate cys-aqua ligated henie in P450s, a similar 
interpretation can be employed, whereby the shift in the 
NIR—CT band arises not as a result of a change in the nature 
of the ligation, but due to a change in the strength (as a 
consequence of a change in length) of the Fe—Cys bond. 
Although our observed shift is considerably smaller than that 
observed for a ligand change, it is large enough to be 
significant and consistent with a change in axial bond 
strength rather than bond type. Whether the change in the 
strength of the Fe—S bond is equivalent to the same 
magnitude of shift in the reduction potential observed 
between wild-type and the F393H mutant, is questionable. 
The crystal structure of the F393H-HD mutant (solved to 
2.0 A) clearly shows the presence of the five-membered  
imidazole ring of histidine, in place of the six memhc 
phenyl ring of phenylalanine. This appears to he the ol 
significant difference in the heme-binding region hetv 
the F393H mutant- and wild-type structures. Unfortunat 
this does not help to explain how the presence of a hist,d: 
in place of a phenylalanine can so severely change 
physical properties of the heme. No obvious conformatn 
change is observed, and so the modification to the cata I 
properties must he due to a more subtle, yet signifi. 
change in the protein superstructure or the way in whiLl 
interacts with the heme. 
While inspection of the crystal structure does not I 
mediately answer the question of how the reduction pote,i 
in the F393H mutant is being modulated, it does providc 
structural context for discussion. The two dominant fact 
which influence reduction potentials in proteins are (a) 
dielectric environment of the heme and (b) bonding intei:i: 
tions at, and to, the redox center (35). Both of these fact 
will be discussed in the context of the F393H mutant and 
comparison with wild-type. 
The study of the F393H mutant enzyme allows ti 
qualitatively evaluate how, or even if, changes in st.' 
hydrophohicity, and electrostatics (due to the substitution 
phenylalanine to histidine). affects the heme reducin 
potential. The Phe—His substitution does not grossly incrc: 
the exposure of the heme to solvent, or dramatically cli 
the hydrophobicity of the heme binding pocket. Whil. 
Na I of the His393 is solvent exposed [formation 
His "'H20 H-bond (Figure 4)], the steric bulk of the hist: 
residue is sufficient to prevent the penetration of water whici 
would alter the dielectric environment at the iron, and henc: 
the redox properties, of the heme. The crystal structure wa 
determined at pH 6.5, a pH at which His may be expected 
to be partially protonated. with the resulting imidazoliu,,i 
interacting with Cys400. Redox titrations of both wild-typc 
and the F393H mutant have been performed over a pH rangL 
6-8 (data not shown) and neither show a significant (<I 
mV) deviation from the value of the reduction potential 
determined at pH 7.0. Since the redox potential of the F39311 
mutant is not pH dependent, one must conclude that His393  
remains in the same protonation state through the pH rang': 
6-8. How the His-water hydrogen bond affects the pK 01 
this residue is unquantifyable. but if, for example. it i, 
dramatically increased (i.e., toward the pK, of free imidazok. 
pKa = 9). it is plausible that the residue would have maini' 
imidazolium character within the range pH 6-8. Thc 
presence of a positive charge so close to the heme-ligand 
would introduce a significant electrostatic interaction between 
His393 and Cys400. This increase in Lewis acidity would 
destabilize the Fe—S bond, probably by drawing electron 
density away from the iron and toward His393 and have the 
concomitant effect of lengthening, hence weakening. thc 
Fe—S bond. 
On the basis of structural evidence, there is little confor-
mational difference in the heme binding region between the 
F393H mutant and wild-type. In fact, this region of the 
F393H mutant is the most well-defined (con formational ly) 
stretch of polypeptide compared to wild-type. It seems 
unlikely that the substitution of phenylalanine by histidine 
would cause a large enough change in the hydrophobicity 
or dielectric environment of the heme to account for the 
dramatic differences observed in the reduction potentials. The 
Structural Analysis of P45() BM3 F393H Mutant 
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comparison of cytochrome c with the octapeptide (methion-
me; complex (formed by the hydrolysis of cytochrome C) is 
the classic study of how hcmc solvation and the change in 
the dielectric environment of the heme affects redox proper-
ties (36). Here a heme reduction potential shift of 300 mV 
is observed between the semiexposed, partially solvated heme 
of cytochrome c, with the fully exposed and solvated heme 
of the octapeptide (hence, the difference in solvation being 
substantial and influential). It is also interesting to note that 
the reduction potential in a series of F82 mutants of cyto-
chrome c (a highly conserved phenylalanine in cytochrome 
c, in a similar environment to F393 in P450 BM3) shift only 
slightly (by 43 my) upon substitution of phenylalanine by 
glvcine (37). Previously, the minor redox potential changes 
of these cytochrorne c Phe82 mutants had been rationalized 
by assuming the removal of the steric bulk of phenylalanine 
was compensated for by a refolding of the peptide. While 
this resulted in a change in the dielectric environment of 
the heme (increased the number of polar amide backbone 
groups in the hydrophobic heme pocket, due to the re-
folding), no overall increase in the degree of heme solvation 
was observed compared to wild-type cytochrome c (38. 39). 
The fact the F393H mutant involves such a slight steric 
substitution suggests that the changes in hydrophobicity and 
heme-exposure. would he minimal compared to wild-type 
P450 BM3. 
Distortions to the heme-plane would cause perturbations 
in the energy levels of the porphyrin macrocycle. leading to 
modifications of the thermodynamic properties of heme. 
Residue 393 is within van der Waals contact of the heme 
plane. so any increase or decrease in steric bulk at this 
position would have an impact on the degree of this 
interaction. How this change would manifest itself is unclear, 
but it is conceivable that the energy levels in the porphyrin 
could be perturbed. Direct comparison of heme planes is 
difficult, as the degree of distortion depends highly upon 
the constraints placed on the heme during refinement of the 
structure. Neither heme looks particularly distorted with no 
significant difference in the b-factor of the hemes between 
the two structures. 
More plausible reasons for the modification of the redox 
properties observed are the factors affecting the bonding 
interactions of the redox center. The iron—cysteine bond is 
central to the reactivity of P450s. It has been suggested that 
the cysteinate ligand provides a "push" effect, whereby the 
strong electron donating nature of the thiolate pushes electron 
density toward the heme iron. This increases the heme 
electronegativity (40.41), facilitating the stabilization of high 
iron oxidation states, and also helping the heterolytic cleavage 
of the 02 bond. Therefore, it is likely that factors affecting 
the nature of the Fe—S bond are likely to have significant 
implications on the P450 catalytic cycle. In nitric oxide 
synthases (NOS5), there is a highly conserved tryptophan 
residue six residues downstream of the cysteine ligand, which 
forms an intramolecular hydrogen-bond with the heme ligand 
(33). The formation of such a bond in the F393H mutant 
would have the effect of removing electron density from the 
Fe—S bond, reducing the ability of the thiolate to stabilize 
high oxidation states. Alternatively, this thiolate can be 
considered as being more highly tuned to stabilizing low 
oxidation states leg.. nNOS. E 112  = — 239 mV (42)]. Wild-
type P450 BM3 does not have the potential to form a 
Phe393" Cys400 hydrogen-bond, yet the F393H mutant 
does. The F393H mutant has an elevated reduction potential, 
which equates to as a more stable ferrous-form. The question 
is whether this increase in the reduction potential is due to 
His393 forming an intramolecular hydrogen bond to the 
cysteine or not. Our results suggest this might not be the 
case, for three different reasons. First, the His393• Cys400 
distance is too long (3.5 M for an efficient hydrogen bond. 
Second, a region of electron density is observed between 
Nàl of His393 and a solvent water molecule, indicative of 
a protein—solvent hydrogen-bond. This does not immediately 
preclude the presence of an intramolecular hydrogen-bond, 
as the nature of the His393"'H 20 bond is dependent on 
whether His393 is acting as the hydrogen-donor or hygrogen-
acceptor. a feature undeterminable at the resolution of the 
crystal structure. Third, it would appear that the available 
sulfur lone pair is pointing in an orientation unsuitable for 
efficient hydrogen-bonding geometry with respect to His393. 
Such a hydrogen bond, if formed, would be severely strained. 
Porphyrin complexes with sulfur donors as axial ligands 
have been studied as a method of modeling features specific 
to P450s, such as control of their spin-state, reduction 
potential, and activity (43). For these types of complexes. 
the length of the ferric Fe—S bond is in excess of 2.3 A and 
can be assumed as the equilibrium length of an Fe—S bond 
(44. 45). In P450cani and BM3, this distance is significantly 
shortened to 2.17 and 2.05 A, respectively. It is clear that 
the protein superstructure in these P450s forces this distance 
to a nonequilibrium value, holding the sulfur closer to the 
iron. This is likely to be a key to P450 reactivity. The 
artificially short and strained (unfavorable interaction with 
pyrrole nitrogens of the porphyrin) Fe—S bond exaggerates 
the electron donating nature of the sulfur, increasing the 
electronegativity of the heme iron. In wild-type P450 BM3, 
Phe393 is sandwiched between G1n403 and Pro392 which 
prevents rotation of the phenyl ring. In the F393H structure, 
His393 adopts the same sandwiched orientation but is slightly 
tilted toward Cys400. As a result of this, the imidazole ring 
moves closer to Cys400 [distance of closest contact F393-
(H393)'"Cys400 = 3.67 A (3.50 A)]. The increased steric 
interaction between His393 and Cys400 could lengthen the 
Fe—S bond, causing a decrease in the electronegativity of 
the iron. A comparison of the substrate-free heme-domain 
crystal structures of wild-type and the F393H mutant may 
lend some support to this suggestion. The Fe—S distances 
of wild-type and the F393H mutant are 2.05 and 2.13 A, 
respectively, suggesting a slight increase in the bond length 
induced by the substitution of phenylalanine by histidine. 
However, at the resolution to which these structures have 
been solved (2.0 A), the difference in the Fe—S bond lengths 
falls within the error associated with each bond (±0.2 A). 
Clearly. further investigation of this hypothesis is required 
before a formal conclusion can he drawn as to whether this 
increase in bond length is genuine. However, if it were, such 
a lengthening would account for the observed increased in 
redox potential. 
CONCLUSION 
The spectroscopic and structural comparison of wild-type 
and the F393H mutant of P450 BM3 has provided important 
information pertaining to the thermodynamic control exerted 
over the heme by phenylalanine 393. Our investigations have 
shown that this control is achieved not by a gross confor-
mational change in the heme binding region of the polypep-
tide. Rather, it arises as a consequence of a combination of 
a number of subtle. intimately linked factors. These include 
the close proximity of Phe393 to the heme porphyrin and to 
the cysteine ligand and their unavoidable interaction, its 
electrochemical neutrality, hydrophobicity. and ability to 
prevent exposure of the heme or the cysteine ligand to 
solvent. 
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